2014 CPMC
Research Institute
Annual Report
RESEARCH FOR BETTER MEDICINE
1
2
TABLE OF CONTENTS
Message from Leadership................................................. 5
Highlights............................................................................. 7
CPMCRI Investigator Achievements............................... 8
Recent Hires and Investigator News............................. 10
Research for Better Medicine.......................................... 11
Sutter Pacific Epilepsy Program................................... 12
Center for Melanoma Research and Treatment............ 14
Ray Dolby Brain Health Center..................................... 16
Sutter Research Consortia........................................... 17
Sutter Cancer Research Consortium............................ 19
Sutter Neuroscience Research Consortium.................. 22
Key Investigators and Team Members........................... 27
Liliana Soroceanu......................................................... 28
Greg Tranah................................................................. 29
Kevin Kim.................................................................... 30
Arshia Sadreddin......................................................... 31
ALS Research Team..................................................... 32
CPMCRI Team Members.................................................. 35
Lynne Day.................................................................... 36
Jamey Schmidt............................................................ 37
Joy Becker................................................................... 38
Martin Wu.................................................................... 39
Grants Team................................................................ 40
Featured Studies............................................................... 41
Lung-Map.................................................................... 42
RReACT Repository..................................................... 44
MrOS Study................................................................. 46
Media Activity and Exposure........................................... 49
Financials........................................................................... 52
Compendium..................................................................... 53
3
4
California Pacific Medical Center Research Institute
2014 Annual Report
California Pacific Medical Center Research Institute
(CPMCRI) is a division of CPMC and an important
part of Sutter Health’s transformation of healthcare to
enhance well-being in our communities. CPMCRI has
played a vital role in the creation and growth of the
Sutter Research Enterprise. In 2014, we continued
to demonstrate the value of research in reaching the
highest levels of patient-centered quality care, access
and affordability. Within this report, we’ve profiled
the achievements of some of our investigators, highlight
critically important clinical trials, summarize the breadth
of our research, and showcase how CPMCRI investigators
have had a profound influence on the lives of our patients. Attached to this report
is the 2014 annual CPMCRI Scientific Activities Compendium of Peer-Reviewed
Publications.
Research at CPMCRI can be divided into three large groups: basic science, primarily
focused on cancer; clinical research, with a portfolio of innovative and important
clinical trials, investigator-initiated studies, and translational research, and; the San
Francisco Coordinating Center, a national leader in epidemiology and cohort-based
research in many disease areas.
Recognizing the many centers of research expertise in oncology and neuroscience
and an outstanding investigator base, CPMCRI played a key role in the creation of the
Sutter Cancer Research Consortium in late 2013 and the Sutter Neuroscience Research
Consortium in 2014. Both facilitate communication between investigators and are
already leading to initiation of new system-wide studies. Through newer trials initiated
at CPMC and disseminated throughout the Sutter system, such as Lung-MAP—the
first of many system-wide studies—the entire clinical trial infrastructure will be made
more efficient and reduce recruitment roadblocks for patients and physicians.
As the transformation of research at Sutter Health continues, CPMCRI will remain
a foundation for the scientific discoveries and clinical advances that catalyze Sutter’s
excellence in healthcare delivery.
Michael Rowbotham, M.D.
Scientific Director
California Pacific Medical Center Research Institute
5
6
HIGHLIGHTS
Greg Tranah, Ph.D.
Senior Scientist
7
CPMCRI Investigator Achievements
Findings by scientists Liliana Soroceanu, M.D., Ph.D., and co-author Sean
McAllister, Ph.D., shed new light on the mechanisms of resistance to brain cancer
therapy, focusing on intracellular levels of reactive oxygen species. As published in
the Nature Group publication, Cell Death & Disease, they investigated the response of
glioma stem cells, to cannabidiol (CBD), a non-toxic, non-psychoactive cannabinoid
compound. Results suggest that combining small-molecule reactive oxygen modulators
represents a promising treatment for glioblastoma, especially since these agents may
also enhance the efficacy of chemotherapy.
Mohammed Kashani-Sabet, M.D., a physician with Sutter Pacific Medical
Foundation, CPMCRI Senior Scientist, and Medical Director of the Center for
Melanoma Research and Treatment at CPMC, was honored with a Humanitarian
Award from the Melanoma Research Foundation. The award is presented to individuals
who have committed to fighting melanoma through exemplary patient care, cuttingedge research and scientific leadership. Dr. Kashani leads CPMCRI’s largest basic
science laboratory.
Global findings from the Repository of Registered Migraine Trials (RReMiT) database
were published in a September issue of Neurology. To capture a snapshot of registered
clinical trials related to migraine and a scorecard of the availability of trial results,
Michael Rowbotham, M.D.—Scientific Director of CPMCRI and senior study
author—and colleagues created RReMiT. The initiative follows their earlier work in
creating a similar database for registered analgesic trials (RReACT) of common pain
disorders.
Research by scientists Sean McAllister, Ph.D., and Pierre-Yves Desprez, Ph.D. led to
FDA orphan drug designation for cannabidiol to treat aggressive brain tumors. Orphan
drug approval of the compound represents the first time in the U.S. that a cannabinoid
compound has been recognized by the FDA as a potential potent anti-cancer agent in
treating this aggressive form of brain cancer.
The leadership of Stanley Leong, M.D. and Mohammed Kashani-Sabet, M.D. in
melanoma research was recognized earlier this year when their research on predictors
of sentinel lymph node metastasis in thin melanoma —in collaboration with the
Sentinel Lymph Node Working Group—was highlighted by the American Society of
Clinical Oncology (ASCO), published in the high-impact Journal of Clinical Oncology,
and summarized in a daily news summary for all ASCO members as the lead story.
8
H I G H L I G H TS
Cawthon
Cummings
Desprez
Kashani-Sabet
Leong
McAllister
Rowbotham
Soroceanu
Stone
Tranah
Research by scientists Katie Stone, Ph.D., and Terri Blackwell, as part of the MrOS
Study, linked poor sleep quality to cognitive decline in older men. Results published
in April in the journal Sleep showed that higher levels of fragmented sleep and lower
sleep efficiency were associated with a 40 to 50 per cent increase in the risk of clinically
significant decline in cognitive function over three to four years.
Greg Tranah, Ph.D., developed new means to investigate the mechanisms underlying
peripheral neuropathy. Dr. Tranah studies mitochondrial dysfunction in age-related
illnesses, and has focused recent investigations on understanding sensory deficits and
neuropathic impairments. His latest study, published in the Journals of Gerontology,
expanded upon this work and examined the influence of inherited and acquired
mitochondrial DNA (mtDNA) mutations, on peripheral neuropathies in the elderly.
Research by senior scientists Steven Cummings, M.D. and Peggy Cawthon, Ph.D.,
M.P.H., led to a clinical diagnosis of ‘dismobility’, which arises from two decades of
studies on the consequences of slow walking speed from the collaborative Mobility
Working Group and other scientists, as published in The Journal of the American
Medical Association in April.
9
Recent Hires and Investigator News
Atri
Chan
Kim
De Semir
Dar
Stone
Sadreddin
Alireza Atri, M.D., Ph.D., joined the Ray Dolby Brain Health Center as Endowed Chair
in Brain Health Research. Dr. Atri is an internationally renowned Alzheimer’s disease
clinician-scientist and educator, who will lead the Center’s clinical and discovery research
into healthy brain aging, Alzheimer’s disease and dementia. Dr. Atri will work closely
with the Center’s Founder and Director, Catherine Madison, M.D., and with CPMCRI
Scientific Director Michael Rowbotham, M.D.
Gynecologic oncologist John Chan, M.D., joined Sutter Health and spearheads CPMC’s
gynecologic oncology research. He serves as Gynecologic Oncology Lead for the Sutter
Cancer Research Consortium. Dr. Chan specializes in the surgical and medical treatment
of ovarian and pelvic cancers. He is the first scientist at Sutter who spans two of Sutter’s
research institutes – CPMCRI and the Palo Alto Medical Foundation Research Institute.
Kevin Kim, M.D., joined CPMC’s melanoma program as Director of Clinical Research.
Dr. Kim was previously appointed as physician and professor at the University of Texas
MD Anderson Cancer Center in Houston. A prominent medical oncologist who is
board-certified in internal medicine and medical oncology, Dr. Kim’s research interests
are in melanoma, mucosal melanoma, and targeted therapies.
Arshia Sadreddin, M.D., joined CPMC and its Research Institute as Medical Director
of Movement Disorders and Deep Brain Stimulation, for the Sutter Pacific Medical
Foundation. A renowned neurologist, Dr. Sadreddin specializes in medical and surgical
treatments of movement disorders. She is one of the few neurologists in the U.S. with
special training and expertise in deep brain stimulation for the treatment of Parkinson’s
disease, essential tremor, and dystonia.
David De Semir, Ph.D. and Altaf Dar, Ph.D., were named Associate Scientists. As
members of the Kashani lab, their research is aimed at identifying molecular markers of
melanoma progression.
Katie Stone, Ph.D., was named Senior Scientist, and continued her groundbreaking
research into sleep quality and health outcomes including cognitive function and risk of
falls or injuries in the elderly.
10
H I G H L I G HTS
RESEARCH FOR BETTER MEDICINE
Alireza Atri, M.D., Ph.D.
Catherine Madison, M.D.
11
Quelling an electrical storm in the brain
Research at the Sutter Pacific Epilepsy Program helps lead to FDA approval
of new epilepsy pacer for treating epileptic seizures
Over one third of patients with epilepsy have
persistent seizures despite treatment with
medications. New approaches have been
critical to reducing the frequency and intensity
of these brief periods of abnormal, excessive,
or asynchronous neuronal activity in the brain.
And while resective surgery is an option for
some patients, the procedure increases the risk
of post-operative neurological deficits.
Last year, research at Sutter Pacific’s Epilepsy
Program was key to the Food and Drug
Administration’s approval of a new epilepsy
pacer—in essence, a brain stimulator—in
treating epileptic seizures. The tiny batterypowered device is implanted in the brains of
epilepsy patients for whom medications and/
or surgery have been unsuccessful. Its wires
are threaded into the brain, tracking electrical
activity and preventing or minimizing
impending seizures.
The effectiveness of the epilepsy pacer was
shown in a randomized controlled trial
at multiple centers throughout the U.S.,
with CPMC leading the trials as the largest
implanting facility with the most experience
worldwide.
The epilepsy pacer device
is shown (top) implanted
into an epilepsy patient’s
brain, tracking electrical
activity.
12
R E S E A R C H FOR BE TTE R ME DICINE
“The device has dramatically reduced seizures in our patients, from dozens
daily to just a couple every few months in many cases,” says David King-Stephens,
M.D., CPMC’s Director of Neurophysiology, and Co-Director of the Sutter
Pacific Epilepsy Program. “It’s truly an evolution: we’re seeing the tangible
benefit of this research improving patients’ quality of life and their ability to
function at work, as parents, and in leading well-rounded lives free from symptoms.”
One of these patients is Gina Smith, a twenty-eight year old mother who experienced
devastating seizures since developing epilepsy in her teens. Even after treatment with
seven different drug combinations, six weeks was her longest seizure-free period, and
surgery wasn’t an option due to a high risk of short-term memory loss.
After being implanted with the epilepsy pacer, Smith’s frequency of seizures was
reduced by eighty-five per cent. “Before the device, I felt as if my life were falling apart,
and with it my ability to care for my kids,” says Smith. “There’s clarity now with months
in my life where I feel as if epilepsy were a distant memory.”
This year, Dr. King-Stephens and colleagues Peter Weber, M.D. and Kenneth Laxer,
M.D. uncovered new findings about the device that may provide evidence supporting
its wider use in specific types of epilepsy patients and through stimulation of different
areas of the cortex.
“The new data reinforce that brain stimulation is an excellent treatment for patients in
whom we know where the seizures originate, but who are not candidates for resective
surgery,” says Dr. King-Stephens.
David King-Stephens, M.D.
CPMC’s Director of
Neurophysiology, and
Co-Director of the Sutter
Pacific Epilepsy Program
“The device has
dramatically reduced
seizures in our patients,
from dozens daily to just a
couple every few months in
many cases,” says
David King-Stephens, M.D.
13
Investigating the molecular pathways underlying
the development and progression of skin cancer
Research and clinical trials at CPMC’s Center for Melanoma Research
and Treatment were key to FDA approval of nivolumab for the treatment
of melanoma, bringing patients one step closer to cure
One of the newest classes of agents to
treat melanoma and other types of cancer,
checkpoint inhibitors have emerged as
promising therapies in slowing tumor growth
and shrinking cancers. With the Food
and Drug Administration (FDA) approval
in December of the checkpoint inhibitor
nivolumab for advanced melanoma, these
drugs are expected to bring new hope to the
more than 76,000 people in the U.S. diagnosed
annually with this deadly form of skin cancer.
Checkpoint inhibitor
drugs act as a natural
immune system ‘brake’
known as PD-1, which
some tumors use to
evade immune system
attack.
Studies at CPMC’s Center for Melanoma
Research and Treatment were key to approval
of the drug, with the Center’s investigators
entering more patients on the pivotal study than any other cancer center worldwide. Nivolumab is an immunosuppressive agent that releases a natural immune system
brake known as PD-1 which some tumors use to evade immune system attack. Studies
have shown that anti-PD1 antibodies show a higher rate of durable responses with less
severe toxicity than previously approved immunotherapies for melanoma.
“This research is changing the landscape of cancer therapy, based on these new insights
into tumor biology and the molecular pathways underlying metastasis,” says David
Minor, M.D., clinician-scientist at CPMCRI. “Many of our patients treated with the
drug are continuing to do well and show no signs of tumor progression.”
14
R E S E A R C H FOR BE TTE R ME DICINE
“The drug shows significant promise in saving the lives of patients with
late-stage disease who have few options for therapy,” says Mohammed
Kashani-Sabet, M.D., Director of CPMC’s Center for Melanoma Research
and Treatment, and Senior Scientist at CPMCRI. “Anti-PD-1 drugs, because
they are effective in other diseases such as lung cancer and melanoma, will make
the immunotherapy of cancer a mainstream treatment like surgery, radiation, and
chemotherapy.”
Dr. Minor and Dr. Kashani are already seeing dramatic improvements in patients
treated with the drug. Fifty-six year old John Heebink, for example, had advanced
melanoma and was told he’d live about five months, before being treated with
nivolumab at CPMC. After two months his tumors had shrunk by 80 per cent. Two
years later, Heebink has had continued success on the drug and feels “as if this therapy
has been a game changer for my path of recovery,” he says.
David Minor, M.D.,
clinician-scientist at
CPMCRI
“This research is changing
Intrigued by the potential of immunotherapies to engage the body’s cellular defense
mechanisms to fight cancer, CPMC’s melanoma team began investigating checkpoint
inhibitors several years ago. They found that agents like PD-1 inhibitors reactivate T
cells after their suppression during the cancerous process, thus boosting the immune
system’s capacity to stop metastasis.
the landscape of cancer
Dr. Minor worked with scientists at Bristol-Myers-Squibb to expand the eligibility
criteria for the study. This enabled he and other physicians to place more patients on
the study sooner, speeding FDA approval of the drug.
metastasis,” says
therapy, based on these
new insights into tumor
biology and the molecular
pathways underlying
David Minor, M.D.
15
CPMC’s Ray Dolby Brain Health Center boosts its
research initiatives to expand the Center’s innovative
approach to caring for patients with memory disorders
Alireza Atri, M.D., Ph.D, joins the Center as Endowed Chair in Brain Health
Research
The Ray Dolby Brain Health Center (RDBHC) at CPMC built upon its impressive
reputation for patient care with the successful recruitment of Alireza Atri,
M.D., Ph.D., an internationally renowned Alzheimer’s disease (AD) clinicianscientist and educator, to lead the Center’s clinical and discovery research into
healthy brain aging, AD and dementia.
Alireza Atri, M.D., Ph.D.,
internationally renowned
Alzheimer’s disease (AD)
clinician-scientist and
educator
More than 500,000
Californians are affected
by AD, dementia, or a
related memory disorder.
The RDBHC —one of the
only programs of its kind
in Northern California and
first to develop partnership
with the Alzheimer’s
Association—opened its
doors in 2012, and has
delivered comprehensive
and innovative evaluation,
support and treatment for
thousands of Bay Area
residents.
16
Dr. Atri will work closely with the Center’s Founder and Director, Catherine
Madison, M.D., and with CPMCRI Scientific Director Michael Rowbotham,
M.D. He joins CPMC from Massachusetts General Hospital and Harvard
Medical School in Boston, where he and colleagues published the first long-term
study to show sustained benefits of combination therapies to slow clinical decline in
Alzheimer’s disease.
“The Bay Area is so fortunate to entice a clinician-researcher with the depth of
knowledge and devotion evident in Dr. Atri. We look forward to his work advancing
the delivery of evidence-based care for our patients and helping us all address the
epidemic of dementia,” says Dr. Madison.
Rachelle S. Doody, M.D., Ph.D., the Effie Marie Cain Chair and Director of the
Alzheimer’s Disease and Memory Disorders Center at Baylor College, says, “Dr. Atri
brings tremendous clinical excellence and a rare dedication to research-based patient
care to the Center. He is poised to lead the group in providing standard care while
advancing new treatment approaches, which will translate into new options for patients
in the region. Dr. Atri will continue to advance the field of AD therapeutics research
while training an array of care providers to deliver care in the future.”
A lead investigator for international AD treatment trials, Dr. Atri studies new
diagnostic and therapeutic strategies to detect and slow cognitive disorders. He will
collaboratively initiate new clinical trials at Sutter Health, and establish partnerships
for treatment trials, cohort and epidemiological studies, and dementia education
programs throughout Northern California.
“Few of us will be spared the personal effects of cognitive changes and—what is
increasingly recognized as one of the most challenging afflictions of our time—
dementia,” says Dr. Atri. “The Bay Area is a hub for research innovation, collaboration,
community and progress. With equal spirit and drive in our approach to research
advances at CPMC, I believe we can substantially ameliorate the significant health and
social impacts of dementia.”
R E S E A R C H FOR BE TTE R ME DICINE
The Sutter Cancer Research Consortium and
the Sutter Neuroscience Research Consortium
Overview
A coordinated approach to implementing clinical research and trials in key areas
of Sutter Health expertise was a vision yet to be realized until Sutter Health’s
Lea Ann Bernick, MHA, met with several system-wide oncologists two years
ago to discuss its execution; but her initial work (with the support of oncology
investigator leadership) in helping organize and implement a more efficient
strategy for initiating large National Cancer Institute (NCI) and industrysponsored oncology clinical trials soon led to the genesis of the Sutter Cancer
Research Consortium (SCRC). The consortium now represents efforts of the
Sutter Research Enterprise to streamline and expand its system-wide clinical
oncology research.
“From the start, there has been overwhelming support and collaboration for a new
means to coordinate more efficient initiation of system-wide oncology clinical trials,”
says Bernick. “It’s incredibly motivating to see physician engagement in this process,
and the knowledge that our patients are benefiting from faster, easier access to
promising new therapies and follow-up services.”
Lea Ann Bernick, MHA,
Sutter Cancer Research
Consortium Director
As the SCRC continued to grow and achieve early success, a similar strategy to
coordinate system-wide clinical neuroscience research evolved a year later with
leadership from CPMCRI Scientific Director Michael Rowbotham, M.D., in creating
the Sutter Neuroscience Research Consortium (SNRC).
“Neuroscience research is amazing in its diversity,” says Dr. Rowbotham. “There is no
equivalent of the NCI cooperative groups in the neurosciences. The SNRC is organized
to bring together research experts from all sub-specialties to share ideas, develop new
investigator-led studies, and work toward including multiple sites within Sutter for all
major clinical trials.”
Together, the consortia are key initiatives enabling an efficient shared services model
that eliminates redundancies, provides consistent administrative and regulatory
support, and reduces costs to CPMCRI and other Sutter Health research affiliates.
SCRC and SNRC facilitate dissemination of the One Sutter approach into clinical
research programs system-wide.
While maintaining a strong physician-scientist orientation, an integrated system
gives patients access to a cutting-edge, large, diverse range of treatment options and
programs to support their care plan and their entry into oncology and neuroscience
clinical trials.
17
Why create consortia centered around Sutter’s oncology and
neuroscience research expertise?
For patients:
• Expands options for clinical care and prevention research across a wide range of
tumor types and neurological disorders
• Provides coordinated access to cutting-edge clinical research, even in remote and/
or urban areas within the Sutter system
• Assures patients that the clinical research excellence they seek can be found at
Sutter affiliates
For physicians:
• Offers a broader array of clinical trial options to deliver care unavailable by other
means
• Provides an efficient infrastructure to support physician-scientists who offer
patients innovative clinical trial treatment options
• Enhances the scientific peer-review process via a system-wide science committee
• Encourages collaborative research opportunities among oncologists and
neurologists, and other specialized care providers
• Provides a more efficient structure for investigator-initiated studies and
participation in large-scale pharmaceutical studies
For Sutter:
• Aligns the affordability agenda with an efficient consortia structure
• Facilitates the work of RISA toward a consolidated operations and budget
• Encourages interdependence for clinical expertise, with less patient ‘leakage’ to
outside academic systems in Northern and Central California
• Provides a model for other Sutter service lines to consider duplicating, and
enables bridge-building between institutions and clinical staff
• Presents an attractive structure to pharmaceutical companies and academic
networks for including Sutter patients and physician-scientists in large clinical
trials and cohort studies
18
R E S E A R C H FOR BE TTE R ME DICINE
The Sutter Cancer Research Consortium:
A robust clinical trials portfolio
By simplifying the process for patient entry into clinical trials and facilitating the
development of a Sutter-wide tumor biorepository, Sutter Health oncologists are
coordinating their efforts to improve cancer research and treatment outcomes for
patients, and collaborating in large, phase 1-3 national clinical studies sponsored by
NCI and the pharmaceutical industry.
By the numbers: How SCRC leadership and expertise
improves patient care
• There are 115 registered NCI investigators at 21 sites across the Sutter Health
network.
• In 2014, 110 patients were enrolled into national NCI funded clinical trials.
• On any given day, the SCRC offers 65-70 clinical studies open to enrollment. One
hundred and five studies are in long-term follow-up with thousands of patients
formerly on active treatment.
• We ranked as the ninth-largest main member within the national NRG Oncology
Group, one of the four cooperative groups led by the NCI. Historically, Sutter
NCI research programs have been recognized by the NCI as one of the top
community based enrolling entities.
• Seven of our oncologists are appointed to sit on NCI national cooperative group
Disease Committees, helping lead the design and creation of these studies. Their
findings are published in peer-reviewed journals with our physicians as lead or
co-authors who present at national oncology meetings.
SCRC Governance:
Comprised of a 12-member Executive Committee, the SCRC is governed by Stacy
D’Andre, M.D., Executive Committee Chair. Ari Baron, M.D., acts as Science
Committee Chair and organizes review of all new NCI studies. The Executive
Committee makes policy decisions, ensures representation of all oncology subspecialties and Sutter geographies, and helps inform the direction of SCRC. They
participate on national NCI cooperative group investigator committees where these
trials are designed, and enroll patients into the studies.
Michael Rowbotham, M.D., is a non-voting member of the Executive Committee.
Lynne Day, Operations Director at CPMCRI, provides logistical support through
her role in integrating research services across the system. Lea Ann Bernick is the
Director of the SCRC. She and her team coordinate SCRC physicians, manage all
NCI-sponsored trials at Sutter Health, educate and train staff on studies and quality
assurance, and provide a critical link to the NCI and the rapidly changing world of
oncology clinical trials.
19
Regional Leads
Stacy D’Andre, M.D., Sacramento-Sierra Lead and SCRC Executive Committee Chair;
Medical Director, Gastrointestinal and Gynecologic Tumor Programs at the Sutter Health
Cancer Center; Department Chair of Medical Oncology
Leading research advances in the treatment of gynecologic and gastrointestinal cancers
in the elderly
Ari Baron, M.D., West Bay Lead
Medical Director of the Clinical Oncology Research Program at CPMC; Chief of the
Division of Hematology-Oncology
Renowned for expertise in advancing clinical trials for pancreatic, prostate, colon, liver,
lung, breast, and ovarian cancers
Peter Yu, M.D., Peninsula Coastal Lead
Director of Cancer Research at Palo Alto Medical Foundation; President, American
Society of Clinical Oncology
Pioneering health information technologies to improve the quality of cancer diagnosis,
care, and prevention
Milana Dolezal, M.D., East Bay Lead
Medical Director of Gastrointestinal Oncology at Alta Bates Summit Comprehensive
Cancer Center
Enabling new approaches to the treatment of solid tumors and hematologic
malignancies
David Shiba, M.D., Central Valley Lead
Oncologist/hematologist; Sutter Gould Medical Foundation physician
Leading clinical trials to advance the treatment of patients with solid tumors and
hematological malignancies
20
R E S E A R C H FOR BE TTE R ME DICINE
System Leads
Gregory Graves, M.D., Surgical Oncology Lead
Surgical Oncologist; Regional Medical Director of Cancer Services, Sacramento-Sierra
Region; Medical Director, Sutter Cancer Center, Sacramento; Chief of the Department of
Surgery, Sutter Medical Center
Developing new surgical and radiotherapy techniques to treat cancer
Elizabeth Kim, M.D., FACS, Surgical Oncology Lead
Surgical Oncologist; Sutter Roseville Medical Center
Pioneering surgical advances for the treatment of high-risk breast diseases and breast
cancer
John Chung-Kai Chan, M.D., Gynecologic Oncology Lead
Sutter Health Director of Gynecologic Oncology
Leading research advances in the treatment of gynecologic cancers
Kathleen Grant, M.D., Symptom Control Lead
Medical Oncologist-Hematologist; Chief of the Division of Hematology-Oncology
at CPMC
Advancing the diagnosis and treatment of hematological malignancies; developing
novel therapies for breast, esophageal, and bowel cancer
Kevin Knopf, M.D., M.P.H., Prevention Lead
Medical Oncologist and Hematologist at CPMC
Improving research into the cost-effectiveness of cancer care; implementing clinical
pathways, decision analysis, and health economics modeling; leading large-scale
database analytics in cancer care; studying patterns of cancer care and health disparities
Christopher Jones, M.D., F.A.C.R., Radiation Oncology Co-Lead
Radiation Oncologist, Sutter Health Medical Group
Leading advances in new radiotherapy techniques; optimizing imaging technologies to
predict tumor recurrence and visualize response to therapy; internationally renowned
expertise in head and next cancers
Jamie Rembert, M.D., Radiation Oncology Co-Lead
Radiation Oncologist, Alta Bates Comprehensive Cancer Center; Chair of Clinical
Services, Alta Bates Hospital
Pioneering new radiotherapy techniques to treat cancer; optimizing imaging
technologies to predict tumor recurrence and visualize response to therapy
21
Sutter Health Neuroscience Research Consortium:
Research to advance the treatment
of neurological disorders
Sutter Health offers its adult and pediatric patients some of the leading
neurosurgery, neurology, and neuro-oncology specialists in Northern
California, with state-of-the-art diagnostic and surgical technologies. Sutter’s
neuroscience experts are at the forefront of clinical research in essentially
all areas of clinical neuroscience. Their coordinated efforts include research
on new treatments, diagnostic tools, and disease biology; multidisciplinary
teams with enhanced clinical expertise and personalized approaches to patient
care, and; coordinated access to a large portfolio of clinical trials and other
innovative clinical research studies.
SNRC Governance:
Nobl Barazangi, M.D.,
Ph.D., Director of the
Stroke/Neurocritical Care
Research and Education
Program at CPMC
Comprised of a 30-member Executive Committee, the SNRC is governed by Executive
Committee Chair Michael Rowbotham, M.D. The Executive Committee has four
Regional Leads ensuring representation and perspectives from all geographic areas of
Sutter Health.
The SNRC is comprised of 16 disease areas, some with up to four Executive Committee
members to better integrate longstanding individual affiliate research programs.
The entire spectrum of neuroscience subspecialties are represented, including brain
tumors and other cancers of the nervous system, Alzheimer’s disease and dementia,
pain and peripheral nerve disorders, migraine and headache, multiple sclerosis,
pediatric neurology and autism, movement disorders and Parkinson’s Disease, ALS
and neuromuscular diseases, neuro-critical care, neuro-imaging, neuro-interventions
(such as stents to prevent stroke and deep brain stimulation for movement disorders),
epilepsy, neuro-trauma (including head injury and sports concussions), spine
disorders, rehabilitation, and stroke. Lynne Day advises the SNRC through her role in
integrating research services across the system. CPMCRI’s Virginia Giblin and Sutter
Institute for Medical Research’s Bobbie Benabides coordinate all SNRC activities.
Regional Leads
Michael Rowbotham, M.D.
Scientific Director of CPMCRI, SNRC Executive Committee Chair
Unraveling the mechanisms and improving management of chronic pain; advancing
pain research
Nobl Barazangi, M.D., Ph.D., Stroke/Neurocritical Care Lead
Director of the Stroke/Neurocritical Care Research and Education Program at CPMC
Pioneering advances in stroke research and care, including neuroimaging,
neurovascular disorders, and neuromonitoring
22
R E S E A R C H FOR BE TTE R ME DICINE
Shawn Kile, M.D., Dementia and Cognition Lead
Medical Director of Neurology, Sutter Medical Group Neurology Care Center; Medical
Director, Sutter Neuroscience Concussion and Traumatic Brain Injury Clinic; Co-Director,
Sutter Neuroscience Memory Clinic
Leading research advances in the treatment of dementia, traumatic brain injury,
autism, encephalopathy, and other neurocognitive illnesses; conducting physicianinitiated trials and phase 2-3 clinical studies assessing the efficacy of new therapies for
Alzheimer’s disease and adult autism
Joanna Cooper, M.D., Multiple Sclerosis Lead
Medical Director of the Alta Bates Summit Medical Center Research Institute (REDI)
Developing new approaches to the treatment of multiple sclerosis, epilepsy, spasticity
disorders, and other neurologic conditions
Disease Area Leads
Jonathan Katz, M.D., Neuromuscular/Peripheral Nerve Lead
Director of Neuromuscular Research at the Forbes Norris MDA/ALS Research and
Treatment Center at CPMC
Investigating treatments to delay the progression of motor neuron diseases including
ALS and myasthenia gravis; initiating clinical trials for pain management, peripheral
neuropathy, poliomyelitis, radiculopathies, and spinal muscular atrophy
Edie Zusman, M.D., F.A.C.S., Neurosurgery Lead
Medical Director, Sutter Health East Bay Neuroscience Institute at Eden Medical Center
Advancing the neurosurgical treatment of brain tumors, neurovascular conditions,
epilepsy and spinal disorders
Richard Riemer, D.O., Spine Lead
Regional Medical Director of Sutter Spine Care, Sutter Neuroscience Institute and Sutter
Medical Foundation
Advancing the treatment of spinal disorders and chronic pain; investigating opioid use
and the ‘opioid epidemic’, chronic pain, and conservative treatment for spine disorders
Michael Chez, M.D., Pediatric Neurology Lead
Director of Pediatric Neurology at Sutter Memorial Hospital, Director of the Pediatric
Epilepsy and Autism Programs for the Sutter Neuroscience Group
Expertise in pediatric neurology; pioneering new treatments for childhood epilepsy,
autism and autism spectrum disorders
Kenneth Laxer, M.D., Epilepsy Lead
Director of the Sutter Pacific Epilepsy Program
Leading research on neuroimaging techniques, cerebellar physiology, and
pharmacologic approaches to treating epilepsy
23
Tyler Kang, M.D., Neuro-Oncology Lead
Hematologist and Medical Oncologist, Alta Bates Summit Medical Center
Conducting research and clinical trials to advance the treatment of pediatric brain
and spinal tumors; seeking new insights into the molecular and genetic mechanics
underlying brain cancer metastasis
Lawrence Dickinson, M.D., Neuro-Trauma Lead
Medical Director, Intensive Care Unit, Sutter Health Eden Medical Center
Developing new approaches to the treatment of traumatic brain and spinal injuries;
advancing the surgical management of stroke and cerebrovascular illnesses
Scott Rome, M.D., Rehabilitation Lead
Medical Director of Stroke and Brain Injury Rehabilitation Programs at CPMC
Pioneering research that facilitates patients’ rehabilitation after traumatic brain injury
Jennifer Ault, D.O., Pain Lead
Neurologist, Sutter East Bay Medical Foundation, Alta Bates Summit Medical Center
Leading studies to advance the treatment of musculoskeletal injuries; pioneering
new approaches to the diagnosis and treatment of spinal disorders including disc
herniations, spinal stenosis, and sciatica, as well as complex regional pain syndrome,
thoracic outlet syndrome, and refractory pain after back surgery
Arshia Sadreddin, M.D., Movement Disorders Lead
Medical Director of Movement Disorders and Deep Brain Stimulation, Sutter Pacific
Medical Foundation at CPMC
Developing novel therapies for Parkinson’s disease and essential tremor, and the
treatment of dystonia; developing strategies to refine and improve the use of deep brain
stimulation for movement disorders
David Tong, M.D., Stroke/Neuro-Intensive Care Lead
Director of the Center for Stroke Research at CMPC
Leading advances in early diagnosis, treatment and recovery of acute stroke; helping
lead effective strategies for use of SMART (Simplified Management of Acute Stroke
using Revised Treatment) criteria for IV rt-PA treatment; creating stroke telemedicine
networks across Northern California
Alireza Atri, M.D., Dementia and Cognition Lead
Endowed Chair in Brain Health Research and Education, Ray Dolby Brain Health Center
at CPMC
Improving the diagnosis and care of patients with memory disorders and dementia;
leading clinical and discovery research into healthy brain aging, dementia, and
Alzheimer’s disease and memory disorders
David Chesak, M.D., Multiple Sclerosis Lead
Neurologist, Sutter Neuroscience Group, East Bay Region
Creating new approaches to the treatment of multiple sclerosis, epilepsy and seizure
disorders, headaches and migraines, and neuromuscular disease
24
R E S E A R C H FOR BE TTE R ME DICINE
Bradley Wrubel, M.D., Headache Lead
Neurologist, Sutter East Bay Medical Foundation
Leading clinical research and trials to advance the treatment of migraine and other
headaches
Joey English, M.D., Neuro-interventional Lead
Neurointerventional surgeon and Medical Director of Neurointerventional Services
at CPMC
Developing novel neurointerventional approaches including endovascular therapies to
treat acute ischemic stroke and other cerebrovascular diseases
David Seidenwurm, M.D., Neuroimaging Lead
Neuroradiologist, Sutter Medical Group, Sacramento
Pioneering appropriate use and performance measurement of leading-edge radiology
techniques to advance the diagnosis of brain and spinal injuries
Featured SNRC Research Program Areas at CPMC:
The Sutter Pacific Epilepsy Program maintains a comprehensive research program with
approximately 13 active approved protocols for studies of neuromodulation devices, new
anti-epileptic drugs, and brain pathology in epilepsy patients.
CPMC’s stroke researchers are using telemedicine to rapidly and remotely evaluate
and treat patients with acute stroke, and to study neurovascular techniques such as
stents and vascular reconstruction devices. Several researchers in the stroke group are
involved in industry-sponsored trials of new therapies.
The Forbes Norris MDA/ALS Research and Treatment Center at CPMC—one
of the largest clinical research centers worldwide—has been integral to essentially
every significant study of ALS treatment conducted over the past 15 years. The
Center’s physicians are active in many ALS research consortia, and lead research into
myasthenia gravis, muscular dystrophy, and peripheral neuropathies.
CPMC’s Ray Dolby Brain Health Center collaborates with the Alzheimer’s Association
of Northern California to provide patient care, education and research in memory loss.
Employing a multidisciplinary team of health professionals, the Brain Health Center
provides a variety of services for individuals with early memory loss, dementia, and
Alzheimer’s disease, and to support patients’ caregivers.
CPMC has added a movement disorder physician specialist that treats and conducts
research on neurological conditions such as Parkinson’s disease, essential tremor,
dystonia, Huntington’s disease, and others. Providing both medical management and
surgical options such as deep brain stimulation, our movement disorder team is skilled
and knowledgeable in treating a wide array of movement-related conditions.
25
26
KEY INVESTIGATORS AND TEAM MEMBERS
Liliana Soroceanu,caption
Ph.D., M.D.
here
Senior Scientist
27
CPMCRI scientist a game-changer
in brain cancer research
Leading cutting-edge work in a new area of cancer research: the hypothesis that
viruses can cause cancer, and that anti-viral therapies can prevent tumor growth
Liliana Soroceanu, M.D., Ph.D.
Approximately 23,000 Americans are diagnosed with a primary brain and other
nervous system tumor every year, and almost 60% of them will eventually
die from the illness. Glioblastoma multiforme (GBM) is the most common,
aggressive type of primary malignant brain tumor, accounting for approximately
40% of cases. Patients with GBM deteriorate quickly; 90% die within two years
after starting therapy, and only five per cent are alive after five years.
A disheartening prognosis, and one that drives Liliana Soroceanu, M.D., Ph.D.,
to search for new treatments.
One of the country’s few female scientist authorities on GBM, Dr. Soroceanu had a
banner year, publishing research on human cytomegalovirus (HCMV), the causal link
to GBM, and the effects of anti-viral therapy.
“We anticipate these findings will revolutionize the treatment of brain tumors,” says Dr.
Soroceanu. “No prior evidence has shown a role for cidofovir as a potent anti-cancer
agent against glioblastoma. We were surprised that, even in the absence of HCMV
infection, the drug caused tumor cell death and augmented the effects of radiation in
delaying tumor progression.”
Nine years ago, her first breakthrough work at CPMCRI arose in collaboration with the
leading neurosurgeon Charles Cobbs, M.D., and involved a novel avenue of inquiry—
research to explore the role of HCMV, a common herpes virus, in tumor growth and
metastasis.
Dr. Soroceanu’s other pivotal research this year revealed, for the first time, a specific
HCMV gene signature and related mechanisms underlying the viral attack that triggers
GBM progression.
After infecting human glioblastoma stem cells with several HCMV strains and
measuring the viral gene expression patterns, tumor stem cells infected with HCMV
were shown to persist twice as long as uninfected cells. Prolonged survival was
accompanied by the activation of signaling pathways that drive glioblastoma survival
and recurrence.
“We found a specific set of genes common to the GBM cells infected with HCMV that
contributes to multiple tumor-promoting pathways,” says Dr. Soroceanu, who led the
research. “Developing anti-viral therapies to target this signature could therefore help
prevent disease progression and the recurrence of brain tumors.”
28
K E Y I N V E S TIGATOR S AND TE AM ME MB E R S
Investigating the mechanisms underlying
peripheral neuropathy
Research leads to new strategies to preserve nerve function in the elderly
Greg Tranah, Ph.D.
Loss of touch sensation, poor motor nerve function, and in some cases pain,
burning or tingling in the feet or hands—these and other symptoms of poor
peripheral nerve function commonly afflict the elderly, and can severely
impact quality of life, physical functioning, and wellbeing.
Greg Tranah, Ph.D., CPMCRI and San Francisco Coordinating Center
(SFCC) scientist, and Adjunct Professor in the Department of Epidemiology &
Biostatistics at UCSF, studies mitochondrial dysfunction in age-related illnesses
including dementia and Alzheimer’s disease. As mitochondrial dysfunction is
a common characteristic of several neuropathies including peripheral neuropathy,
Dr. Tranah focused key investigations this year on understanding sensory deficits and
neuropathic impairments.
He is among a select group of researchers in the U.S. uncovering how alterations
in mitochondrial DNA (mtDNA) play a much greater role than once believed in
neurodegeneration and age-related brain illnesses. And while the study of mtDNA
is well established, the availability of inexpensive, high-throughput genotyping and
DNA sequencing has allowed researchers to examine mtDNA in much larger studies of
disease and aging.
“The genetic information
Dr. Tranah’s latest study expanded upon this work and examined the influence of
inherited and acquired mtDNA mutations on peripheral neuropathies in the elderly.
insight into new targets
Studying over 2,000 elderly participants from the Health, Aging and Body
Composition (Health ABC) cohort, Dr. Tranah and colleagues investigated the role of
mtDNA sequence variation on peripheral nerve function.
nerve function in the
coding for mitochondrial
protein synthesis and
assembly is associated
with peripheral nerve
function, and may provide
for therapies that preserve
elderly,” says Dr. Tranah.
Even though common individual genetic variants were found to play a much smaller
role in peripheral nerve functioning than initially hypothesized, groups or aggregates
of multiple sequence variants had a stronger impact on motor nerve conduction
velocity and amplitude.
“The genetic information coding for mitochondrial protein synthesis and assembly is
associated with peripheral nerve function, and may provide insight into new targets
for therapies that preserve nerve function in the elderly,” says Dr. Tranah. “Since poor
peripheral nerve function strongly correlates with diminished physical functioning,
new approaches to safeguarding the mitochondrial DNA governing the integrity of
these nerves can help extend physical wellbeing in the elderly and prevent sensory and
motor nerve degradation.”
New directions in this area of research will see Dr. Tranah and colleagues at the SFCC
explore how proportions of normal and mutant mtDNA impact the risk of inherited
mitochondrial diseases.
29
Targeting the molecular underpinnings of cancer
for more precise, personalized melanoma treatments
Kevin B. Kim, M.D.
Previously appointed at the University of Texas MD Anderson Cancer Center in
Houston, Kevin B. Kim, M.D., joined CPMC’s melanoma program as Medical
Director of Clinical Research. A prominent medical oncologist, Dr. Kim
investigates targeted therapies, immunotherapies, and melanoma.
Collaborating with Medical Director for Cancer Programs Mohammed
Kashani-Sabet, M.D., Dr. Kim is leading phase 1 and 2 clinical trials on the
biology of genetic mutations in melanoma, and new combinations of targeted
and immunotherapies.
“This is an incredibly exciting time in melanoma research,” says Dr. Kim. “With
the advancement of these treatments and our expanding knowledge of biomarkers,
we can focus our efforts on bringing novel, more personalized therapies to patients.”
“This is an incredibly
exciting time in melanoma
research,” says Dr. Kim.
“With the advancement of
these treatments and our
expanding knowledge of
biomarkers, we can focus
our efforts on bringing
novel, more personalized
therapies to patients.”
Research into targeted treatments for cancer has rapidly increased over the past 15
years with the discovery that agents including trastuzumab (Herceptin®) could disrupt
specific receptors in a cancer cell’s membrane, halting tumor growth and progression.
More recently, small-molecule targeted therapies including BRAF and MEK inhibitors
against melanoma have significantly improved patients’ prognosis and increased
momentum in this area of research.
“But despite these targeted treatments, cancer is incredibly insidious in that a tumor
can mutate and become resistant to therapy,” says Dr. Kim. “The goal is to overcome
a tumor’s resistance and adaptive capabilities by attacking the cancer at multiple
pathways and critical points of cell growth, with combination therapy.”
With experience in translational melanoma research into novel molecular targeted
therapies, Dr. Kim was an integral part of the early drug development of small
molecules that are now FDA-approved drugs for patients with BRAF-mutant
metastatic melanoma.
As Director of Clinical Research in the melanoma group and in collaboration with Dr.
Kashani-Sabet and others, Dr. Kim will lead CPMC’s efforts to build a database and
tumor bank of tissue samples from patients with melanoma—an initiative that will
advance personalized therapies.
30
K E Y I N V E S TIGATOR S AND TE AM ME MB E R S
Pioneering new approaches to the treatment of
Parkinson’s disease and movement disorders
Arshia Sadreddin, M.D.
One of the few neurologists in the U.S. with special training and expertise in deep
brain stimulation for the treatment of Parkinson’s disease, Arshia Sadreddin, M.D.,
was recruited to lead CPMC’s new movement disorders program. Dr. Sadreddin
was Assistant Professor of Neurology, previously appointed as physician and
Director of the Hyperkinetic Movement Disorders and Huntington’s Disease
Program at the prestigious Barrow Neurological Institute/Muhammad Ali
Parkinson Center at St. Joseph’s Hospital & Medical Center in Phoenix.
A renowned neurologist, Dr. Sadreddin specializes in medical and surgical
treatments of movement disorders. She conducts research studies in Parkinson’s
disease (assessing motor and non-motor functions), Huntington’s disease, and
dystonia, and has experience as a Principal Investigator on numerous national,
multicenter clinical trials evaluating the efficacy and safety of new treatments for these
nervous system disorders.
Collaborating with other Sutter Health movement disorders specialists including
Matthew Arnold, M.D., and Nicklesh Thakur, M.D., Dr. Sadreddin will lead
investigator-initiated and industry-sponsored clinical trials investigating new
approaches to the treatment of Parkinson’s disease and other movement disorders.
“This is an exciting time in movement disorders research,” says Dr. Sadreddin.
“With advances in new technologies, surgical and pharmacologic therapies and our
expanding knowledge of disease mechanisms, we can focus our efforts on bringing
novel treatments to patients to improve their symptoms and quality of life. I am thrilled
to collaborate among the renowned expertise of Sutter Health’s leaders in this area to
help further these discoveries.”
With support from CPMC’s Women’s Board and donors, Dr. Sadreddin is championing
a Parkinson’s disease resource center at the hospital to provide a full range of care
services including educational and support materials, classes, and various activities for
patients and their caregivers.
Dr. Sadreddin began her medical training at Ross University School of Medicine in
Dominica, West Indies, and completed her clinical clerkships at a UCLA-affiliated
hospital. This was followed by residency training in neurology and a fellowship in
movement disorders and deep brain stimulation at the world-renowned Barrow
Neurological Institute/Muhammad Ali Parkinson Center in Phoenix, Arizona.
31
New Advances in ALS Research at California Pacific
Medical Center Research Institute
Focus on the Forbes Norris MDA/ALS Research and Treatment Center
For the 30,000 people in the U.S. with amyotrophic lateral sclerosis (ALS),
progressive neurodegeneration and death of motor neurons causes loss of
control of voluntary muscles and resulting symptoms including muscle
weakness, spasticity, slurred speech and respiratory difficulties. While a cure is
elusive, researchers at CPMCRI are exploring new approaches to treatment, and
pioneering advances that bring improved quality of life for people with ALS.
Robert Miller, M.D.,
Director of the Forbes
Norris MDA/ALS Research
Center
Robert Miller, M.D., Jonathan Katz, M.D., and colleagues at CPMC’s Forbes
Norris MDA/ALS Research and Treatment Center have begun new studies of
approaches to reduce the neuroinflammation suspected to underlie the gradual
progression of ALS.
“We are seeking to understand the mechanisms that selectively trigger motor neurons
to degenerate in ALS, and to find effective approaches that halt the processes leading to
cell death,” says Dr. Miller, Director of the Forbes Norris MDA/ALS Research Center.
Currently, the only FDA-approved drug treatment for ALS (riluzole/Rilutek®) reduces
damage to motor neurons by decreasing the release of glutamate. The drug has
established safety data and prolongs survival in patients by several months.
Ongoing clinical trials led by Dr. Miller and Dr. Katz will assess the efficacy and safety
of a new drug (NP-001) that has shown promise in halting disease progression in a
subset of patients. A separate trial of the drug tirasemtiv is nearing completion. This
drug is a fast skeletal muscle troponin activator, which is helpful in a disease such as
ALS characterized by weakened and wasted muscles.
Other trials led by the ALS team will determine optimal use of non-invasive ventilation
(NIV) machines to ease breathing in patients, and a multicenter, randomized study
of the NeuRX® Diaphragm Pacing System—an approach to support patients with
diaphragm weakness.
32
K E Y I N V E S TIGATOR S AND TE AM ME MB E R S
Later this year, the ALS group will begin collaborating with Cedars-Sinai
Regenerative Medicine Institute on a study funded by the California Institute
for Regenerative Medicine (CIRM). The new project will test the effects of
combined stem cell and gene therapy, along with the protein GDNF (glial
cell-derived neurotrophic factor) to promote the survival of damaged motor
neurons in ALS patients.
Other collaborative initiatives include a project with researchers at the
University of California, San Diego to study mutations in RNA-binding proteins
that cause neuronal dysfunction and death, and several studies of cognition and
behavioral issues in ALS patients.
More About CPMC’s Forbes Norris
MDA/ALS Research and Treatment Center
Jonathan Katz, M.D.,
Director of CPMC’s
Neuromuscular Research
Program and Director of
the ALS Clinic
In recognition of the ALS group’s successes and leadership in the area of motor neuron
disease research, the Forbes Norris Clinic was one of only five centers selected to
present research on quality and outcomes measures at the AAN’s meeting last year.
The research on “Quality improvement in neurology: Quality measures in ALS”
was published in a December 2013 issue of Neurology. Furthermore, the non-profit
organization ALS Worldwide published a book about best practices in the management
of the illness, and highlighted the Forbes Norris Clinic.
33
34
CPMCRI TEAM MEMBERS
CPMCRI’s Grants Administrations Team
35
Lynne Day,
Director of Research Operations
A career spanning more than 20 years in research administration gives
Lynne Day breadth of knowledge and experience unparalleled and
invaluable to CPMCRI.
Day began work with CPMC at its Heart Research Institute, next as
Administrative Manager of the Department of Cardiovascular Surgery,
and then founded the CPMCRI clinical trial operations office that provides
support for physician investigators—and which has been expertly led by
Jamey Schmidt since 2005.
“I have been fortunate to
work with a very strong,
collaborative management
team and a talented group
of basic scientists and
physician investigators at
CPMCRI. A day does not
go by that I don’t learn
something new,” says Day.
“I have been fortunate to work with a very strong, collaborative management team
and a talented group of basic scientists and physician investigators at CPMCRI.
A day does not go by that I don’t learn something new,” says Day, Director of
Research Operations.
Her responsibilities comprise oversight of administration, finance and facilities
for the institute. As well, for the past several years Day has been collaborating
with Sutter’s research institute operations leaders and the system-wide Research,
Development & Dissemination group. Together, they are spearheading initiatives
to integrate processes and provide compliant support that enhances research
opportunities for Sutter’s patients and investigators.
Day adds that “It has always been an honor to work with the investigators and
staff at CPMCRI and Sutter, as we are all dedicated to enhancing the patient
experience.”
Last year through Day’s leadership in collaboration with Scientific Director
Michael Rowbotham, MD, a novel project to advance CPMCRI’s cancer research
was initiated—involving a cross-disciplinary approach and including the institute’s
leading oncology investigators.
36
C P M C R I T E AM ME MBE R S
Jamey Schmidt,
Director of Clinical Research
“It’s all about the patient,” says Jamey Schmidt. “The success of the clinical
research program at CPMC is based on the entire team working together for
the patients we serve. It is that simple.”
Schmidt—who joined the Research Institute in 2002 and has served as its
Director of Clinical Research since 2005—explains that multiple teams at
the hospital and among other Sutter Health affiliates collaborate to ensure
provision of the best clinical trials for CPMC’s patients. Teams of specially
trained staff of clinical research coordinators, supervisors, finance analysts,
lawyers, and compliance and regulatory analysts partner with CPMC’s physicians
toward this common goal.
“As a team, we enjoyed numerous accomplishments resulting in improved care for our
patients,” says Schmidt. In 2014, her group adopted a new clinical trials management
software that efficiently documents the course of clinical trials, as well as patient
enrollment and clinic visits. The entire clinical research team utilizes this database to
ensure billing compliance.
This year, Schmidt’s team also developed pathways to document clinical research
patients in the Sutter Health electronic health record. Working in small groups and led
by the nursing expertise of Supervisor Nata DeVole, R.N., they developed guidance to
inform inpatient and outpatient medical staff when patients are enrolled in a clinical
trial—an important clinical safety measure and one that ensures patients are not
charged for research-associated tests and procedures.
“It’s all about the patient,”
says Jamey Schmidt. “The
success of the clinical
research program at CPMC
is based on the entire team
working together for the
patients we serve. It is that
simple.”
Schmidt commends her team’s work in helping lead development of CPMC’s
gynecological oncology program with surgeon leadership by John Chan, M.D. and
clinical research supervisor Lilian Hu. Collectively, the group enrolled 16 patients in
just six months. “Clinical research is an integral part of the ‘gyn/onc’ program, and
each patient entering the clinic is assessed to determine if a clinical trial is an option
for their care,” she says.
David Minor, M.D.—an oncologist specializing in melanoma who worked tirelessly
with CPMCRI for 20 years on improving the care and drugs available to treat
melanoma until his retirement this year—initiated hundreds of clinical trials including
ones that led to the approval of two new breakthrough immunotherapy drugs. “Our
collaborations with Dr. Minor exemplify the dedication of CPMC’s clinical team,” says
Schmidt. “With only two days to prepare, the oncology team led by Manager Peter
Gasper prepared for the audit. The post-audit review provided CPMCRI with many
opportunities to improve our current process, ensuring we provide even better care for
our melanoma patients.”
37
Joy Becker,
Administrator of Comparative Medicines
“CPMCRI held unique
appeal because of its
smaller size and the
opportunity for closer
proximity to support
researchers,” says Becker.
“Now, more than 15 years
since I joined the Institute,
we have average days
within the animal facility
but it’s more common to
experience twists and turns
not unlike working with
human patients.”
Much of the inner workings and success of the animal care facility at CPMCRI
are credited to the dedicated efforts of Joy Becker, Administrator of Comparative
Medicines.
Having previously worked at UCSF as the Academic Coordinator managing several
research animal facilities city-wide, Becker joined CPMCRI in 1999 and initially
resided at the Pacific Campus Gerbode building. Her leadership and technician
skills, as well as specialized knowledge of disease areas such as oncology, quickly
led to her reputation for professionalism, efficiency, and unique capabilities.
“CPMCRI held unique appeal because of its smaller size and the opportunity for
closer proximity to support researchers,” says Becker. “Now, more than 15 years
since I joined the Institute, we have average days within the animal facility but it’s
more common to experience twists and turns not unlike working with human
patients.”
Becker comments on the highly regulated work and strict adherence to national
guidelines and internal procedures—used to assess the health status of study
animals, review proposed studies before final approval by the Institutional Animal
Care and Use Committee, and liaise with vendors to procure appropriate mice for
each study.
In an average year, 25 studies are supported by Becker and her staff, including
procurement and care of over 1,000 animals.
This year, it was a coup for Becker to help lead recruitment of several
biotechnology companies now working near the animal facility, some of which
have begun collaborations with CPMCRI investigators and that are expected to
broaden the Institute’s research expertise and impact.
38
C P M C R I T E AM ME MBE R S
Martin Wu,
Facilities Manager
Few people have as much history invested in the Research Institute as Martin
Wu, nor as varied responsibilities for its day-to-day maintenance at the
Brannan campus.
After almost 40 years supporting facilities at CPMCRI, Wu is on-call 24/7 and
now oversees all aspects of the laboratory, including support for equipment,
employees, supplies, and telecommunications, and ensuring the lab’s
compliance with regulatory agencies.
“My aim is to help the Institute function effectively, and to provide a safe, efficient
and comfortable working environment for staff,” says Wu.
He also assists with the on-boarding process for new personnel—providing access cards,
setting up phones, computer access and work areas, and training scientists and general
lab staff in facilities safety—and providing audio-visual support for Research Institute
venues before staff meetings and other research-related speaking events.
Wu’s days start early with a complete walkthrough of the Brannan facility to verify
that processes are running safely, effectively and on schedule. His knowledge about
technologies and equipments in the lab is critical for their upkeep and his liaison with
service vendors and staff that maintain the building systems.
In 2014, Wu and his team trained 12 new staff in lab safety, oversaw the
implementation of a new next-generation sequencer, leading-edge microscope and
autostainer, and successfully condensed the lab to allow for shared space with potential
collaborators.
“Overall, I’m greatly satisfied seeing a project through to completion, using my
knowledge and experience to help my customers achieve their objectives,” says Wu.
39
CPMCRI’s Grants Administrations Team
Love
The Grants and Contracts Office at CPMCRI promotes the research mission of CPMC
by providing high-quality financial and administrative services to CPMC’s researchers,
collaborators and staff. Collectively, the grants team processes applications and
proposals for submission to federal, commercial and foundation sponsors .
“We strive to provide timely preparation of all grant and contract applications and
skillful administration of research awards,” says Sarah Love, CPMC’s Grants and
Contracts Director.
Matin
Jackson
In 2014, the ease and efficiency of CPMCRI grants and contracts applications and
proposals were significantly enhanced with division of the grants administration group
into pre- and post-award teams. Pre-award processes, compliance, and subcontracting
are led by Sarah Love and Humaira Matin, pre-award supervisor. The post-award team
is led by Linda Jackson, Director of Research Finance, with Valerie Pascual as postaward supervisor.
“As a team, our office is entrusted with adhering to the rules and regulations of our
funding agencies, and protecting the legal and intellectual interests of our investigators
and the institute,” says Linda Jackson. “We make every effort to deliver clear and
concise information that fosters confidence and trust in our customers.”
Both teams also provide grant support services to the Research, Development &
Dissemination group (led by Sutter Health’s Buzz Stewart, Ph.D., MPH, and Josh
Liberman, Ph.D.), Samuel Merritt University, Sutter Care at Home and Eden Hospital.
Pascual
40
C P M C R I T E AM ME MBE R S
FEATURED STUDIES
Katie Stone, Ph.D.
Senior Scientist, CPMCRI
41
Sutter Health launched its first system-wide
clinical trial for patients with advanced squamous
cell lung cancer
Involvement in National Cancer Institute’s Lung-MAP initiative expected to
provide patients with faster, streamlined access to promising therapies
An unprecedented collaboration among
federal health agencies, pharmaceutical
companies, advocacy groups and cancer
specialists—and involving Sutter Health
as one of only a few study sites in
Northern California—was announced in
September with the launch of the Lung
Cancer Master Protocol (Lung-MAP)
trial.
Lung-MAP will
simultaneously test
five experimental
drugs in patients with
advanced squamous
cell lung cancer.
42
F E AT U R E D S TUDIE S
Lung-MAP will simultaneously test
five experimental drugs, and will enroll
between 500 to 1,000 patients from 200
medical centers nationwide. Patients with
advanced squamous cell lung cancer will
be screened annually for more than 200
cancer-related genes. Trial investigators
will then use the results of these tests to
assign each patient to a study arm best matched to their tumor’s unique genetic profile.
Lung cancer is the leading cancer killer among men and women, and will affect
approximately 225,000 people in the U.S. this year alone. While other cancers such
as breast cancer and melanoma have benefited from earlier advances in targeted or
precision therapies—in essence the ability to match a therapy to the patient’s specific
genetic tumor type—similar approaches have progressed at a slower pace in lung
cancer research. Lung-MAP will attempt to change that, providing the first means to
efficiently study a large number of rare, advanced lung cancer tumor subsets under one
‘parent’ trial protocol.
“This approach to clinical trials is a first for cancer research and a significant
advance in giving more patients faster access to promising therapies,” says
Alan Kramer, M.D., a medical oncologist at CPMC who leads Sutter Health’s
participation in the trial and sits on the South West Oncology Group (SWOG)
Lung Committee overseeing the study. “Through Lung-MAP and via Sutter
Health’s involvement, the entire clinical trial infrastructure will be made more
efficient and reduce recruitment roadblocks for patients and their physicians.”
Sutter Health enrolls hundreds of patients annually in cancer clinical trials, and
has integrated oncology research and studies across its Northern California affiliate
medical centers through the newly formed Sutter Cancer Research Consortium. This
gives patients access to a large, diverse range of treatment options and follow-up
services to support their care plan, and facilitates their entry into National Cancer
Institute (NCI) and industry-sponsored clinical trials.
Alan Kramer, M.D.,
Medical Oncologist,
CPMC
This fall, Sutter opened the trial at 17 sites from Auburn to Santa Cruz, where patients
are being screened for enrollment. “We envision the trial as a paradigm shift in how we
conduct clinical research,” says Dr. Kramer. “It’s of significant benefit to our patients
and our communities to participate in these state-of-the art clinical trials aimed at not
only identifying the genetic mutations driving cancer, but understanding how best to
stratify patients for appropriate, targeted therapies.”
Lung-MAP is the first of several similarly structured trials that will be conducted by
the National Institutes of Health/NCI’s newly formed National Clinical Trials Network.
43
Global database assessing pain trial results shows
significant gaps in reporting of study results
CPMCRI investigators expand the RReACT repository to all international trial
registries, for a broader snapshot of registered analgesic clinical trials and a
scorecard of publicly available results
Results from more than half of clinical trials for common chronic pain disorders
on the world’s registries are not readily available, according to an updated and
thorough analysis. In May, global results from the Repository of Registered
Analgesic Clinical Trials (RReACT) database were published in the journal
PAIN®.
Michael Rowbotham M.D.,
Scientific Director of
CPMCRI
To capture a snapshot of registered clinical trials related to neuropathic
pain and a scorecard of the availability of trial results, Michael Rowbotham,
M.D.—Scientific Director of CPMCRI and lead study author—and colleagues
created RReACT in 2012, a project of the Analgesic Clinical Trial Translations,
Innovations, Opportunities and Networks (ACTTION). This year’s updated survey
includes results from trials of 15 major registries accessible through the World Health
Organization (WHO)’s International Clinical Trials Registry Platform (ICTRP).
“By initiating RReACT, our goal was to enable greater public access to the results of
clinical research,” says Dr. Rowbotham.
Clinical trials conducted in the U.S. are required to be registered on
ClinicalTrials.gov—the world’s largest global registry and a service of the National
Institutes of Health (NIH)—and certain categories of industry-sponsored trial results
must be posted within one year of a study’s completion.
Earlier findings published by Dr. Rowbotham and colleagues included a survey of the
results from postherpetic neuralgia, fibromyalgia, and diabetic peripheral neuropathy
trials registered on ClinicalTrials.gov. In the present study, they analyzed trial
registration, registry functionality, and results reporting on all 15 primary registries
in the ICTRP for these three most frequently studied pain disorders. Trial results
were searched for in the peer-reviewed literature and the ‘grey literature’ (conference
abstracts and/or posters, and press releases), and only unique trials were analyzed.
In the new project, the researchers identified 447 unique trials, 86 (19%) of which were
located on multiple registries. ClinicalTrials.gov contained 82% of all trials analyzed.
Overall, only 46% of all trials had results available, and peer-reviewed publications
could be found for a disappointing 30% of trials.
“Creating a global database of registered trials proved surprisingly difficult for several
reasons,” says Dr. Rowbotham. “Because the ICTRP does not reliably identify trials
listed on multiple registries, manual searches are necessary. Additionally, searching
44
F E AT U R E D S TUDIE S
ICTRP in its entirety yields different
results than searching individual
registries, and outcome measure
descriptions for multiply registered trials
vary across registries.”
According to Dr. Rowbotham, the grey
literature is not peer-reviewed nor
consistently archived or indexed, and is
therefore an unreliable and impermanent
source of findings.
“Analyses and reviews of published evidence need to consider not only the absence
of over half of findings, but also the known problem of publication bias,” notes Dr.
Rowbotham, referring to the phenomenon in which positive results from clinical trials
are more likely to be published, and studies with negative findings (in the researchers’
evaluation) are often published in ways that convey positive outcome.
“There is a significant
public health benefit to
providing a full picture of
“There is a significant public health benefit to providing a full picture of trial results
to patients,” says Dr. Rowbotham. “Many patients enter clinical trials with the belief
that by taking part in research, they will help other patients in the future. For that to
happen, the results of this research must be transparent and fully available.”
trial results to patients,”
The next steps of the research will be to expand the range of painful disorders analyzed,
and update the scorecards.
belief that by taking part
The study was funded by the ACTTION initiative, a public-private partnership
between the FDA, NIH, industry, and academia. The RReACT database is freely
accessible via the ACTTION website (http://www.acttion.org/).
says Dr. Rowbotham.
“Many patients enter
clinical trials with the
in research, they will help
other patients in the future.
Graph above: The Repository of Registered Analgesic Clinical Trials (RReACT)
database: a scorecard for trial results availability. Green bars represent the total
number of completed trials for postherpetic neuralgia (PHN), fibromyalgia, and
diabetic peripheral neuropathy (DPN). Blue bars represent the number of completed
trials with any results available, and orange bars represent the number of studies
for which results were available in a peer-review publication. Percentages displayed
represent the percentage of the total number of completed studies.
45
MrOS study links poor sleep quality
to cognitive decline in older men
Research by Terri Blackwell and Katie Stone, Ph.D., highlights the importance
of sleep quality in preventing cognitive decline in the elderly
Since almost half of older adults report habitual sleep problems, and at least 10 per
cent of people older than 65 years will develop cognitive impairment, investigators at
CPMCRI are seeking new ways to determine prospective associations between sleep
and cognitive decline.
In April, new results published in the journal Sleep showed that higher levels of
fragmented sleep and lower sleep efficiency were associated with a 40 to 50 per cent
increase in the risk of clinically significant decline in cognitive function over three to
four years. Sleep duration, however, was not related to cognitive decline.
Wrist actigraphy is a
‘sleep watch’ device that
measures total sleep time,
sleep efficiency, wake
after sleep onset, etc.
46
F E AT U R E D S TUDIE S
“Our study provides new evidence supporting the importance of sleep quality
in preventing cognitive decline over time, especially in older people,” says
Terri Blackwell, study author and a Senior Statistician at CPMCRI. In the
population-based, longitudinal study, Blackwell and colleagues measured
sleep parameters in 2,822 men free of cognitive impairment aged 67 years and
older who were enrolled in the multicenter Outcomes of Sleep Disorders in
Men (MrOS Sleep) Study.
Objectively measured sleep data including total sleep time, sleep efficiency, wake
after sleep onset, and number of long-wake episodes were collected from study
participants over an average of five nights’ sleep, using wrist actigraphy (a ‘sleep watch’
device).
Katie Stone, Ph.D.
Senior Scientist, CPMCRI
Cognitive function was assessed by evaluation of attention and executive function (i.e.,
abstract thinking, and the ability for decision making) using the Trails B test. Results
were adjusted for depressive symptoms, comorbidities, medication use and other
potential confounding factors.
“The effect of lower levels of sleep quality on cognitive decline seen in our study is
equivalent to the effects of a five-year increase in age,” says Katie Stone, Ph.D., lead
author and a Senior Scientist at CPMCRI. “With this study we’re seeing a reminder
that—as a key factor in a healthy lifestyle—sleep is essential for optimal cognitive
functioning.”
Dr. Stone notes that the findings may not be generalized to other populations other
than community-dwelling older men, and that more research is needed to determine if
these associations hold after longer follow-up.
The study was funded by the National Institutes of Health (NIH) with support for the
MrOS Sleep study from National Heart, Lung, and Blood Institute (NHLBI), as well
as from the National Institute of Arthritis and Musculoskeletal and Skin Diseases
(NIAMS), the National Institute on Aging (NIA), and the National Cancer Institute
(NCI).
47
48
MEDIA ACTIVITY AND EXPOSURE
49
Media Outlet
Date
Topic
San Francisco Chronicle/SF Gate
December 24
NeuroPace and the research of David King-Stephens,
M.D.
Several, including MedPage Today,
Washington Post, Medical Daily,
and Medical News Today
November 5-6
Use of NSAIDS (especially COX-2 inhibitors) and stroke
risk, as published in Nov. 5 Neurology
San Francisco Chronicle/SF Gate
October 28
Lung-MAP Sutter-wide clinical trial
San Francisco Chronicle/SF Gate
October 22
Stroke warning signs
San Francisco Chronicle/SF Gate
(synopsis only; full article in print)
September 18
New funds support Alzheimer’s disease and dementia
research at CPMC’s Brain Health Center
Virtual Strategy Magazine
September 7
Transparency of clinical trial data reporting in migraine
trials
Market Wired
August 25
FDA grants orphan drug status to cannabidiol for the
treatment of glioblastoma multiforme
Time Magazine
August 11
Osteoporosis drugs and the risk of breast cancer in
select groups of patients
San Francisco Chronicle
July 23
Risk of melanoma in Marin County
Pharmaceutical Business Review
July 29
Phase II clinical trial of new agent for the prophylaxis
of delayed graft function in donor kidney transplant
patients
ABC News
July 18
NeuroPace for epilepsy
California Healthline
June 12
PACT consortium launched to promote clinical trial
efficiency
Medical Xpress News
May 14
RReACT database, and transparency of clinical trial
data reporting
San Francisco Chronicle
May 7
New clinical diagnosis: dismobility
News Medical
April 16
New criteria for diagnosing sarcopenia in older adults
Nature World News
April 1
Sleep quality, and cognitive decline in older men
International Innovation
March15
Profiles of international scientists
Anesthesiology News
February 26
Reporting of clinical trial data/transparency of findings
Oncology Report
February 12
Final results validate sentinel-node biopsy for
melanoma
San Francisco Chronicle
February 5
Sleep in the elderly, and risk of falls
Pain Medicine News
January 10
Clinical trial reporting, and the RReACT database
50
M E D I A A C T IV ITY AND E X POSUR E
Spokesperson (where relevant)
Additional Notes
David King-Stephens, M.D.
Morten Schmidt, M.D. (who was mentored by Karin Petersen,
M.D., CPMCRI Clinical Research Fellowship Program Director)
Alan Kramer, M.D.
Appeared on the front page of the Health
section
Nobl Barazangi, M.D.
Catherine Madison, M.D.
Michael Rowbotham, M.D.
Sean McAllister, Ph.D.
Steven Cummings, M.D. (though not quoted in the story
about the paper, he co-authored with Trisha Hue)
Also received other coverage in specialty media
Mohammed Kashani-Sabet, M.D.
V. Ram Peddi, M.D.
Peter Weber, M.D.
Michael Rowbotham, M.D.
Michael Rowbotham, M.D.
Steven Cummings, M.D.
Peggy Cawthon, Ph.D. (though not specifically quoted
in the story)
Also received other coverage in specialty media
Katie Stone, Ph.D.
Also received other coverage in specialty media
Liliana Soroceanu, Ph.D.
Michael Rowbotham, M.D.
Mohammed Kashani-Sabet, M.D.
Katie Stone, Ph.D.
Michael Rowbotham, M.D.
51
FINANCIALS
Revenue Funding Source
Account
Amount ($)
Number of Studies
Philanthropic/Internal
55010432,926
590451,532,529
1,965,455 96
State
55011
188,363 1
Federal
55013
10,387,145 64
Industry
55012
3,058,124 211
Private Foundation/Other Funding
55012
1,124,241 37
Total Science/Research Funding
16,723,328 409
New Studies FY 2014
The new studies are comprised of:
52
FINANCIALS
12
Federal (3 prime, 9 subcontracts)
4
Private Foundation/Non-Profit Org
3
Professional Services Agreements
10
Intramural — Discretionary, Internal Funding, Residuals, Sutter, etc.
43
Industry
72
Scientific Activities of the
California Pacific Medical Center
Research Institute
Compendium of Peer-Reviewed
Publications for Key Program Areas
2014
Peggy Cawthon
(Ph.D., M.P.H.),
Scientist at CPMCRI.
Discovery researchers at
CPMCRI are investigating
changes on the surface of
cancer cells.
Li-Xi Yang (Ph.D., M.D.) and
Garret Yount (Ph.D.),
Scientists at CPMCRI.
www.cpmcri-currents.org
53
NOTE: Journal names listed in orange are high-impact publications recognized by the ISI Web of Knowledge
as having an impact factor higher than 10.
Addiction Pharmacology
Gantt Galloway (Ph.D.), Scientist; Co-Director of the Addiction and Pharmacology Research Laboratory
Publications
Korcha RA, Polcin DL, Evans K, Bond JC, Galloway GP (2014). Intensive Motivational Interviewing for
women with concurrent alcohol problems and methamphetamine dependence. Journal of Substance Abuse
Treatment, 46:113-119.
De La Garza III R, Galloway GP, Newton TF, Mendelson J, Haile CN, Dib E, Hawkins RY, Chen C-YA,
Mahoney III JJ, Mojsiak J, Lao G, Anderson A, Kahn R (2014). Assessment of safety, cardiovascular and
subjective effects after intravenous cocaine and lofexidine. Progress in Neuro-Psychopharmacology and
Biological Psychiatry, 50:44-52.
Kirkpatrick MG, Baggott MJ, Mendelson JE, Galloway GP, Liechti ME, Hysek CM, de Wit H (2014). MDMA
effects consistent across controlled laboratories. Psychopharmacology, 231:3899–3905.
Polcin DL, Bond J, Korcha R, Nayak MB, Galloway GP, Evans K (2014). Randomized trial of Intensive
Motivational Interviewing for methamphetamine dependence. Journal of Addictive Diseases, 33(3):253-265.
Book Chapter
Pal R, Mendelson J, Galloway GP (2014). GHB. In Ries RK, Fiellin DA, Miller SC, Saitz R (eds.): Principles
of Addiction Medicine (5th ed.), pp. 128-129. Chevy Chase, Maryland: The American Society of Addiction
Medicine.
Presentations
Mendelson J, Clavier O, Kynor D, Galloway G. Attitudes, Beliefs, and Barriers to Adopting an Automated
Naloxone Delivery System to Overcome Opioid Overdose: Interviews of Opioid Injectors. Presented as a
poster at the College on Problems of Drug Dependence 76th Annual Meeting, San Juan, Puerto Rico.
Pal R, Galloway G, Clavier O, Garrison K, Mendelson J. Adherence Monitoring for Substance Abuse Clinical
Trials. Presented as a poster at the College on Problems of Drug Dependence 76th Annual Meeting, San
Juan, Puerto Rico.
John Mendelson (M.D.), Senior Scientist; Co-Director of the Addiction and
Pharmacology Research Laboratory
Publication
Pal, R., Mendelson, J., & Galloway, G. P. (2014). GHB. In R. Ries, D. Fiellin, S. Miller, & R. Saitz (Eds.),
Principles of Addiction Medicine (5th ed.). Lippincott Williams & Wilkins.
Book Chapter
R, P., Mendelson, J., Flower, K., Garrison, K., Yount, G., Coyle, J., & Galloway, G. (2015, January 22).
Impact of Prospectively Determined A118G Polymorphism on Treatment Response to Injectable Naltrexone
Among Methamphetamine-Dependent Patients: An Open-Label, Pilot Study. Journal of Addiction Medicine.
Presentations
Mendelson, J., Clavier, O., Kynor, D., & Galloway, G. (2014). Attitudes, Beliefs, and Barriers to Adopting
an Automated Naloxone Delivery System to Overcome Opioid Overdose: Interviews of Opioid Injectors and
Physicians. San Juan, puert Rico: The College on Problems of Drug Dependence.
Pal, R., Galloway, G., Clavier, O., Garrison, K., & Mendelson, J. (2014). Adherence Monitoring For Substance
Abuse Clinical Trials. San Juan, Puerto Rico: The College on Problems of Drug Dependence.
54
C O M P E N D IUM
Cancer
John Chung-Kai Chan (M.D.), Scientist; Gynecologic Oncologist
Publications
Chan JK, Urban R, Capra AM, Jacoby V, Osann K, Whittemore A, Habel LA. Ovarian cancer rates after
hysterectomy with and without salpingo-oophorectomy. Obstet Gynecol. 2014 Jan;123(1):65-72.
Lin JF, Berger JL, Krivak TC, Beriwal S, Chan JK, Sukumvanich P, Monk BJ, Richard SD. Impact of facility
volume on therapy and survival for locally advanced cervical cancer. Gynecol Oncol. 2014 Feb;132(2):416-22.
Chan, JK, Blansit, K., Kiet, T., Sherman, A., Wong, G., Earle, C., Bourguignon, L.Y.W., The inhibition of miR21 promotes apoptosis and chemosensitivity in ovarian cancer. Gynecol Oncol. 2014 Mar;132(3):739-44.
Lefkowits C, W Rabow M, E Sherman A, K Kiet T, Ruskin R, Chan JK, Chen LM. Predictors of high symptom
burden in gynecologic oncology outpatients: who should be referred to outpatient palliative care? Gynecol
Oncol. 2014 Mar;132(3):698-702.
Previs RA, Bevis KS, Huh W, Tillmanns T, Perry L, Moore K, Chapman J, McClung C, Kiet T, Java J, Chan JK,
Secord AA. A prognostic nomogram to predict overall survival in women with recurrent ovarian cancer treated
with bevacizumab and chemotherapy. Gynecol Oncol. 2014 Mar;132(3):531-6.
Chan JK, Kiet TK, Monk BJ, Young-Lin N, Blansit K, Kapp DS, Amanam I. Applications for oncologic drugs: a
descriptive analysis of the oncologic drugs advisory committee reviews. Oncologist. 2014 Mar;19(3):299-304.
Chan JK, Herzog TJ, Hu L, Monk BJ, Kiet T, Blansit K, Kapp DS, Yu X. Bevacizumab in treatment of high-risk
ovarian cancer--a cost-effectiveness analysis. Oncologist. 2014 May;19(5):523-7.
Chan, JK, Kiet, T., Blansit, K., Kapp, D.S., Ramasubbaiah, R., Hilton, J.F., Matei, D.E., MicroRNA 378 as a
Biomarker for Response to Bevacizumab in Recurrent Ovarian Cancer. Gynecol Oncol. 2014 Jun;133(3):568-74.
Simons E, Blansit K, Tsuei T, Brooks R, Ueda S, Kapp DS, Chan JK. Foreign- vs US-born patients and the
association of type I uterine cancer. Am J Obstet Gynecol. 2014 Jul 17.
Usach I, Blansit K, Chen LM, Ueda S, Brooks R, Kapp DS, Chan JK. Survival differences in women with
serous tubal, ovarian, peritoneal, and uterine carcinomas. Am J Obstet Gynecol. 2014 Aug 18.
Grendys EC Jr, Fiorica JV, Orr JW Jr, Holloway R, Wang D, Tian C, Chan JK, Herzog TJ. Overview of a
chemoresponse assay in ovarian cancer. Clin Transl Oncol. 2014 Sep;16(9):761-9.
Fuh KC, Shin JY, Kapp DS, Brooks RA, Ueda S, Urban RR, Chen LM, Chan JK. Survival Differences of Asian
and Caucasian Epithelial Ovarian Cancer Patients in the United States. Gynecol Oncol. 2014 Oct 16.
Thompson CA, Gomez SL, Chan A, Chan JK, McClellan SR, Chung S, Olson C, Nimbal V, Palaniappan
LP. Patient and Provider Characteristics Associated with Colorectal, Breast, and Cervical Cancer Screening
among Asian Americans. Cancer Epidemiol Biomarkers Prev. 2014 Nov;23(11):2208-17.
Plamadeala V, Kelley JL, Chan JK, Krivak TC, Gabrin MJ, Brower SL, Powell MA, Rutherford TJ, Coleman
RL. A cost-effectiveness analysis of a chemoresponse assay for treatment of patients with recurrent epithelial
ovarian cancer. Gynecol Oncol. 2014 Nov 25.
Shanaz Dairkee (Ph.D.), Senior Scientist
Publications
Luciani-Torres MG, Moore DH, Goodson WH 3rd, Dairkee SH. Exposure to the polyester PET precursorterephthalic acid induces and perpetuates DNA damage-harboring non-malignant human breast cells.
Carcinogenesis. 2015 Jan;36(1):168-76.
55
Zhang H, Cohen AL, Krishnakumar S, Wapnir IL, Veeriah S, Deng G, Coram MA, Piskun CM, Longacre TA,
Herrler M, Frimannsson DO, Telli ML, Dirbas FM, Matin AC, Dairkee SH et al. Patient-derived xenografts of
triple-negative breast cancer reproduce molecular features of patient tumors and respond to mTOR inhibition.
Breast Cancer Res. 2014 Apr 7;16(2):R36.
Book Chapter
Dairkee SH. Translational Cellular Models of Breast Cancer Progression and Outcome. In: Linda M. McManus,
Richard N. Mitchell, editors. Pathobiology of Human Disease. San Diego: Elsevier, 2014. p. 952-962.
Altaf Dar (Ph.D.), Associate Scientist
Publications
Sun V, Zhou WB, Nosrati M, Majid S, Thummala S, de Semir D, Bezrookove V, de Feraudy S, Chun L,
Schadendorf D, Debs R, Kashani-Sabet M, Dar AA. Antitumor Activity of miR-1280 in Melanoma by
Regulation of Src. Mol Ther. 2015 Jan;23(1):71-8.
Sun V, Zhou WB, Majid S, Kashani-Sabet M, Dar AA. MicroRNA-mediated regulation of melanoma. Br J
Dermatol. 2014 Aug;171(2):234-41.
Bezrookove V, De Semir D, Nosrati M, Tong S, Wu C, Thummala S, Dar AA, Leong SP, Cleaver JE, Sagebiel
RW, Miller JR 3rd, Kashani-Sabet M. Prognostic impact of PHIP copy number in melanoma: linkage to
ulceration. J Invest Dermatol. 2014 Mar;134(3):783-90.
David De Semir (Ph.D.), Associate Scientist
Publication
Bezrookove V, De Semir D, Nosrati M, Tong S, Wu C, Thummala S, Dar AA, Leong SP, Cleaver JE, Sagebiel
RW, Miller JR 3rd, Kashani-Sabet M. Prognostic impact of PHIP copy number in melanoma: linkage to
ulceration. J Invest Dermatol. 2014 Mar;134(3):783-90.
Pierre-Yves Desprez (Ph.D.), Senior Scientist
Publication
R. Murase, R. Kawamura, E. Singer, A. Pakdel, P. Sarma, J. Judkins, E. Elwakeel, S. Dayal, E. MartinezMartinez, M. Amere, R. Gujjar, A. Mahadevan, PY Desprez, and S.D. McAllister (2014) Targeting multiple
cannabinoid antitumor pathways with a resorcinol derivative leads to inhibition of advanced stages of breast
cancer. Br. J. Pharmacol., 171:4464-4477.
William Goodson (M.D.), Surgeon
Publication
Dairkee SH, Luciani-Torres MG, Moore DH, Goodson WH 3rd. Bisphenol-A-induced inactivation of the p53
axis underlying deregulation of proliferation kinetics, and cell death in non-malignant human breast epithelial
cells. Carcinogenesis. 2013 Mar;34(3):703-12.
Mohammed Kashani-Sabet (M.D.), Senior Scientist; Director of the Center for
Melanoma Treatment and Research; Endowed Chair in Melanoma Treatment and
Research
Publications
Kashani-Sabet M. Molecular markers in melanoma. Br J Dermatol. 170: 31-5, 2014.
Nosrati M, Kashani-Sabet M. Immunohistochemical diagnostic and prognostic markers for melanoma.
Methods Mol Biol. 2014; 1102:259-73.
Sun V, Zhou WB, Majid S, Kashani-Sabet M, Dar AA. MicroRNA-mediated regulation of melanoma. Br J
Dermatol 171: 234-41, 2014.
56
C O M P E N D IUM
Bezrookove V, De Semir D, Nosrati M, Tong S, Wu C, Thummala S, Dar AA, Leong SPL, Cleaver JE, Sagebiel
RW, Miller JR III, Kashani-Sabet M. Prognostic impact of PHIP copy number in melanoma: linkage to
ulceration. J Invest Dermatol. 134: 783-790, 2014.
Morton DL, Thompson JF, Cochran AJ, Mozillo N, Nieweg OE, Roses DF, Hoekstra HJ, Karakousis CP, Puleo
CA, Coventry BJ, Kashani-Sabet M, Smithers BM, Paul E, Kraybill WG, McKinnon JG, Wang J-J, Elashoff
R, Faries MB, for the MSLT group. Final trial report of sentinel-node biopsy versus nodal observation in
melanoma. N Engl J Med. 370: 599-609, 2014.
Sun V, Zhou WB, Nosrati M, Majid S, Thummala S, de Semir D, Bezrookove V, de Feraudy S, Chun L,
Schadendorf D, Debs R, Kashani-Sabet M, Dar AA. Antitumor activity of miR-1280 in melanoma by
regulation of Src. Mol Ther. Epub 2014 Sep 8.
Kevin Kim (M.D.), Medical Director of the Melanoma Clinical Research Program
Publications
Kainthla R, Kim KB, Falchook GS. Dabrafenib for treatment of BRAF-mutant melanoma. Pharmacogenomics
and Personalized Medicine. 7:21-29, 01/2014.
Zhou JH, Kim KB, Fox PS, Myers JN, Hasanein H, Prieto VG. Immunohistochemical expression of hormone
receptors in melanoma of pregnant women, non-pregnant women and men. Am J Dermatol. 36(1):74-9,
01/2014.
Trinh VA, Davis JE, Anderson JE, Kim KB. Dabrafenib therapy for advanced melanoma. Ann Pharmacother.
48(4):519-29, 03/2014.
Curry JL, Torres-Cabala CA, Kim KB, Tetzlaff MT, Duvic M, Tsai K, Hong D, Prieto VG. Dermatologic toxicities
to targeted cancer therapy: shared clinical and histologic adverse skin reactions. Int J Dermatol. 53(3):376-84,
03/2014.
Amaria RN, Kim KB. Dabrafenib for the treatment of melanoma. Expert Opin. Pharmacother. 15(7):10431050, 3/2014.
Kainthla R, Kim KB, Falchook GS. Dabrafenib. Recent Results Cancer Res. 201:227-40, 3/2014.
Curry JL, Tetzlaff MT, Nicholson K, Duvic M, Kim KB, Tsai KY, Hwu WJ, Hong DS, Prieto VG, Torres-Cabala
CA. Histological features associated with vemurafenib-induced skin toxicities: examination of 141 cutaneous
lesions biopsied during therapy. Am J Dermatopathol. 36(7):557-61, 7/2014.
Kim CY, Kim DW, Kim K, Curry J, Torres-Cabala C, Patel S. GNAQ mutation in a patient with metastatic
mucosal melanoma. BMC Cancer 2014, 14(1):516. 07/2014.
Yorio JT, Mays SR, Ciurea AM, Cohen PR, Wang WL, Hwu WJ, Gonzalez N, Richard JL, Kim KB. A case of
vemurafenib-induced Sweet’s syndrome. J Dermatol. 41(9):817-20, 09/2014.
Alrwas A, Papadopoulos NE, Cain S, Patel SP, Kim KB, Deburr TL, Bassett R Jr, Hwu WJ, Bedikian AY,
Davies MA, Woodman SE, Hwu P. Phase I trial of biochemotherapy with cisplatin, temozolomide, and
dose escalation of nab-paclitaxel combined with interleukin-2 and interferon-α in patients with metastatic
melanoma. Melanoma Res. 24(4):342-8, 08/2014.
Kim KB, Alrwas A Treatment of KIT-mutated metastatic mucosal melanoma. Chin Clin Oncol. 3(3):35,
10/2014.
Ott PA, Hamid O, Pavlick AC, Kluger H, Kim KB, Boasberg PD, Simantov R, Crowley E, Green JA,
Hawthorne T, Davis TA, Sznol M, Hwu P. A phase I/II study of the antibody-drug conjugate, glembatumumab
vedotin (CDX-011 or CR011-vcMMAE), in patients with advanced melanoma. J Clin Oncol. 32(32):3659-66,
11/2014.
Falchook GS, Long GV, Kurzrock R, Kim KB, Arkenau HT, Brown MP, Hamid O, Infante JR, Millward MJ,
Pavlick A, Chin M, O’Day S, Blackman SC, Curtis MC Jr, Lebowitz PF, Ma B, Ouellet D, Kefford RF. Dose
Selection, Pharmacokinetics, and Pharmacodynamics of BRAF-inhibitor Dabrafenib (GSK2118436). Clin
Cancer Res. 20(17):4449-58, 09/2014.
57
Johnson D, Flaherty K, Weber J, Infante J, Kim KB, Kefford R, Hamid O, Schuchter L, Cebon J, Sharfman
W, McWilliams R, Sznol M, Lawrence D, Gibney G, Burris H, Falchook G, Algazi A, Lewis K, Long G, Patel K,
Ibrahim N, Sun P, Cunningham E, Sosman J, Daud A, Gonzalez R. Combined BRAF (Dabrafenib) and MEK
Inhibition (Trametinib) in Patients With BRAFV600-Mutant Melanoma Progressing on Single-Agent BRAF
Inhibitor. J Clin Oncol. 32(33):3697-704, 11/2014.
Siroy AE, Boland GM, Milton DR, Roszik J, Frankian S, Malke J, Haydu L, Prieto VG, Tetzlaff M, Ivan D, Wang
WL, Torres-Cabala C, Curry J, Roy-Chowdhuri S, Broaddus R, Rashid A, Stewart J, Gershenwald JE, Amaria
RN, Patel SP, Papadopoulos NE, Bedikian A, Hwu WJ, Hwu P, Diab A, Woodman SE, Aldape KD, Luthra R,
Patel KP, Shaw KR, Mills GB, Mendelsohn J, Meric-Bernstam F, Kim KB, Routbort MJ, Lazar AJ, Davies MA.
Beyond BRAFV600: Clinical Mutation Panel Testing by Next-Generation Sequencing in Advanced Melanoma.
J Invest Dermatol. 135(2):508-15, 02/2015.
Menzies AM, Ashworth MT, Swann S, Kefford RF, Flaherty K, Weber J, Infante JR, Kim KB, Gonzalez R,
Hamid O, Schuchter L, Cebon J, Sosman JA, Little S, Sun P, Aktan G, Ouellet D, Jin F, Long GV, Daud A.
Characteristics of pyrexia in BRAFV600E/K metastatic melanoma patients treated with combined dabrafenib
and trametinib in a phase I/II clinical trial. Ann Oncol. 2015 Feb;26(2):415-21.
Kevin Knopf (M.D.), Medical Oncologist and Hematologist
Publications
Knopf KB, Duh MS, Lafeuille MH, Gravel J, Lefebvre P, Niculescu L, Ba-Mancini A, Ma E, Shi H, Comenzo
RL. Meta-analysis of the efficacy and safety of bortezomib re-treatment in patients with multiple myeloma. Clin
Lymphoma Myeloma Leuk. 2014 Oct;14(5):380-8. Epub 2014 Jun 11.
Nordstrom BL, Knopf KB, Teltsch DY, Engle R, Beygi H, Sterchele JA. The safety of bendamustine in
patients with chronic lymphocytic leukemia or non-Hodgkin lymphoma and concomitant renal impairment: a
retrospective electronic medical record database analysis. Leuk Lymphoma. 2014 Jun;55(6):1266-73. Epub
2013 Oct 3.
Stanley Leong (M.D.), Chief of Cutaneous Oncology; Associate Director of the
Center for Melanoma Research and Treatment
Publications
Miranda EP, Bellevue OC, Leong SP. Reoperative selective sentinel lymphadenectomy combined with
lymphoscintigraphy is technically feasible for cutaneous tumors of the upper extremity after radical dissection
of regional lymph node basins for breast cancer. Eplasty. 2014 Sep 12;14:e32.
Parrett BM, Kashani-Sabet M, Leong SP, Buncke N, Singer MI. The safety of and indications for immediate
reconstruction of head and neck melanoma defects: our early experience. Ann Plast Surg. 2014 May;72 Suppl
1:S35-7.
Balch CM, Thompson JF, Gershenwald JE, Soong SJ, Ding S, McMasters KM, Coit DG, Eggermont AM,
Gimotty PA, Johnson TM, Kirkwood JM, Leong SP, et al. Age as a predictor of sentinel node metastasis
among patients with localized melanoma: an inverse correlation of melanoma mortality and incidence of
sentinel node metastasis among young and old patients. Ann Surg Oncol. 2014 Apr;21(4):1075-81. Epub
2014 Feb 15.
Leong SP, Tseng WW. Micrometastatic cancer cells in lymph nodes, bone marrow, and blood: Clinical
significance and biologic implications. CA Cancer J Clin. 2014 May-Jun;64(3):195-206. Epub 2014 Feb 5.
Review.
Slagelse C, Petersen KL, Dahl JB, Finnerup K, Greene K, Leong SP, Levine J, Rowbotham M, Werner MU,
Finnerup NB. Persistent postoperative pain and sensory changes following lymph node excision in melanoma
patients: a topical review. Melanoma Res. 2014 Apr;24(2):93-8. Review.
Bezrookove V, De Semir D, Nosrati M, Tong S, Wu C, Thummala S, Dar AA, Leong SP, Cleaver JE, Sagebiel
RW, Miller JR 3rd, Kashani-Sabet M. Prognostic impact of PHIP copy number in melanoma: linkage to
ulceration. J Invest Dermatol. 2014 Mar;134(3):783-90. Epub 2013 Sep 4.
58
C O M P E N D IUM
Sean McAllister (Ph.D.), Scientist
Publications
McAllister SD, Soroceanu L, Desprez PY (2014). The antitumor activity of plant-derived non-psychoactive
cannabinoids. Journal of Neuroimmune Pharmacology (invited review).
Murase R, Kawamura R, Singer E, Pakdel A, Sarma P, Judkins J, Elwakeel E, Dayal S, Amere M, Gujjar R,
Mahadevan A, Desprez P and McAllister SD (2014). Targeting multiple cannabinoid antitumor pathways with
a resorcinol derivative leads to inhibition of advanced stages of breast cancer. British Journal of Pharmacology.
(Epub ahead of print)
Cobbs C, Khan S, Matlaf L, McAllister SD, Zider A, Yount G, Rahlin K, Harkins L, Bezrookove V, Singer E,
and Soroceanu L (2014). HCMV glycoprotein B is expressed in primary glioblastomas and enhances growth
and invasiveness via PDGFR-alpha activation. Oncotarget Feb 28;5(4):1091-100.
David Minor (M.D.), Associate Director of the Center for Melanoma Research
and Treatment
Publications
Minor DR, Kashani M: Biochemotherapy with interleukin-2 for metastatic melanoma: long term results in 100
patients. J Clin Onc 32:5s,2014 (suppl; abstr 9047).
Hamid O, Minor DR, Orford KW, et al:Phase 1 study of the BRAF inhibitor dabrafenib (D) with or without the
MEK inhibitor trametinib (T) in combination with ipilimumab (Ipi) for V600E/K mutation positive unresectable or
metastatic melanoma MM) J Clin Onc 32:5s, 2014 (suppl; abstr 2511).
Coventry J, Neuhasu SJ, Minor DR et al: Efficacy of intralesional Rose Bengal in patients receiving injection of
all existing melanoma in phase II study PV-10-MM-02 J Clin Onc 32: 5s, 2014 (suppl: abstr 9027).
Ascierto PA, Minor DR, Singer JM, et al: Long-term safety and overall survival update for BREAK-2, a phase
2, single-arm, open-label study of dabrafenib in previously treated metastatic melanoma (NCT01153763)
J Clin Onc 32:5s, 2014 (suppl: abstr 9034).
Hans R, Andbacka I, Minor DR, et al: Primary analysis of a phase 1b multicenter trial to evaluate the safety
and efficacy of talimogene laherparapvec (T-VEC) and ipilimumab (Ipi) in previously untreated, unresected
stage IIIB-IV melanoma J Clin Onc 32: 5s, 2014(9029).
Liliana Soroceanu (M.D., Ph.D.), Scientist
Publications
Singer E, Judkins J, Salomonis N, Matlaf L, Soteropoulos P, McAllister S, Soroceanu L. Reactive oxygen
species-mediated therapeutic response and resistance in glioblastoma. Cell Death Dis. 2015 Jan 15;6:e1601.
Fiallos E, Judkins J, Matlaf L, Prichard M, Dittmer D, Cobbs C, Soroceanu L. Human cytomegalovirus gene
expression in long-term infected glioma stem cells. PLoS One. 2014 Dec 30;9(12):e116178. doi: 10.1371/
journal.pone.0116178. eCollection 2014.
Cobbs C, Khan S, Matlaf L, McAllister S, Zider A, Yount G, Rahlin K, Harkins L, Bezrookove V, Singer E,
Soroceanu L. HCMV glycoprotein B is expressed in primary glioblastomas and enhances growth and
invasiveness via PDGFR-alpha activation. Oncotarget. 2014 Feb 28;5(4):1091-100.
Presentation
Reactive oxygen species mediate therapeutic response and resistance in glioblastoma. Abstract DR-06.
Presented as a poster at the Society for Neuro-Oncology Annual Meeting, Miami, November 2014.
59
Esther K. Wei (Sc.D.), Scientist
Publications
Austin SB, Pazaris MJ, Wei EK, Rosner B, Kennedy GA, Bowen D, Spiegelman D. Application of the RosnerWei Risk-Prediction Model to Estimate Sexual Orientation Patterns in Colon Cancer Risk in a Prospective
Cohort of U.S. Women. Cancer Causes Control. 2014 Aug;25(8):999-1006.
Holt EW, Wei EK, Bennett N, Zhang LM. Low skin carotenoid concentration measured by resonance
Raman spectroscopy is associated with metabolic syndrome in adults. Nutr Res. 2014 Sep 6. pii: S02715317(14)00168-7.
Presentation
Esther K. Wei, Graham A. Colditz, Edward L. Giovannucci, Kana Wu, Charles S. Fuchs, Meir Stampfer, Walter
Willett, Shuji Ogino, Bernard A. Rosner. A comprehensive model of colorectal cancer by risk factor status and
sub-site using data from the Nurses’ Health Study. Presented at the Society for Epidemiologic Research (SER)
Annual Meeting. June 2014. Seattle, Washington.
Li-Xi Yang (M.D., Ph.D.), Senior Scientist
Publications
Le DL, Cao H and Yang LX. Cardiotoxicity of Molecular Targeted Drug Therapy. Anticancer Research.
34(7):3243-3249, 2014. Anticancer Res. 2014 Jul;34(7):3243-9.
Oliai C and Yang LX. Radioprotectants To Reduce The Risk of Radiation-induced Carcinogenesis.
International Journal of Radiation Biology. 90(3):203-213, 2014. Int J Radiat Biol. 2014 Mar;90(3):203-13. doi:
10.3109/09553002.2014.859762. Epub 2013 Nov 14.
Garret Yount (Ph.D.), Scientist; Director of the Mind-Body Medicine Research Group
Publications
Yount G & Rachlin K. A novel mouthwash protocol for noninvasive genomic analyses. Intl. J. Psychosocial &
Cultural Genomics Consciousness & Health Res. 2014 Oct Issue 1:12-15.
Cobbs C, Khan S, Matlaf L, McAllister S, Zider A, Yount G, Rahlin K, Harkins L, Bezrookove V, Singer
E, Soroceanu L. HCMV glycoprotein B is expressed in primary glioblastomas and enhances growth and
invasiveness via PDGFR-alpha activation. Oncotarget. 2014 Feb 28;5(4):1091-100.
Cardiology
Richard Hongo (M.D.), Cardiac Electrophysiologist, Assistant Director of the
Electrophysiology Laboratory
Publications
Mohanty S, Santangeli P, Mohanty P, Di Biase L, Trivedi C, Bai R, Horton R, Burkhardt JD, Sanchez JE,
Zagrodzky J, Bailey S, Gallinghouse JG, Hranitzky PM, Sun AY, Hongo R, Beheiry S, Natale A. Outcomes
of atrioesophageal fistula following catheter ablation of atrial fibrillation treated with surgical repair versus
esophageal stenting. J Cardiovasc Electrophysiol. 2014 Jun;25(6):579-84.
Mohanty S, Mohanty P, Di Biase L, Bai R, Trivedi C, Santangeli P, Santoro F, Hongo R, Hao S, Beheiry
S, Burkhardt D, Gallinghouse JG, Horton R, Sanchez JE, Bailey S, Hranitzky PM, Zagrodzky J, Natale A.
Long-term outcome of catheter ablation in atrial fibrillation patients with coexistent metabolic syndrome and
obstructive sleep apnea: impact of repeat procedures versus lifestyle changes. J Cardiovasc Electrophysiol.
2014 Sep;25(9):930-8.
Mohanty S, Santangeli P, Mohanty P, Di Biase L, Holcomb S, Trivedi C, Bai R, Burkhardt D, Hongo R, Hao S,
Beheiry S, Santoro F, Forleo G, Gallinghouse JG, Horton R, Sanchez JE, Bailey S, Hranitzky PM, Zagrodzky J,
Natale A. Catheter ablation of asymptomatic longstanding persistent atrial fibrillation: impact on quality of life,
exercise performance, arrhythmia perception, and arrhythmia-free survival. J Cardiovasc Electrophysiol. 2014
Oct;25(10):1057-64.
60
C O M P E N D IUM
Haines DE, Beheiry S, Akar JG, Baker JL, Beinborn D, Beshai JF, Brysiewicz N, Chiu-Man C, Collins KK, Dare
M, Fetterly K, Fisher JD, Hongo R, Irefin S, Lopez J, Miller JM, Perry JC, Slotwiner DJ, Tomassoni GF, Weiss
E. Heart Rythm Society expert consensus statement on electrophysiology laboratory standards: process,
protocols, equipment, personnel, and safety. Heart Rhythm. 2014 Aug;11(8):e9-51.
Di Biase L, Burkhardt JD, Santangeli P, Mohanty P, Sanchez JE, Horton R, Gallinghouse GJ, Themistoclakis
S, Rossillo A, Lakkireddy D, Reddy M, Hao S, Hongo R, Beheiry S, Zagrodzky J, Rong B, Mohanty S,
Elayi CS, Forleo G, Pelargonio G, Narducci ML, Dello Russo A, Casella M, Fassini G, Tondo C, Schweikert
RA, Natale A. Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of
atrial fibrillation with different anticoagulation management: results from the Role of Coumadin in Preventing
Thromboembolism in Atrial Fibrillation (AF) Patients Undergoing Catheter Ablation (COMPARE) randomized
trial. Circulation. 2014 Jun 24;129(25):2638-44.
Bai R, di Biase L, Mohanty P, Santangeli P, Mohanty S, Pump A, Elayi CS, Reddy YM, Forleo GB, Hongo
R, Beheiry S, Dello Russo A, Casella M, Pelargonio G, Santarelli P, Horton R, Sanchez J, Gallinghouse J,
Burkhardt JD, Ma C, Lakkireddy D, Tondo C, Natale A. Catheter ablation of atrial fibrillation in patients with
mechanical mitral valve: long-term outcome of single procedure of pulmonary vein antrum isolation with or
without nonpulmonary vein trigger ablation. J Cardiovasc Electrophysiol. 2014 Aug;25(8):824-33.
Andrea Natale (M.D., FACC), Electrophysiologist
Publications
Santoro F, DI Biase L, Hranitzky P, Sanchez JE, Santangeli P, Perini AP, Burkhardt JD, Natale A. Ventricular
tachycardia originating from the septal papillary muscle of the right ventricle: electrocardiographic and
electrophysiological characteristics. J Cardiovasc Electrophysiol. 2015 Feb;26(2):145-50.
Santangeli P, Di Biase L, Natale A. Ablation versus drugs: what is the best first-line therapy for paroxysmal
atrial fibrillation? Antiarrhythmic drugs are outmoded and catheter ablation should be the first-line option for all
patients with paroxysmal atrial fibrillation: pro. Circ Arrhythm Electrophysiol. 2014 Aug;7(4):739-46.
Price MJ, Gibson DN, Yakubov SJ, Schultz JC, Di Biase L, Natale A, Burkhardt JD, Pershad A, Byrne TJ,
Gidney B, Aragon JR, Goldstein J, Moulton K, Patel T, Knight B, Lin AC, Valderrábano M. Early safety and
efficacy of percutaneous left atrial appendage suture ligation: results from the U.S. transcatheter LAA ligation
consortium. J Am Coll Cardiol. 2014 Aug 12;64(6):565-72.
Mohanty S, Santangeli P, Mohanty P, Di Biase L, Trivedi C, Bai R, Horton R, Burkhardt JD, Sanchez JE,
Zagrodzky J, Bailey S, Gallinghouse JG, Hranitzky PM, Sun AY, Hongo R, Beheiry S, Natale A. Outcomes
of atrioesophageal fistula following catheter ablation of atrial fibrillation treated with surgical repair versus
esophageal stenting. J Cardiovasc Electrophysiol. 2014 Jun;25(6):579-84.
Di Monaco A, Pelargonio G, Narducci ML, Manzoli L, Boccia S, Flacco ME, Capasso L, Barone L, Perna F,
Bencardino G, Rio T, Leo M, Di Biase L, Santangeli P, Natale A, Rebuzzi AG, Crea F. Safety of transvenous
lead extraction according to centre volume: a systematic review and meta-analysis. Europace. 2014
Oct;16(10):1496-507.
Santoro F, Di Biase L, Hranitzky P, Sanchez JE, Santangeli P, Perini AP, Burkhardt JD, Natale A. Ventricular
fibrillation triggered by PVCs from papillary muscles: clinical features and ablation. J Cardiovasc Electrophysiol.
2014 Nov;25(11):1158-64.
Mohanty S, Mohanty P, Di Biase L, Bai R, Trivedi C, Santangeli P, Santoro F, Hongo R, Hao S, Beheiry S,
Burkhardt D, Gallinghouse JG, Horton R, Sanchez JE, Bailey S, Hranitzky PM, Zagrodzky J, Natale A.
Long-term outcome of catheter ablation in atrial fibrillation patients with coexistent metabolic syndrome and
obstructive sleep apnea: impact of repeat procedures versus lifestyle changes. J Cardiovasc Electrophysiol.
2014 Sep;25(9):930-8.
Mohanty S, Santangeli P, Mohanty P, Di Biase L, Holcomb S, Trivedi C, Bai R, Burkhardt D, Hongo R, Hao S,
Beheiry S, Santoro F, Forleo G, Gallinghouse JG, Horton R, Sanchez JE, Bailey S, Hranitzky PM, Zagrodzky J,
Natale A. Catheter ablation of asymptomatic longstanding persistent atrial fibrillation: impact on quality of life,
exercise performance, arrhythmia perception, and arrhythmia-free survival. J Cardiovasc Electrophysiol. 2014
Oct;25(10):1057-64.
61
Pillarisetti J, Reddy N, Biria M, Ryschon K, Nagarajan D, Murray C, Atkins D, Bommana S, Reddy MY,
DiBiase L, Pimentel R, Berenbom L, Dawn B, Natale A, Lakkireddy D. Elevated brain natriuretic peptide level
in patients undergoing atrial fibrillation ablation: is it a predictor of failed ablation or a mere function of atrial
rhythm and rate at a point in time? J Interv Card Electrophysiol. 2014 Aug;40(2):161-8.
Di Biase L, Burkhardt JD, Santangeli P, Mohanty P, Sanchez JE, Horton R, Gallinghouse GJ, Themistoclakis
S, Rossillo A, Lakkireddy D, Reddy M, Hao S, Hongo R, Beheiry S, Zagrodzky J, Rong B, Mohanty S, Elayi
CS, Forleo G, Pelargonio G, Narducci ML, Dello Russo A, Casella M, Fassini G, Tondo C, Schweikert RA,
Natale A. Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of
atrial fibrillation with different anticoagulation management: results from the Role of Coumadin in Preventing
Thromboembolism in Atrial Fibrillation (AF) Patients Undergoing Catheter Ablation (COMPARE) randomized
trial. Circulation. 2014 Jun 24;129(25):2638-44.
Lakkireddy D, Kanmanthareddy A, Biria M, Madhu Reddy Y, Pillarisetti J, Mahapatra S, Berenbom L, Chinitz
L, Atkins D, Bommana S, Tung R, DI Biase L, Shivkumar K, Natale A. Radiofrequency ablation of drug
refractory ventricular tachycardia related to cocaine use: a feasibility, safety, and efficacy study. J Cardiovasc
Electrophysiol. 2014 Jul;25(7):739-46.
Bai R, di Biase L, Mohanty P, Santangeli P, Mohanty S, Pump A, Elayi CS, Reddy YM, Forleo GB, Hongo
R, Beheiry S, Dello Russo A, Casella M, Pelargonio G, Santarelli P, Horton R, Sanchez J, Gallinghouse J,
Burkhardt JD, Ma C, Lakkireddy D, Tondo C, Natale A. Catheter ablation of atrial fibrillation in patients with
mechanical mitral valve: long-term outcome of single procedure of pulmonary vein antrum isolation with or
without nonpulmonary vein trigger ablation. J Cardiovasc Electrophysiol. 2014 Aug;25(8):824-33.
Dello Russo A, Fassini G, Casella M, Bologna F, Al-Nono O, Colombo D, Biagioli V, Santangeli P, Di Biase L,
Zucchetti M, Majocchi B, Marino V, Gallinghouse JJ, Natale A, Tondo C. Simultaneous assessment of contact
pressure and local electrical coupling index using robotic navigation. J Interv Card Electrophysiol. 2014
Jun;40(1):23-31.
Di Biase L, Gaita F, Toso E, Santangeli P, Mohanty P, Rutledge N, Yan X, Mohanty S, Trivedi C, Bai R, Price J,
Horton R, Gallinghouse GJ, Beheiry S, Zagrodzky J, Canby R, Leclercq JF, Halimi F, Scaglione M, Cesarani
F, Faletti R, Sanchez J, Burkhardt JD, Natale A. Does periprocedural anticoagulation management of atrial
fibrillation affect the prevalence of silent thromboembolic lesion detected by diffusion cerebral magnetic
resonance imaging in patients undergoing radiofrequency atrial fibrillation ablation with open irrigated
catheters? Results from a prospective multicenter study. Heart Rhythm. 2014 May;11(5):791-8.
Reddy YM, Chinitz L, Mansour M, Bunch TJ, Mahapatra S, Swarup V, Di Biase L, Bommana S, Atkins D, Tung
R, Shivkumar K, Burkhardt JD, Ruskin J, Natale A, Lakkireddy D. Percutaneous left ventricular assist devices
in ventricular tachycardia ablation: multicenter experience. Circ Arrhythm Electrophysiol. 2014 Apr;7(2):244-50.
Michowitz Y, Rahkovich M, Oral H, Zado ES, Tilz R, John S, Denis A, Di Biase L, Winkle RA, Mikhaylov EN,
Ruskin JN, Yao Y, Josephson ME, Tanner H, Miller JM, Champagne J, Della Bella P, Kumagai K, Defaye
P, Luria D, Lebedev DS, Natale A, Jais P, Hindricks G, Kuck KH, Marchlinski FE, Morady F, Belhassen
B. Effects of sex on the incidence of cardiac tamponade after catheter ablation of atrial fibrillation: results
from a worldwide survey in 34 943 atrial fibrillation ablation procedures. Circ Arrhythm Electrophysiol. 2014
Apr;7(2):274-80.
Altman RK, Proietti R, Barrett CD, Paoletti Perini A, Santangeli P, Danik SB, Di Biase L, Natale A.
Management of refractory atrial fibrillation post surgical ablation. Ann Cardiothorac Surg. 2014 Jan;3(1):91-7.
Giglio AF, Basile E, Santangeli P, Di Biase L, Trotta F, Natale A. Increased risk of myocardial infarction with
dabigatran: fact or fiction? J Cardiovasc Med (Hagerstown). 2014 Jan;15(1):19-26.
Lakkireddy D, Reddy YM, Di Biase L, Vallakati A, Mansour MC, Santangeli P, Gangireddy S, Swarup V,
Chalhoub F, Atkins D, Bommana S, Verma A, Sanchez JE, Burkhardt JD, Barrett CD, Baheiry S, Ruskin J,
Reddy V, Natale A. Feasibility and safety of uninterrupted rivaroxaban for periprocedural anticoagulation in
patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry.
J Am Coll Cardiol. 2014 Mar 18;63(10):982-8.
Proietti R, Santangeli P, Di Biase L, Joza J, Bernier ML, Wang Y, Sagone A, Viecca M, Essebag V, Natale A.
Comparative effectiveness of wide antral versus ostial pulmonary vein isolation: a systematic review and metaanalysis. Circ Arrhythm Electrophysiol. 2014 Feb;7(1):39-45.
62
C O M P E N D IUM
Whitbeck MG, Charnigo RJ, Shah J, Morales G, Leung SW, Fornwalt B, Bailey AL, Ziada K, Sorrell VL,
Zegarra MM, Thompson J, Hosn NA, Campbell CL, Gurley J, Anaya P, Booth DC, Di Biase L, Natale A,
Smyth S, Moliterno DJ, Elayi CS; AFFIRM investigators. QRS duration predicts death and hospitalization
among patients with atrial fibrillation irrespective of heart failure: evidence from the AFFIRM study. Europace.
2014 Jun;16(6):803-11.
Richard Shaw (Ph.D.), Director of Clinical Informatics and Reporting; Research Director
of the Cardiology Fellowship Training Program
Publications
Grau JB, Johnson CK, Kuschner CE, Ferrari G, Shaw RE, Brizzio ME, Zapolanski A. Impact of pump status
and conduit choice in coronary artery bypass: A 15-year follow-up study in 1412 propensity-matched patients.
J Thorac Cardiovasc Surg. 2014 Dec 20.
Branchetti E, Bavaria JE, Grau JB, Shaw RE, Poggio P, Lai EK, Desai ND, Gorman JH, Gorman RC, Ferrari
G. Circulating soluble receptor for advanced glycation end product identifies patients with bicuspid aortic valve
and associated aortopathies. Arterioscler Thromb Vasc Biol. 2014 Oct;34(10):2349-57.
Holt EW, Yimam KK, Ma H, Shaw RE, Sundberg RA, Verhille MS. Patient tolerability of bowel preparation is
associated with polyp detection rate during colonoscopy. J Gastrointestin Liver Dis. 2014 Jun;23(2):135-40.
Ferrari G, Quackenbush J, Strobeck J, Hu L, Johnson CK, Mak A, Shaw RE, Sayles K, Brizzio ME,
Zapolanski A, Grau JB. Comparative genome-wide transcriptional analysis of human left and right internal
mammary arteries. Genomics. 2014 Jul;104(1):36-44.
Steinberg JS, Romanov A, Musat D, Preminger M, Bayramova S, Artyomenko S, Shabanov V, Losik D,
Karaskov A, Shaw RE, Pokushalov E. Prophylactic pulmonary vein isolation during isthmus ablation for atrial
flutter: the PReVENT AF Study I. Heart Rhythm. 2014 Sep;11(9):1567-72.
Arshad A, Johnson CK, Mittal S, Buch E, Hamam I, Tran T, Shaw RE, Musat D, Preminger M, Sichrovsky
T, Herweg B, Shivkumar K, Hummel J, Steinberg JS. Comparative safety of periablation anticoagulation
strategies for atrial fibrillation: data from a large multicenter study. Pacing Clin Electrophysiol. 2014
Jun;37(6):665-73.
Edwards FH, Shahian DM, Grau-Sepulveda MV, Grover FL, Mayer JE, O’Brien SM, DeLong E, Peterson
ED, McKay C, Shaw RE, Garratt KN, Dangas GD, Messenger J, Klein LW, Popma JJ, Weintraub WS.
Composite outcomes in coronary bypass surgery versus percutaneous intervention. Ann Thorac Surg. 2014
Jun;97(6):1983-8; discussion 1988-90.
Park LG, Mahar D, Shaw RE, Dracup K. The impact of a heart failure educational program for physicians
varies based upon physician specialty. J Clin Med Res. 2014 Jun;6(3):173-83.
Weilert F, Bhat YM, Binmoeller KF, Kane S, Jaffee IM, Shaw RE, Cameron R, Hashimoto Y, Shah JN. EUSFNA is superior to ERCP-based tissue sampling in suspected malignant biliary obstruction: results of a
prospective, single-blind, comparative study. Gastrointest Endosc. 2014 Jul;80(1):97-104.
Steinberg JS, Palekar R, Sichrovsky T, Arshad A, Preminger M, Musat D, Shaw RE, Mittal S. Very long-term
outcome after initially successful catheter ablation of atrial fibrillation. Heart Rhythm. 2014 May;11(5):771-6.
Ren X, Banki NM, Shaw RE, McNulty EJ, Williams SC, Pencina M, Schiller NB. Doppler-detected valve
movement in aortic stenosis: a predictor of adverse outcome. Clin Cardiol. 2014 Mar;37(3):167-71.
Mittal S, Shaw RE, Michel K, Palekar R, Arshad A, Musat D, Preminger M, Sichrovsky T, Steinberg JS.
Cardiac implantable electronic device infections: incidence, risk factors, and the effect of the AigisRx
antibacterial envelope. Heart Rhythm. 2014 Apr;11(4):595-601.
Shaw RE, Johnson CK, Ferrari G, Brizzio ME, Sayles K, Rioux N, Zapolanski A, Grau JB. Blood transfusion
in cardiac surgery does increase the risk of 5-year mortality: results from a contemporary series of 1714
propensity-matched patients. Transfusion. 2014 Apr;54(4):1106-13.
63
Gastrointestinal Disorders
Yasser Bhat (M.D.), Medical Director of Esophageal Imaging and Therapy
Publications
Bhat YM, Kane SD, Shah JN, Hamerski CM, Binmoeller KF. Single-session circumferential EMR and metal
stent placement for the treatment of long-segment Barrett’s esophagus with high-grade intraepithelial
neoplasia. Gastrointest Endosc. 2014 Aug;80(2):331.
Weilert F, Bhat YM, Binmoeller KF, Kane S, Jaffee IM, Shaw RE, Cameron R, Hashimoto Y, Shah JN. EUSFNA is superior to ERCP-based tissue sampling in suspected malignant biliary obstruction: results of a
prospective, single-blind, comparative study. Gastrointest Endosc. 2014 Jul;80(1):97-104.
Binmoeller KF, Shah JN, Bhat YM, Kane SD. Suck-ligate-unroof-biopsy by using a detachable 20-mm
loop for the diagnosis and therapy of small subepithelial tumors (with video). Gastrointest Endosc. 2014
May;79(5):750-5.
Bhat YM. Tissue adhesives for endoscopic use. Gastroenterol Hepatol (N Y). 4014 Apr;10(4):251-3.
Vohra S, Holt EW, Bhat YM, Kane S, Shah JN, Binmoeller KF. Successful single-session endosonographybased endoscopic retrograde cholangiopancreatography without fluoroscopy in pregnant patients with
suspected choledocholithiasis: a case series. J Hepatobiliary Pancreat Sci. 2014 Feb;21(2):93-7.
Oral Presentation
Nett AS, Shah JN, Binmoeller K, Kane SD, Hamerski CM, Bhat YM. Comparison of ERCP Versus EUSGuided Biliary Interventions in Patients with Surgically altered anatomy. Digestive Disease Week, 2014.
Chicago, IL.
Posters
Lee A, Bhat YM, Binmoeller K, Cello JP, Day LW, Hamerski CM, Kane SD, Shah JN. EUS-Guided
Interventions Decrease the Rate of Therapeutic Biliary ERCP Failures: Comparison of ERCP Outcomes at
Centers with and without Interventional EUS. Digestive Disease Week, 2014. Chicago, IL.
Shah JN, Bhat YM, Hamerski C, Kane SD, Binmoeller KF. Feasibility of EUS-directed biliary stone removal
without fluoroscopy in patients with uncomplicated choledocholithiasis. Digestive Disease Week, 2014.
Chicago, IL.
Hamerski C, Binmoeller KF, Shah JN, Bhat YM, Kane SD. Underwater Endoscopic Mucosal Resection (UEMR)
without submucosal injection of polyps with prior resection attempts. Digestive Disease Week, 2014. Chicago, IL.
Kenneth Binmoeller (M.D.), Interventional Endoscopy Program Director
Publications
Weilert F, Binmoeller KF. Gastroenterol Clin North Am. 2014 Dec;43(4):807-18
Bhat YM, Kane SD, Shah JN, Hamerski CM, Binmoeller KF. Single-session circumferential EMR and
metal stent placement for the treatment of long-segment Barrett’s esophagus with high-grade intraepithelial
neoplasia. Gastrointest Endosc. 2014 Aug;80(2):331.
Weilert F, Bhat YM, Binmoeller KF, Kane S, Jaffee IM, Shaw RE, Cameron R, Hashimoto Y, Shah JN.
EUS-FNA is superior to ERCP-based tissue sampling in suspected malignant biliary obstruction: results of a
prospective, single-blind, comparative study. Gastrointest Endosc. 2014 Jul;80(1):97-104.
Binmoeller KF, Shah JN, Bhat YM, Kane SD. Suck-ligate-unroof-biopsy by using a detachable 20-mm
loop for the diagnosis and therapy of small subepithelial tumors (with video). Gastrointest Endosc. 2014
May;79(5):750-5.
Vohra S, Holt EW, Bhat YM, Kane S, Shah JN, Binmoeller KF. Successful single-session endosonographybased endoscopic retrograde cholangiopancreatography without fluoroscopy in pregnant patients with
suspected choledocholithiasis: a case series. J Hepatobiliary Pancreat Sci. 2014 Feb;21(2):93-7.
64
C O M P E N D IUM
Oral Presentation
Nett AS, Shah JN, Binmoeller K, Kane SD, Hamerski CM, Bhat YM. Comparison of ERCP Versus EUSGuided Biliary Interventions in Patients with Surgically altered anatomy. Digestive Disease Week, 2014.
Chicago, IL.
Posters
Lee A, Bhat YM, Binmoeller K, Cello JP, Day LW, Hamerski CM, Kane SD, Shah JN. EUS-Guided
Interventions Decrease the Rate of Therapeutic Biliary ERCP Failures: Comparison of ERCP Outcomes at
Centers with and without Interventional EUS. Digestive Disease Week, 2014. Chicago, IL.
Shah JN, Bhat YM, Hamerski C, Kane SD, Binmoeller KF. Feasibility of EUS-directed biliary stone removal
without fluoroscopy in patients with uncomplicated choledocholithiasis. Digestive Disease Week, 2014.
Chicago, IL.
Hamerski C, Binmoeller KF, Shah JN, Bhat YM, Kane SD. Underwater Endoscopic Mucosal Resection
(UEMR) without submucosal injection of polyps with prior resection attempts. Digestive Disease Week, 2014.
Chicago, IL.
Janak Shah (M.D.), Director of Pancreatic and Biliary Endoscopy
Publications
Bhat YM, Kane SD, Shah JN, Hamerski CM, Binmoeller KF. Single-session circumferential EMR and metal
stent placement for the treatment of long-segment Barrett’s esophagus with high-grade intraepithelial
neoplasia. Gastrointest Endosc. 2014 Aug;80(2):331.
Weilert F, Bhat YM, Binmoeller KF, Kane S, Jaffee IM, Shaw RE, Cameron R, Hashimoto Y, Shah JN. EUSFNA is superior to ERCP-based tissue sampling in suspected malignant biliary obstruction: results of a
prospective, single-blind, comparative study. Gastrointest Endosc. 2014 Jul;80(1):97-104.
Binmoeller KF, Shah JN, Bhat YM, Kane SD. Suck-ligate-unroof-biopsy by using a detachable 20-mm
loop for the diagnosis and therapy of small subepithelial tumors (with video). Gastrointest Endosc. 2014
May;79(5):750-5.
Vohra S, Holt EW, Bhat YM, Kane S, Shah JN, Binmoeller KF. Successful single-session endosonographybased endoscopic retrograde cholangiopancreatography without fluoroscopy in pregnant patients with
suspected choledocholithiasis: a case series. J Hepatobiliary Pancreat Sci. 2014 Feb;21(2):93-7.
Oral Presentation
Nett AS, Shah JN, Binmoeller K, Kane SD, Hamerski CM, Bhat YM. Comparison of ERCP Versus EUSGuided Biliary Interventions in Patients with Surgically altered anatomy. Digestive Disease Week, 2014.
Chicago, IL.
Posters
Lee A, Bhat YM, Binmoeller K, Cello JP, Day LW, Hamerski CM, Kane SD, Shah JN. EUS-Guided
Interventions Decrease the Rate of Therapeutic Biliary ERCP Failures: Comparison of ERCP Outcomes at
Centers with and without Interventional EUS. Digestive Disease Week, 2014. Chicago, IL.
Shah JN, Bhat YM, Hamerski C, Kane SD, Binmoeller KF. Feasibility of EUS-directed biliary stone removal
without fluoroscopy in patients with uncomplicated choledocholithiasis. Digestive Disease Week, 2014.
Chicago, IL.
Hamerski C, Binmoeller KF, Shah JN, Bhat YM, Kane SD. Underwater Endoscopic Mucosal Resection
(UEMR) without submucosal injection of polyps with prior resection attempts. Digestive Disease Week, 2014.
Chicago, IL.
65
William Snape (M.D.), Medical Director of the Center for Neurogastroenterology and
Motility Services
Publication
Bernard CE, Gibbons SJ, Mann IS, Froschauer L, Parkman HP, Harbison S, Abell TL, Snape WJ, Hasler
WL, McCallum RW, Sarosiek I, Nguyen LA, Koch KL, Tonascia J, Hamilton FA, Kendrick ML, Shen KR,
Pasricha PJ, Farrugia G; NIDDK Gastroparesis Clinical Research Consortium (GpCRC). Association of low
numbers of CD206-positive cells with loss of ICC in the gastric body of patients with diabetic gastroparesis.
Neurogastroenterol Motil. 2014 Sep;26(9):1275-84.
Abstracts
Kedar A, Abell TL, Bernard CR, Farrugia G, Lahr CJ, Hasler WL, et al. Intra-Operative Electrophysiological and
Interstitial Cell of Cajal Findings in Patients With the Symptoms of Gastroparesis. Digestive Diseases Week
2014:Washington, DC May 2014. Gastroenterology 2014; 146(5 Suppl): S609.
Pasricha PJ, Yates KP, Clarke JO, Unalp A, Tonascia J, Koch KL, et al. Morbidity, Mortality and Predictors
of Improvement in Patients With Gastroparesis: 4-Year Outcomes From the Gastroparesis Clinical Research
Consortium. Digestive Diseases Week 2014:Washington, DC May 2014. Gastroenterology 2014; 146(5
Suppl): S136.
Hasler WL, Belt P, Wilson L, McCallum RW, Parkman HP, Koch KL, et al. Correlation of Fermentable
Carbohydrate Consumption With Symptoms and Quality of Life in Patients With Diabetic and Idiopathic
Gastroparesis. Digestive Diseases Week 2014:Washington, DC May 2014. Gastroenterology 2014; 146(5
Suppl): S610.
Koch KL Hasler WL, Parkman HP, VanNatta ML, Abell TL, McCallum RW, et al. Correlations of Liquid Nutrient
Meal-Induced Symptpoms With Satiety Test Volumes in Idiopathic Gastroparesis: Relation to Gastric Emptying
and Myoelectric Activity. Digestive Diseases Week 2014:Washington, DC May 2014. Gastroenterology
2014; 146(5 Suppl): S608.
Calles-Escandon J, Hasler WL, Koch KL, VanNatta ML, Vaughn IA, Parkman HP, et al. Continuous Blood
Glucose Patterns in Diabetic Patients With Gastroparesis: Baseline Findings From the GPCRC GLUMIT-DG
Study. Digestive Diseases Week 2014:Washington, DC May 2014. Gastroenterology 2014; 146(5 Suppl):
S616.
Snape W, Lin, M., Shaw, R The importance of the pylorus in patients with gastroparesis evaluated by
concurrent intraluminal pressure and EndoFLIP Abstracts of the 1st Federation Neurogastroenterology and
Motility Scientific Meeting, September 5-7, 2014, Guangzhou, China NEUROGASTROENTEROL MOTIL 2014,
26, SUPPLEMENT 1, pages 1–88.
Liver Diseases
Lia Avanesyan (Ph.D.), Associate Scientist
Publication
Crane CA, Austgen K, Haberthur K, Hofmann C, Moyes KW, Avanesyan L, Fong L, Campbell MJ, Cooper
S, Oakes SA, Parsa AT, Lanier LL. Immune evasion mediated by tumor-derived lactate dehydrogenase
induction of NKG2D ligands on myeloid cells in glioblastoma patients. Proc Natl Acad Sci U S A. 2014 Sep
2;111(35):12823-8.
Maurizio Bonacini (M.D.), Transplant Hepatologist at the Hepatology and
Gastroenterology Research Center
Presentation
Edward J. Gane, Richard A. Robson, Maurizio Bonacini, Benedict Maliakkal, Brian Kirby, Lin Liu, Karim
Sajwani,Luisa M. Stamm, Diana M. Brainard, John G. McHutchison, Catherine A. Stedman, Eric Lawitz.
Safety, Antiviral Efficacy, and Pharmacokinetics of Sofosbuvir in Patients With Severe Renal Impairment.
Prsented at the 2014 AASLD Meeting.
66
C O M P E N D IUM
Stewart Cooper (M.D.), Senior Scientist; Chief, Division of Hepatology;
Director of Research & Kalmanovitz Liver Immunology Laboratory
Publications
Rachakonda V, Gabbert C, Raina A, Bell LN, Cooper S, Malik S, Behari J. Serum metabolomic profiling in
acute alcoholic hepatitis identifies multiple dysregulated pathways. PLoS One. 2014 Dec 2;9(12):e113860.
eCollection 2014.
Crane CA, Austgen K, Haberthur K, Hofmann C, Moyes KW, Avanesyan L, Fong L, Campbell MJ, Cooper
S, Oakes SA, Parsa AT, Lanier LL. Immune evasion mediated by tumor-derived lactate dehydrogenase
induction of NKG2D ligands on myeloid cells in glioblastoma patients. Proc Natl Acad Sci U S A. 2014 Sep
2;111(35):12823-8. Epub 2014 Aug 18.
Ghany MG, Perrillo R, Li R, Belle SH, Janssen HL, Terrault NA, Shuhart MC, Lau DT, Kim WR, Fried MW,
Sterling RK, Di Bisceglie AM, Han SH, Ganova-Raeva LM, Chang KM, Lok AS; Hepatitis B Research Network.
Characteristics of adults in the hepatitis B research network in North America reflect their country of origin and
hepatitis B virus genotype. Clin Gastroenterol Hepatol. 2015 Jan;13(1):183-92.
Timothy Davern (M.D.), Gastroenterologist/Hepatologist; Director of the Acute Liver
Failure Program
Publications
Holt EW, DeMartini S, Davern T. Acute Liver Failure Due to Acetaminophen Poisoning in Patients With Prior
Weight Loss Surgery: A Case Series. J Clin Gastroenterol. 2014 Dec 30.
Navarro VJ, Barnhart H, Bonkovsky HL, Davern T, Fontana RJ, Grant L, Reddy KR, Seeff LB, Serrano J,
Sherker AH, Stolz A, Talwalkar J, Vega M, Vuppalanchi R. Liver injury from herbals and dietary supplements in
the U.S. Drug-Induced Liver Injury Network. Hepatology. 2014 Oct;60(4):1399-408.
Long D, Fix OK, Deng X, Seielstad M, Lauring AS; Acute Liver Failure Study Group. Whole genome
sequencing to identify host genetic risk factors for severe outcomes of hepatitis a virus infection. J Med Virol.
2014 Oct;86(10):1661-8.
Dubin PH, Yuan H, Devine RK, Hynan LS, Jain MK, Lee WM; Acute Liver Failure Study Group. Micro-RNA-122
levels in acute liver failure and chronic hepatitis C. J Med Virol. 2014 Sep;86(9):1507-14.
Fontana RJ, Hayashi PH, Gu J, Reddy KR, Barnhart H, Watkins PB, Serrano J, Lee WM, Chalasani N, Stolz A,
Davern T, Talwakar JA; DILIN Network. Idiosyncratic drug-induced liver injury is associated with substantial
morbidity and mortality within 6 months from onset. Gastroenterology. 2014 Jul;147(1):96-108.e4.
Karvellas CJ, Cavazos J, Battenhouse H, Durkalski V, Balko J, Sanders C, Lee WM; US Acute Liver Failure
Study Group. Effects of antimicrobial prophylaxis and blood stream infections in patients with acute liver
failure: a retrospective cohort study. Clin Gastroenterol Hepatol. 2014 Nov;12(11):1942-9.e1.
Karvellas CJ, Fix OK, Battenhouse H, Durkalski V, Sanders C, Lee WM; US Acute Liver Failure Study Group.
Outcomes and complications of intracranial pressure monitoring in acute liver failure: a retrospective cohort
study. Crit Care Med. 2014 May;42(5):1157-67.
Court MH, Peter I, Hazarika S, Vasiadi M, Greenblatt DJ, Lee WM; Acute Liver Failure Study Group. Candidate
gene polymorphisms in patients with acetaminophen-induced acute liver failure. Drug Metab Dispos. 2014
Jan;42(1):28-32.
Kleiner DE, Chalasani NP, Lee WM, Fontana RJ, Bonkovsky HL, Watkins PB, Hayashi PH, Davern T, Navarro
V, Reddy R, Talwalkar JA, Stolz A, Gu J, Barnhart H, Hoofnagle JH; Drug-Induced Liver Injury Network
(DILIN). Hepatic histological findings in suspected drug-induced liver injury: systematic evaluation and clinical
associations. Hepatology. 2014 Feb;59(2):661-70.
Karkhanis J, Verna EC, Chang MS, Stravitz RT, Schilsky M, Lee WM, Brown RS Jr; Acute Liver Failure Study
Group. Steroid use in acute liver failure. Hepatology. 2014 Feb;59(2):612-21.
Metushi IG, Sanders C; Acute Liver Study Group, Lee WM, Uetrecht J. Detection of anti-isoniazid and anticytochrome P450 antibodies in patients with isoniazid-induced liver failure. Hepatology. 2014 Mar;59(3):1084-93.
67
Todd Frederick (M.D.), Director of Clinical Protocol Development and Liver Support
Services at CPMC; Director of the Transplant Hepatology Fellowship Program
Publications
Mullen KD, Sanyal AJ, Bass NM, Poordad FF, Sheikh MY, Frederick RT, Bortey E, Forbes WP. Rifaximin is
Safe and Well Tolerated for Long-Term Maintenance of Remission From Overt Hepatic Encephalopathy. Clin
Gastroenterol Hepatol. 2014 Aug 12(8):1390-1397.
Kowdley KV, Gordon SC, Reddy KR et al, Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without
cirrhosis. N Eng J Med 2014 May 15;370(20):1879-88 (Listed as Collaborator).
Afdhal N, Reddy KR, Nelson DR et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1
infection. N Engl J Med 2014 Apr 17;370(16):1483-93 (Listed as Collaborator).
Chou C, Yimam K, Frederick RT, Swenson S. A rare case of icteric acute hepatitis C infection acquired
through intranasal methamphetamine use. ACG Case Rep J 2014;1(2):112-114.
Abstracts
Sanyal A, Boyer TD, Frederick RT, et al. Reversal of hepatorenal syndrome Type 1 (HRS-1) with terlipressin
plus albumin versus placebo plus albumin- Not all responses are created equal - An analysis of the REVERSE
and OT-0401 trials. Hepatology 2014;60 (4 Suppl):322A.
Boyer TD, Sanyal AJ, Wong F, Frederick RT et al. Initial report of a large, randomized, double blind, placebocontrolled, phase 3 trial of terlipressin plus albumin for the treatment of Type 1 hepatorenal syndrome (HRS-1):
The REVERSE study. Hepatology 2014;60 (4 Suppl):255A.
Ripper S, Holt EW, Cooper S, Wakil A, Davern T, Merriman R, Guy J, Frederick RT. Simeprevir plus
Sofosbuvir for Patients with Recurrence of Genotype 1 Hepatitis C Infection after Liver Transplantation.
Hepatology 2014;60 (4 Suppl): 684A.
S Ripper, E Holt, S Cooper, A Wakil, R Merriman, J Guy, RT Frederick. Combination Therapy with Simeprevir
and Sofosbuvir for Genotype 1 HCV after Liver Transplantation. Late Breaker Oral Abstract, World Transplant
Congress, San Francisco, CA July 2014.
Jennifer Guy (M.D.), Director of the Liver Cancer Program
Publications
Goel A, Mehta N, Guy J, Fidelman N, Yao F, Roberts J, Terrault N. Hepatic artery and biliary complications
in liver transplant recipients undergoing pretransplant transarterial chemoembolization. Liver Transpl. 2014
Oct;20(10):1221-8.
Frenette CT, Osorio RC, Stark J, Fok B, Boktour MR, Guy J, Rhee J, Osorio RW. Conventional TACE and
drug-eluting bead TACE as locoregional therapy before orthotopic liver transplantation: comparison of explant
pathologic response. Transplantation. 2014 Oct 15;98(7):781-7.
Presentation
Neil Mehta, M.D.; Jennifer Guy, M.D.; Catherine T. Frenette, M.D.; Monika Sarkar, M.D.; Robert W. Osorio,
M.D.; William B. Minteer, M.D.; John P. Roberts, M.D.; Francis Y. Yao, M.D.. AASLD, Boston, MA November
2014. Clinical Plenary Session: Multicenter Study of Down-staging of Hepatocellular Carcinoma (HCC) to
within Milan Criteria before Liver Transplantation.
Assad Hassoun (M.D., FACS), Surgical Director, Transplant Surgery
Publication
Khalaf H, Marwan I, Al-Sebayel M, El-Meteini M, Hosny A, Abdel-Wahab M, Amer K, El-Shobari M, Kamel
R, Al-Qahtani M, Khan I, Bashir A, Hammoudi S, Smadi S, Khalife M, Faraj W, Bentabak K, Khalfallah T,
Hassoun A, Bukrah A, Mustafa I. Status of liver transplantation in the Arab world. Transplantation. 2014 Apr
15;97(7):722-4.
68
C O M P E N D IUM
Presentation
Hassoun A, Farajifar S, Rabkin JM, Osorio R: Innovative surgical techniques in Pacreaticoduodenectomy:
Cohort analysis using validated outcomes0based quality metrics. International Hepato-Pacreato-Biliary
Association (IHPBA) 11th World Congress, Seoul, South Korea, March 22-27, 2014. Oral Presentation.
Garrett Hisatake (M.D., FACS), Surgeon
Publication
Wang Z, Hisatake G, Yang L. Liver-specific deceased donor risk indices. Hepatol Res. 2014 Feb;44(2):159-64.
Edward Holt (M.D.), Director, Fatty Liver Disease Program; Transplant Hepatologist
Publications
Holt EW, Yimam KK, Ma H, Shaw RE, Sundberg RA, Verhille MS. Patient tolerability of bowel preparation is
associated with polyp detection rate during colonoscopy. J Gastrointestin Liver Dis. 2014 Jun;23(2):135-40.
Holt EW, Wei EK, Bennett N, Zhang LM. Low skin carotenoid concentration measured by resonance Raman
spectroscopy is associated with metabolic syndrome in adults. Nutr Res. 2014 Oct;34(10):821-6.
Holt EW, DeMartini S, Davern TJ. Acute Liver Failure Due to Acetaminophen Poisoning in Patients With Prior
Weight Loss Surgery: A Case Series. J Clin Gastroenterol. 2014 Dec 30. [Epub ahead of print]
Ralph Merriman (M.D.), Medical Director, Liver Transplantation; Director, Metabolic Liver
Disease Research
Publication
American Association for the Study of Liver Diseases; European Association for the Study of the Liver. Hepatic
encephalopathy in chronic liver disease: 2014 practice guideline by the European Association for the Study of
the Liver and the American Association for the Study of Liver Diseases. J Hepatol. 2014 Sep;61(3):642-59.
Epub 2014 Jul 8.
Robert W. Osorio (M.D., FACS) Chair of the Department of Transplantation and
Surgical Director of the Liver Disease and Liver Transplant Program
Publication
Frenette CT, Osorio RC, Stark J, Fok B, Boktour MR, Guy J, Rhee J, Osorio RW. Conventional TACE and
drug-eluting bead TACE as locoregional therapy before orthotopic liver transplantation: comparison of explant
pathologic response. Transplantation. 2014 Oct 15;98(7):781-7.
Microvascular Surgery
Rudolf F. Buntic (M.D.), Chief of the Division of Microsurgery
Publication
Momeni A, Buntic RF, Buncke GM. Cross-leg flaps: preferred alternative to free flaps? J Am Coll Surg. 2014
Feb;218(2):308-9.
Mind-Body Medicine
Cassandra Vieten (Ph.D.), Scientist; Co-Director of the Mind-Body Medicine
Research Group
Publication
Thomas M, Vieten C, Adler N, Ammondson I, Coleman-Phox K, Epel E, Laraia B. Potential for a stress
reduction intervention to promote healthy gestational weight gain: focus groups with low-income pregnant
women. Womens Health Issues. 2014 May-Jun;24(3):e305-11.
69
Garret Yount (Ph.D.), Scientist; Director of the Mind-Body Medicine Research Group
Publications
Yount G & Rachlin K. A novel mouthwash protocol for noninvasive genomic analyses. Intl. J. Psychosocial &
Cultural Genomics Consciousness & Health Res. 2014 Oct Issue 1:12-15.
Cobbs C, Khan S, Matlaf L, McAllister S, Zider A, Yount G, Rahlin K, Harkins L, Bezrookove V, Singer
E, Soroceanu L. HCMV glycoprotein B is expressed in primary glioblastomas and enhances growth and
invasiveness via PDGFR-alpha activation. Oncotarget. 2014 Feb 28;5(4):1091-100.
Neuroscience
Nobl Barazangi (M.D., Ph.D.), Director of the Stroke/Neurocritical Care Research
and Education Program
Publication
Spokoyny I, Barazangi N, Jaramillo V, Rose J, Chen C, Wong C, Tong D. Reduced clopidogrel metabolism in
a multiethnic population: prevalence and rates of recurrent cerebrovascular events. J Stroke Cerebrovasc Dis.
2014 Apr;23(4):694-8.
Presentation
Poster presented by Dr Chandra, CPMC medicine resident, at the Neurocritical Care Society Annual Meeting
2014 Cerebral Toxemia from Hyperammonemia: Adult-Onset Disorders of Urea Cycle Metabolism; Mekhala
Chandra, M.D., Nobl Barazangi, M.D., Ph.D., Alan H. Yee, D.O.
Jonathan Katz (M.D.), Director of Neuromuscular Research at the Forbes Norris
MDA/ALS Research and Treatment Center
Publications
Miller RG, Zhang R, Block G, Katz J, Barohn R, Kasarskis E, Forshew D, Gopalakrishnan V, McGrath MS.
NP001 regulation of macrophage activation markers in ALS: a phase I clinical and biomarker study. Amyotroph
Lateral Scler Frontotemporal Degener. 2014 Dec;15(7-8):601-9.
McElhiney M, Rabkin JG, Goetz R, Katz J, Miller RG, Forshew DA, David W, Cudkowicz M, Glass JD, Appel
S, Simpson E, Mitsumoto H. Seeking a measure of clinically meaningful change in ALS. Amyotroph Lateral
Scler Frontotemporal Degener. 2014 Sep;15(5-6):398-405. Epub 2014 Aug 15. Erratum in: Amyotroph Lateral
Scler Frontotemporal Degener. 2014 Dec;15(7-8):627.
Zhao Y, Cudkowicz ME, Shefner JM, Krivickas L, David WS, Vriesendorp F, Pestronk A, Caress JB, Katz J,
Simpson E, Rosenfeld J, Pascuzzi R, Glass J, Rezania K, Harmatz JS, Schoenfeld D, Greenblatt DJ. Systemic
pharmacokinetics and cerebrospinal fluid uptake of intravenous ceftriaxone in patients with amyotrophic lateral
sclerosis. J Clin Pharmacol. 2014 Oct;54(10):1180-7.
Rabkin J, Ogino M, Goetz R, McElhiney M, Hupf J, Heitzman D, Heiman-Patterson T, Miller R, Katz J,
Lomen-Hoerth C, Imai T, Atsuta N, Morita M, Tateishi T, Matsumura T, Mitsumoto H. Japanese and American
ALS patient preferences regarding TIV (tracheostomy with invasive ventilation): a cross-national survey.
Amyotroph Lateral Scler Frontotemporal Degener. 2014 Jun;15(3-4):185-91.
Wills AM, Hubbard J, Macklin EA, Glass J, Tandan R, Simpson EP, Brooks B, Gelinas D, Mitsumoto H, Mozaffar T,
Hanes GP, Ladha SS, Heiman-Patterson T, Katz J, Lou JS, Mahoney K, Grasso D, Lawson R, Yu H, Cudkowicz
M; MDA Clinical Research Network. Hypercaloric enteral nutrition in patients with amyotrophic lateral sclerosis: a
randomised, double-blind, placebo-controlled phase 2 trial. Lancet. 2014 Jun 14;383(9934):2065-72.
Mitsumoto H, Factor-Litvak P, Andrews H, Goetz RR, Andrews L, Rabkin JG, McElhiney M, Nieves J, Santella
RM, Murphy J, Hupf J, Singleton J, Merle D, Kilty M, Heitzman D, Bedlack RS, Miller RG, Katz JS, Forshew
D, Barohn RJ, Sorenson EJ, Oskarsson B, Fernandes Filho JA, Kasarskis EJ, Lomen-Hoerth C, Mozaffar T,
Rollins YD, Nations SP, Swenson AJ, Shefner JM, Andrews JA, Koczon-Jaremko BA; ALS COSMOS Study
Group. ALS Multicenter Cohort Study of Oxidative Stress (ALS COSMOS): study methodology, recruitment,
and baseline demographic and disease characteristics. Amyotroph Lateral Scler Frontotemporal Degener.
2014 Jun;15(3-4):192-203.
70
C O M P E N D IUM
Kenneth Laxer (M.D.), Director of the Sutter Pacific Epilepsy Program
Publications
Mueller SG, Bateman LM, Laxer KD. Evidence for brainstem network disruption in temporal lobe epilepsy
and sudden unexplained death in epilepsy. Neuroimage Clin. 2014 Jul 9;5:208-16.
Laxer KD, Trinka E, Hirsch LJ, Cendes F, Langfitt J, Delanty N, Resnick T, Benbadis SR. The consequences
of refractory epilepsy and its treatment. Epilepsy Behav. 2014 Aug;37:59-70. Epub 2014 Jun 27.
Robert Miller (M.D.), Director of the Forbes Norris MDA/ALS Research and Treatment
Center
Publications
Miller RG, Zhang R, Block G, Katz J, Barohn R, Kasarskis E, Forshew D, Gopalakrishnan V, McGrath MS.
NP001 regulation of macrophage activation markers in ALS: a phase I clinical and biomarker study. Amyotroph
Lateral Scler Frontotemporal Degener. 2014 Dec;15(7-8):601-9. doi: 10.3109/21678421.2014.951940. Epub
2014 Sep 5.
McElhiney M, Rabkin JG, Goetz R, Katz J, Miller RG, Forshew DA, David W, Cudkowicz M, Glass JD, Appel
S, Simpson E, Mitsumoto H. Seeking a measure of clinically meaningful change in ALS. Amyotroph Lateral
Scler Frontotemporal Degener. 2014 Sep;15(5-6):398-405. doi: 10.3109/21678421.2014.942668. Epub 2014
Aug 15. Erratum in: Amyotroph Lateral Scler Frontotemporal Degener. 2014 Dec;15(7-8):627.
Miller RG, Brooks BR, Swain-Eng RJ, Basner RC, Carter GT, Casey P, Cohen AB, Dubinsky R, Forshew D,
Jackson CE, Kasarskis E, Procaccini NJ, Sanjak M, Tolin FP. Quality improvement in neurology: amyotrophic
lateral sclerosis quality measures. Report of the Quality Measurement and Reporting Subcommittee of the
American Academy of Neurology. Amyotroph Lateral Scler Frontotemporal Degener. 2014 Jun;15(3-4):165-8.
doi: 10.3109/21678421.2013.875706. Epub 2014 Apr 7.
Wills AM, Hubbard J, Macklin EA, Glass J, Tandan R, Simpson EP, Brooks B, Gelinas D, Mitsumoto H,
Mozaffar T, Hanes GP, Ladha SS, Heiman-Patterson T, Katz J, Lou JS, Mahoney K, Grasso D, Lawson R, Yu
H, Cudkowicz M; MDA Clinical Research Network. Lancet. 2014 Jun 14;383(9934):2065-72. doi: 10.1016/
S0140-6736(14)60222-1. Epub 2014 Feb 28. Hypercaloric enteral nutrition in patients with amyotrophic lateral
sclerosis: a randomised, double-blind, placebo-controlled phase 2 trial.
Mitsumoto H, Factor-Litvak P, Andrews H, Goetz RR, Andrews L, Rabkin JG, McElhiney M, Nieves J, Santella
RM, Murphy J, Hupf J, Singleton J, Merle D, Kilty M, Heitzman D, Bedlack RS, Miller RG, Katz JS, Forshew
D, Barohn RJ, Sorenson EJ, Oskarsson B, Fernandes Filho JA, Kasarskis EJ, Lomen-Hoerth C, Mozaffar T,
Rollins YD, Nations SP, Swenson AJ, Shefner JM, Andrews JA, Koczon-Jaremko BA; ALS COSMOS Study
Group. ALS Multicenter Cohort Study of Oxidative Stress (ALS COSMOS): study methodology, recruitment,
and baseline demographic and disease characteristics. Amyotroph Lateral Scler Frontotemporal Degener.
2014 Jun;15(3-4):192-203.
Michael C. Rowbotham (M.D.), Senior Scientist; Scientific Director of CPMCRI;
Sutter Health Research Enterprise Integration Leader—Basic Science;
Sutter Health Research Enterprise Integration Leader—Clinical Trials
Publications
Munch T, Dufka FL, Greene K, Smith SM, Dworkin RH, Rowbotham MC. RReACT goes global: perils and
pitfalls of constructing a global open-access database of registered analgesic clinical trials and trial results.
Pain. 2014 Jul;155(7):1313-7. Epub 2014 Apr 13.
Slagelse C, Petersen KL, Dahl JB, Finnerup K, Greene K, Leong SP, Levine J, Rowbotham MC, Werner MU,
Finnerup NB. Persistent postoperative pain and sensory changes following lymph node excision in melanoma
patients: a topical review. Melanoma Res. 2014 Apr;24(2):93-8.
Farrar JT, Troxel AB, Haynes K, Gilron I, Kerns RD, Katz NP, Rappaport BA, Rowbotham MC, Tierney AM, Turk
DC, Dworkin RH. Effect of variability in the 7-day baseline pain diary on the assay sensitivity of neuropathic pain
randomized clinical trials: an ACTTION study. Pain. 2014 Aug;155(8):1622-31. Epub 2014 May 14.
71
Gewandter JS, Dworkin RH, Turk DC, McDermott MP, Baron R, Gastonguay MR, Gilron I, Katz NP, Mehta C,
Raja SN, Senn S, Taylor C, Cowan P, Desjardins P, Dimitrova R, Dionne R, Farrar JT, Hewitt DJ, Iyengar S, Jay
GW, Kalso E, Kerns RD, Leff R, Leong M, Petersen KL, Ravina BM, Rauschkolb C, Rice AS, Rowbotham
MC, Sampaio C, Sindrup SH, Stauffer JW, Steigerwald I, Stewart J, Tobias J, Treede RD, Wallace M, White
RE. Research designs for proof-of-concept chronic pain clinical trials: IMMPACT recommendations. Pain.
2014 Sep;155(9):1683-95. Epub 2014 May 24.
Dufka FL, Dworkin RH, Rowbotham MC. How transparent are migraine clinical trials? Repository of
Registered Migraine Trials (RReMiT). Neurology. 2014 Oct 7;83(15):1372-81. Epub 2014 Sep 5.
Gewandter JS, McDermott MP, McKeown A, Smith SM, Pawlowski JR, Poli JJ, Rothstein D, Williams MR,
Bujanover S, Farrar JT, Gilron I, Katz NP, Rowbotham MC, Turk DC, Dworkin RH. Reporting of intention-totreat analyses in recent analgesic clinical trials: ACTTION systematic review and recommendations. Pain. 2014
Dec;155(12):2714-9. Epub 2014 Oct 2.
Gewandter JS, McKeown A, McDermott MP, Dworkin JD, Smith SM, Gross RA, Hunsinger M, Lin AH,
Rappaport BA, Rice AS, Rowbotham MC, Williams MR, Turk DC, Dworkin RH. Data interpretation in
analgesic clinical trials with statistically non-significant primary analyses: An ACTTION systematic review. J
Pain. 2014 Oct 23. [Epub ahead of print] Review.
Susan Woolley-Levine (Ph.D., ABPP), Clinical Neuropsychologist
Presentations
Longitudinal Cognitive and Behavioral Results from the COSMOS Study. Platform Presentation, International
Symposium on MND/ALS, Brussels, Belgium, Dec 2014.
Neuropsychology of ALS: Screening Tools for ALS-FTD. Invited lecturer, ALS Research Group Meeting,
Minneapolis, MN Sept 2014.
Organ Transplant
V. Ram Peddi (M.D.), Transplant Nephrologist; Director of Transplant Clinical Research
Publications
Ueda K, McCague KM, Wiland A, Peddi VR. Early corticosteroid withdrawal in the real world: a long-term
analysis of kidney transplant recipients from the Mycophenolic Acid Observational Renal Transplant Registry.
Ann Transplant. 2014;19:84-92.
Roedder S, Sigdel T, Salomonis N, Hsieh S, Dai H, Bestard O, Metes D, Zeevi A, Gritsch A, Cheeseman J,
Macedo C, Peddi VR, Medeiros M, Vincenti F, Asher N, Salvatierra O, Shapiro R, Kirk A, Reed E, Sarwal
MM. The kSORT Assay to Detect Renal Transplant Patients at High Risk for Acute Rejection: Results of the
Multicenter AART Study. PLoS Med. 2014 Nov 11;11(11).
Presentations
V. Peddi, Y. Qazi, D. Shaffer, F. Luan, F. Shihab, S. Tomlanovich, K. McCague, D. Patel, S. Mulgaonkar for
CRAD001AUS92 Study Group. Effect of Everolimus With Low Dose Tacrolimus Vs Mycophenolate With
Standard Tacrolimus Regimen in African-American De Novo Renal Transplant Recipients. World Transplant
Congress. San Francisco, CA. July 2014.
F. Shihab, D. Shaffer, Y. Qazi, B. Kaplan, F. Vincenti, K. McCague, D. Patel, S. Mulgaonkar, V. Peddi. For
CRAD001AUS92 Study Group. Reduced Incidence of CMV and BK Virus Infection With Everolimus vs
Mycophenolate Based Regimen in De Novo Renal Transplant Recipients. World Transplant Congress. San
Francisco, CA. July 2014.
F. Shihab, Y. Qazi, B. Kaplan, D. Kim, S. Mulgaonkar, V. Peddi, D. Shaffer, D. Patel, K. McCague, F. Vincenti
for CRAD001AUS92 Study Group. Everolimus-Facilitated Tacrolimus Minimization Preserves Renal Function in
De Novo Renal Transplant Recipients. World Transplant Congress. San Francisco, CA. July 2014.
H. Tedesco-Silva, V. Peddi, A. Sanchez-Frutuoso, B. Marder, G. Russ, A. Flynn, C. Hahn, M. Tortorici, S.
Schulman. Open-Label Study of Planned Transition From Tacrolimus to Sirolimus vs Continued Tacrolimus in
Renal Allograft Recipients. World Transplant Congress. San Francisco, CA. July 2014.
72
C O M P E N D IUM
F. Diekmann, H. Tedesco-Silva, V. Peddi, A. Sanchez-Fructoso, B. Marder, G. Russ, A. Flynn, C. Hahn, H. Li,
M. Tortorici, S. Schulman. Transition From Tacrolimus to Sirolimus vs Continued Tacrolimus in Renal Allograft
Recipients: Impact On Glycemic Parameters. World Transplant Congress. San Francisco, CA. July 2014.
S. Roedder, T. Sigdel, N. Salomonis, S. Hsiehs, H. Dai, D. Metes, A. Zeevi, H. Gritsch, J. Cheeseman, V.
Peddi, M. Medeiros, O. Bestard, F. Vincenti, N. Asher, R. Shapiro, A. Kirk, E. Reed, M. Sarwal. A 17 Gene
Blood Assay (kSORT) for Diagnosis and Prediction of Acute Renal Transplant Rejection: Results of the
Multicenter AART Study. World Transplant Congress. San Francisco, CA. July 2014.
V. Peddi, L. Ratner, M. Cooper, O. Gaber, S. Feng, P. Tso, V. Bowers, R. Naraghi, K. Budde, M. Polinsky, E.
Squiers, S. Erlich, for QPI-1002 Study Investigators Group. Treatment with QPI-1002, a Short Interfering (SI)
RNA for the Prophylaxis of Delayed Graft Function. World Transplant Congress. San Francisco, CA. July 2014.
Kimi Ueda (PharmD, BCPS), Kidney/Pancreas Transplant Pharmacist
Publication
Ueda K, McCague KM, Wiland A, Peddi VR. Early corticosteroid withdrawal in the real world: a long-term
analysis of kidney transplant recipients from the Mycophenolic Acid Observational Renal Transplant Registry.
Ann Transplant. 2014 Feb 17;19:84-92.
Pulmonology/Critical Care
George Horng (M.D.), Division Chief of Pulmonary and Critical Care Medicine
Publication
Carlsson A, Nair VS, Luttgen MS, Keu KV, Horng G, Vasanawala M, Kolatkar A, Jamali M, Iagaru AH,
Kuschner W, Loo BW Jr, Shrager JB, Bethel K, Hoh CK, Bazhenova L, Nieva J, Kuhn P, Gambhir SS.
Circulating tumor microemboli diagnostics for patients with non-small-cell lung cancer. J Thorac Oncol. 2014
Aug;9(8):1111-9.
Sean R. Townsend (M.D.), Vice President of Quality & Safety
Publications
Ferrer R, Martin-Loeches I, Phillips G, Osborn TM, Townsend S, Dellinger RP, Artigas A, Schorr C, Levy MM.
Empiric antibiotic treatment reduces mortality in severe sepsis and septic shock from the first hour: results
from a guideline-based performance improvement program. Crit Care Med. 2014 Aug;42(8):1749-55.
Osborn TM, Phillips G, Lemeshow S, Townsend S, Schorr CA, Levy MM, Dellinger RP. Sepsis severity score:
an internationally derived scoring system from the surviving sepsis campaign database. Crit Care Med. 2014
Sep;42(9):1969-76.
Casserly B, Phillips GS, Schorr C, Dellinger RP, Townsend SR, Osborn TM, Reinhart K, Selvakumar N, Levy
MM. Lactate Measurements in Sepsis-Induced Tissue Hypoperfusion: Results From the Surviving Sepsis
Campaign Database. Crit Care Med. 2014 Dec 4. [Epub ahead of print]
Levy MM, Rhodes A, Phillips GS, Townsend SR, Schorr CA, Beale R, Osborn T, Lemeshow S, Chiche JD,
Artigas A, Dellinger RP. Surviving Sepsis Campaign: association between performance metrics and outcomes
in a 7.5-year study. Intensive Care Med. 2014 Nov;40(11):1623-33.
San Francisco Coordinating Center
Terri Blackwell (MA), Senior Statistician
Publications
Walsh CM, Blackwell T, Tranah GJ, Stone KL, Ancoli-Israel S, Redline S, Paudel M, Kramer JH, Yaffe K.
Weaker Circadian Activity Rhythms are Associated with Poorer Executive Function in Older Women. Sleep.
2014 Dec 1;37(12):2009-16.
Ensrud KE, Blackwell TL, Cauley JA, Dam TT, Cawthon PM, Schousboe JT, Barrett-Connor E, Stone KL,
Bauer DC, Shikany JM, Mackey DC; Osteoporotic Fractures in Men Study Group. Objective measures of
activity level and mortality in older men. J Am Geriatr Soc. 2014 Nov;62(11):2079-87.
73
Cauley JA, Blackwell TL, Redline S, Ensrud KE, Ancoli-Israel S, Fink HA, Orwoll ES, Stone KL. Hypoxia
during sleep and the risk of falls and fractures in older men: the osteoporotic fractures in men sleep study. J
Am Geriatr Soc. 2014 Oct;62(10):1853-9.
Patel SR, Hayes AL, Blackwell T, Evans DS, Ancoli-Israel S, Wing YK, Stone KL; Osteoporotic Fractures
in Men (MrOS); Study of Osteoporotic Fractures (SOF) Research Groups. The association between sleep
patterns and obesity in older adults. Int J Obes (Lond). 2014 Sep;38(9):1159-64.
Cawthon PM, Blackwell TL, Marshall LM, Fink HA, Kado DM, Ensrud KE, Cauley JA, Black D, Orwoll ES,
Cummings SR, Schousboe JT; Osteoporotic Fractures in Men (MrOS) Research Group. Physical performance
and radiographic and clinical vertebral fractures in older men. J Bone Miner Res. 2014 Sep;29(9):2101-8.
Ensrud KE, Taylor BC, Peters KW, Gourlay ML, Donaldson MG, Leslie WD, Blackwell TL, Fink HA, Orwoll
ES, Schousboe J; Osteoporotic Fractures in Men Study Group. Implications of expanding indications for
drug treatment to prevent fracture in older men in United States: cross sectional and longitudinal analysis of
prospective cohort study. BMJ. 2014 Jul 3;349:g4120.
Blackwell T, Yaffe K, Laffan A, Ancoli-Israel S, Redline S, Ensrud KE, Song Y, Stone KL. Associations of
Objectively and Subjectively Measured Sleep Quality with Subsequent Cognitive Decline in Older CommunityDwelling Men: The MrOS Sleep Study. Sleep. 2014 Apr 1;37(4):655-63.
Szulc P, Blackwell T, Schousboe JT, Bauer DC, Cawthon P, Lane NE, Cummings SR, Orwoll ES, Black DM,
Ensrud KE. High hip fracture risk in men with severe aortic calcification: MrOS study. J Bone Miner Res. 2014
Apr;29(4):968-75.
Stone KL, Blackwell TL, Ancoli-Israel S, Cauley JA, Redline S, Marshall LM, Ensrud KE; Osteoporotic
Fractures in Men Study Group. Sleep Disturbances and Risk of Falls in Older Community-Dwelling Men: The
Outcomes of Sleep Disorders in Older Men (MrOS Sleep) Study. J Am Geriatr Soc. 2014 Feb;62(2):299-305.
Koo BB, Mehra R, Blackwell T, Ancoli-Israel S, Stone KL, Redline S; Osteoporotic Fractures in Men (MrOS)
Study Group. Periodic Limb Movements during Sleep and Cardiac Arrhythmia in Older Men (MrOS Sleep). J
Clin Sleep Med. 2014 Jan 15;10(1):7-11.
Peggy Cawthon (Ph.D., MPH), Scientist
Publications
Cawthon PM, Haslam J, Fullman R, Peters KW, Black D, Ensrud KE, Cummings SR, Orwoll ES, Barrett-
Connor E, Marshall L, Steiger P, Schousboe JT; for the Osteoporotic Fractures in Men (MrOS) Research
Group. Response to BONE-D-14-00884. Bone. 2014 Dec 4. [Epub ahead of print]
Katzman WB, Harrison SL, Fink HA, Marshall LM, Orwoll E, Barrett-Connor E, Cawthon PM, Kado DM;
for the Osteoporotic Fractures in Men (MrOS) Study Research Group. Physical Function in Older Men With
Hyperkyphosis. J Gerontol A Biol Sci Med Sci. 2014 Nov 27. [Epub ahead of print]
Nardo L, Lane NE, Parimi N, Cawthon PM, Fan B, Shepherd J, Cauley J, Zucker-Levin A, Murphy RA,
Katzman WB. Diffuse idiopathic skeletal hyperostosis association with thoracic spine kyphosis: a crosssectional study for the Health Aging and Body Composition Study. Spine (Phila Pa 1976). 2014 Nov
15;39(24):E1418-24.
Ensrud KE, Blackwell TL, Cauley JA, Dam TT, Cawthon PM, Schousboe JT, Barrett-Connor E, Stone KL,
Bauer DC, Shikany JM, Mackey DC; Osteoporotic Fractures in Men Study Group. Objective measures of
activity level and mortality in older men. J Am Geriatr Soc. 2014 Nov;62(11):2079-87. Epub 2014 Nov 3.
Wong AK, Cawthon PM, Peters KW, Cummings SR, Gordon CL, Sheu Y, Ensrud K, Petit M, Zmuda JM,
Orwoll E, Cauley J; Osteoporotic Fractures in Men (MrOS) Research Group. Bone-muscle indices as risk
factors for fractures in men: the Osteoporotic Fractures in Men (MrOS) Study. J Musculoskelet Neuronal
Interact. 2014 Sep;14(3):246-54.
Fink HA, Kuskowski MA, Cauley JA, Taylor BC, Schousboe JT, Cawthon PM, Ensrud KE; Osteoporotic Fractures
in Men (MrOS) Study Group. Association of stressful life events with accelerated bone loss in older men: the
osteoporotic fractures in men (MrOS) study. Osteoporos Int. 2014 Dec;25(12):2833-9. Epub 2014 Aug 29.
74
C O M P E N D IUM
Fragala MS, Dam TT, Barber V, Judge JO, Studenski SA, Cawthon PM, McLean RR, Harris TB, Ferrucci L,
Guralnik JM, Kiel DP, Kritchevsky SB, Shardell MD, Vassileva MT, Kenny AM. Strength and function response
to clinical interventions of older women categorized by weakness and low lean mass using classifications
from the foundation for the national institute of health sarcopenia project. J Gerontol A Biol Sci Med Sci. 2015
Feb;70(2):202-9. Epub 2014 Aug 18.
Eriksson J, Evans DS, Nielson CM, Shen J, Srikanth P, Hochberg M, McWeeney S, Cawthon PM, Wilmot
B, Zmuda J, Tranah G, Mirel DB, Challa S, Mooney M, Crenshaw A, Karlsson M, Mellström D, Vandenput L,
Orwoll E, Ohlsson C. Limited clinical utility of a genetic risk score for the prediction of fracture risk in elderly
subjects. J Bone Miner Res. 2015 Jan;30(1):184-94.
Cawthon PM, Blackwell TL, Marshall LM, Fink HA, Kado DM, Ensrud KE, Cauley JA, Black D, Orwoll ES,
Cummings SR, Schousboe JT; Osteoporotic Fractures in Men (MrOS) Research Group. Physical performance
and radiographic and clinical vertebral fractures in older men. J Bone Miner Res. 2014 Sep;29(9):2101-8.
Murphy RA, Patel KV, Kritchevsky SB, Houston DK, Newman AB, Koster A, Simonsick EM, Tylvasky FA,
Cawthon PM, Harris TB; Health, Aging, and Body Composition Study. Weight change, body composition,
and risk of mobility disability and mortality in older adults: a population-based cohort study. J Am Geriatr Soc.
2014 Aug;62(8):1476-83. doi: 10.1111/jgs.12954. Epub 2014 Jul 15.
Cawthon PM, Haslam J, Fullman R, Peters KW, Black D, Ensrud KE, Cummings SR, Orwoll ES, BarrettConnor E, Marshall L, Steiger P, Schousboe JT; OsteoporoticFractures in Men (MrOS) Research Group.
Methods and reliability of radiographic vertebral fracture detection in older men: the osteoporotic fractures in
menstudy. Bone. 2014 Oct;67:152-5. Epub 2014 Jul 6.
Mackey DC, Cauley JA, Barrett-Connor E, Schousboe JT, Cawthon PM, Cummings SR; Osteoporotic
Fractures in Men Research Group. Life-space mobility and mortality in older men: a prospective cohort study.
J Am Geriatr Soc. 2014 Jul;62(7):1288-96. Epub 2014 Jun 16.
Lee DS, Markwardt S, Goeres L, Lee CG, Eckstrom E, Williams C, Fu R, Orwoll E, Cawthon PM, Stefanick
ML, Mackey D, Bauer DC, Nielson CM. Statins and physical activity in older men: the osteoporotic fractures in
men study. JAMA Intern Med. 2014 Aug;174(8):1263-70.
Dam TT, Peters KW, Fragala M, Cawthon PM, Harris TB, McLean R, Shardell M, Alley DE, Kenny A, Ferrucci
L, Guralnik J, Kiel DP, Kritchevsky S, Vassileva MT, Studenski S. An evidence-based comparison of operational
criteria for the presence of sarcopenia. J Gerontol A Biol Sci Med Sci. 2014 May;69(5):584-90.
McLean RR, Shardell MD, Alley DE, Cawthon PM, Fragala MS, Harris TB, Kenny AM, Peters KW, Ferrucci
L, Guralnik JM, Kritchevsky SB, Kiel DP, Vassileva MT, Xue QL, Perera S, Studenski SA, Dam TT. Criteria
for clinically relevant weakness and low lean mass and their longitudinal association with incident mobility
impairment and mortality: the foundation for the National Institutes of Health (FNIH) sarcopenia project. J
Gerontol A Biol Sci Med Sci. 2014 May;69(5):576-83.
Cawthon PM, Peters KW, Shardell MD, McLean RR, Dam TT, Kenny AM, Fragala MS, Harris TB, Kiel DP,
Guralnik JM, Ferrucci L, Kritchevsky SB, Vassileva MT, Studenski SA, Alley DE. Cutpoints for low appendicular
lean mass that identify older adults with clinically significant weakness. J Gerontol A Biol Sci Med Sci. 2014
May;69(5):567-75.
Alley DE, Shardell MD, Peters KW, McLean RR, Dam TT, Kenny AM, Fragala MS, Harris TB, Kiel DP, Guralnik
JM, Ferrucci L, Kritchevsky SB, Studenski SA, Vassileva MT, Cawthon PM. Grip strength cutpoints for the
identification of clinically relevant weakness. J Gerontol A Biol Sci Med Sci. 2014 May;69(5):559-66.
Studenski SA, Peters KW, Alley DE, Cawthon PM, McLean RR, Harris TB, Ferrucci L, Guralnik JM, Fragala
MS, Kenny AM, Kiel DP, Kritchevsky SB, Shardell MD, Dam TT, Vassileva MT. The FNIH sarcopenia project:
rationale, study description, conference recommendations, and final estimates. J Gerontol A Biol Sci Med Sci.
2014 May;69(5):547-58.
Kado DM, Miller-Martinez D, Lui LY, Cawthon P, Katzman WB, Hillier TA, Fink HA, Ensrud KE. Hyperkyphosis,
kyphosis progression, and risk of non-spine fractures in older community dwelling women: the study of
osteoporotic fractures (SOF). J Bone Miner Res. 2014 Oct;29(10):2210-6.
75
Bajaj A, Stone KL, Peters K, Parimi N, Barrett-Connor E, Bauer D, Cawthon PM, Ensrud KE, Hoffman AR,
Orwoll E, Schernhammer ES. Circulating vitamin D, supplement use, and cardiovascular disease risk: the
MrOS Sleep Study. J Clin Endocrinol Metab. 2014 Sep;99(9):3256-62. Epub 2014 Mar 26.
Ward RE, Caserotti P, Faulkner K, Boudreau RM, Zivkovic S, Lee C, Goodpaster BH, Cawthon PM, Newman
AB, Cauley JA, Strotmeyer ES; Osteoporotic Fractures in Men (MrOS) Research Group. Peripheral nerve
function and lower extremity muscle power in older men. Arch Phys Med Rehabil. 2014 Apr;95(4):726-33.
Epub 2013 Dec 16.
Lane NE, Parimi N, Lui LY, Wise BL, Yao W, Lay YA, Cawthon PM, Orwoll E; Osteoporotic Fractures in Men
Study Group. Association of serum uric acid and incident nonspine fractures in elderly men: the Osteoporotic
Fractures in Men (MrOS) study. J Bone Miner Res. 2014 Jul;29(7):1701-7.
Shikany JM, Barrett-Connor E, Ensrud KE, Cawthon PM, Lewis CE, Dam TT, Shannon J, Redden DT;
Osteoporotic Fractures in Men (MrOS) Research Group. Macronutrients, diet quality, and frailty in older men. J
Gerontol A Biol Sci Med Sci. 2014 Jun;69(6):695-701. Epub 2013 Dec 4.
Wise BL, Parimi N, Zhang Y, Cawthon PM, Barrett-Connor E, Ensrud KE, Lane NE; Osteoporotic Fractures
in Men (MrOS) Group. Frailty and hip osteoarthritis in men in the MrOS cohort. J Gerontol A Biol Sci Med Sci.
2014 May;69(5):602-8. Epub 2013 Nov 19.
Murphy RA, Ip EH, Zhang Q, Boudreau RM, Cawthon PM, Newman AB, Tylavsky FA, Visser M, Goodpaster
BH, Harris TB; Health, Aging, and Body Composition Study. Transition to sarcopenia and determinants of
transitions in older adults: a population-based study. J Gerontol A Biol Sci Med Sci. 2014 Jun;69(6):751-8.
Epub 2013 Sep 7.
Szulc P, Blackwell T, Schousboe JT, Bauer DC, Cawthon P, Lane NE, Cummings SR, Orwoll ES, Black DM,
Ensrud KE. High hip fracture risk in men with severe aortic calcification: MrOS study. J Bone Miner Res. 2014
Apr;29(4):968-75.
Steven Cummings (M.D.), Senior Scientist; Director of the San Francisco Coordinating
Center
Publications
Murphy RA, Register TC, Shively CA, Carr JJ, Ge Y, Heilbrun ME, Cummings SR, Koster A, Nevitt MC,
Satterfield S, Tylvasky FA, Strotmeyer ES, Newman AB, Simonsick EM, Scherzinger A, Goodpaster BH,
Launer LJ, Eiriksdottir G, Sigurdsson S, Sigurdsson G, Gudnason V, Lang TF, Kritchevsky SB, Harris TB.
Adipose Tissue Density, a Novel Biomarker Predicting Mortality Risk in Older Adults. J Gerontol A Biol Sci Med
Sci. 2014 Jan;69(1):109-17.
Johansson H, Kanis JA, Oden A, McCloskey E, Chapurlat RD, Christiansen C, Cummings SR, Diez-Perez
A, Eisman JA, Fujiwara S, Gluer CC, Goltzman D, Hans D, Khaw KT, Krieg MA, Kroger H, Lacroix AZ, Lau E,
Leslie WD, Mellstrom D, Melton LJ 3rd, O’Neill TW, Pasco JA, Prior JC, Reid DM, Rivadeneira F, van Staa T,
Yoshimura N, Zillikens MC. A meta-analysis of the association of fracture risk and body mass index in women.
J Bone Miner Res. 2014 Jan: 29(1):223-33.
Lewerin C, Nilsson-Ehle H, Jacobsson S, Johansson H, Sundh V, Karlsson MK, Ljunggren O, Lorentzon M,
Kanis JA, Lerner UH, Cummings SR, Ohlsson C, Mellström D. Low holotranscobalamin and cobalamins
predict incident fractures in elderly men: the MrOS Sweden. Osteoporos Int. 2014 Jan;25(1):131-40.
Goto A, Chen BH, Song Y, Cauley J, Cummings SR, Farhat GN, Gunter M, Van Horn L, Howard BV,
Jackson R, Lee J, Rexrode KM, Liu S. Age, body mass, usage of exogenous estrogen, and lifestyle factors
in relation to circulating sex hormone-binding globulin concentrations in postmenopausal women. Clin Chem.
2014 Jan;60(1):174-85.
Tranah GJ, Yokoyama JS, Katzman SM, Nalls MA, Newman AB, Harris TB, Cesari M, Manini TM, Schork NJ,
Cummings SR, Liu Y, Yaffe K; Health, Aging and Body Composition Study. Mitochondrial DNA sequence
associations with dementia and amyloid-β in elderly African Americans. Neurobiol Aging. 2014 Feb;35(2):442.el-8.
Szulc P, Blackwell T, Schousboe JT, Bauer DC, Cawthon P, Lane NE, Cummings SR, Orwoll ES, Black DM,
Ensrud KE. High hip fracture risk in men with severe aortic calcification – MrOS study. J Bone Miner Res. 2014
Apr;29(4):968-75.
76
C O M P E N D IUM
Elbers CC, Garcia ME, Kimura M, Cummings SR, Nalls MA, Newman AB, Park V, Sanders JL, Tranah
GJ, Tishkoff SA, Tarris TB, Aviv A. Comparison Between Southern Blots and qPCR Analysis of Leukocyte
Telomere Length in the Health ABC Study. J Gerontol A Biol Sci Med Sci. 2014 May:69(5):527-31.
Cummings SR, Studenski S, Ferrucci L. A diagnosis of dismobility--giving mobility clinical visibility: a Mobility
Working Group recommendation. JAMA. 2014 May;311(20):2061-2.
Rachel A Murphy, Taylor F. Bureyko, Iva Miljkovic, Jan A. Cauley, Suzanne Satterfield, Trisha F. Hue, Heidi
D. Klepin, Cummings SR, Anne B. Neman, and Tamara B. Harris. Association of total and computed
tomographic measures of regional adiposity with incident cancer risk: a prospective population-based study of
older adults. Applied Physiology, Nutrition, and Metabolism. 2014 Jun;39(6):687-92.
Moayyeri A, Hsu YH, Karasik D, Estrada K, Xiao SM,…Cummings SR, Wareham NJ, Rivadeneira F,
Uitterlinden AG, Prince RL, Kiel DP, Reeve J, Kaptoge SK. Genetic determinants of heel bone properties:
genome-wide association meta-analysis and replication in the GEFOS/GENOMOS consortium. Hum Mol
Genet. 2014 Jun 1;23(11):3054-68.
Murphy RA, Bureyko TF, Miljkovic I, Cauley JA, Satterfield S, Hue TF, Klepin HD, Cummings SR, Newman
AB, Harris TB. Association of total adiposity and computed tomographic measures of regional adiposity with
incident cancer risk: a prospective population-based study of older adults. Appl Physiol Nutr Metab. 2014
Jun;39(6):687-92.
Evans DS, Cailotto F, Parimi N, Valdes AM, Castaño-Betancourt MC, Liu Y, Kaplan RC, Bidlingmaier M, Vasan
RS, Teumer A, Tranah GJ, Nevitt MC, Cummings SR, Orwoll ES, Barrett-Connor E, Renner JB, Jordan
JM, Doherty M, Doherty SA, Uitterlinden AG, van Meurs JB, Spector TD, Lories RJ, Lane NE. Genome-wide
association and functional studies identify a role for IGFBP3 in hip osteoarthritis. Ann Rheum Dis. 2014 Jun 13.
Mackey DC, Cauley JA, Barrett-Connor E, Schousboe JT, Cawthon PM, Cummings SR; Osteoporotic
Fractures in Men Research Group. Life-space mobility and mortality in older men: a prospective cohort study.
J Am Geriatr Soc. 2014 Jul;62(7):1288-96.
Bauer DC, Schwartz A, Palermo L, Cauley J, Hochberg M, Santora A, Cummings SR, Black DM. Fracture
prediction after discontinuation of 4 to 5 years of alendronate therapy: the FLEX study. JAMA Intern Med.
2014 Jul;174(7):1126-34.
Orri M, Lipset CH, Jacobs BP, Costello AJ, Cummings SR. Web-based trial to evaluate the efficacy and
safety of tolterodine ER 4 mg in participants with overactive bladder: REMOTE trial. Contemp Clin Trials. 2014
Jul;38(2):190-7.
Schousboe JT, Rosen HR, Vokes TJ, Cauley JA, Cummings SR, Nevitt M, Black DM, Orwoll ES, Kado DM,
Ensrud KE; Study of Osteoporotic Fractures Research Group. Prediction models of prevalent radiographic
vertebral fractures among older women. J Clin Densitom. 2014 Jul-Sep;17(3):378-85.
Ng MC, Shriner D, Chen BH, Li J, Chen WM, … Cummings SR, Psaty BM, Fornage M, Iyengar SK, Evans
MK, Becker DM, Kao WH, Wilson JG, Rotter JI, Sale MM, Liu S, Rotimi CN, Bowden DW; MEta-analysis
of type 2 DIabetes in African Americans Consortium. Meta-analysis of genome-wide association studies in
African Americans provides insights into the genetic architecture of type 2 diabetes. PLoS Genet. 2014 Aug
7;10(8):e1004517.
Arking DE, Pulit SL, Crotti L, van der Harst P, Munroe PB, … Cummings SR, et al. Genetic association study
of QT interval highlights role for calcium signaling pathways in myocardial repolarization. Nat Genet. 2014
Aug;46(8):826-36.
Cawthon PM, Blackwell TL, Marshall LM, Fink HA, Kado DM, Ensrud KE, Cauley JA, Black D, Orwoll ES,
Cummings SR, Schousboe JT; Osteoporotic Fractures in Men (MrOS) Research Group. Physical performance
and radiographic and clinical vertebral fractures in older men. J Bone Miner Res. 2014 Sep;29(9):2101-8.
Wong AK, Cawthon PM, Peters KW, Cummings SR, Gordon CL, Sheu Y, Ensrud K, Petit M, Zmuda JM,
Orwoll E, Cauley J; Osteoporotic Fractures in Men (MrOS) Research Group. Bone-muscle indices as risk
factors for fractures in men: the Osteoporotic Fractures in Men (MrOS) Study. J Musculoskelet Neuronal
Interact. 2014 Sep;14(3):246-54.
77
Eastell R, Boonen S, Cosman F, Reid IR, Palermo L, Cummings SR, Black DM. Relationship Between Pretreatment Rate of Bone Loss and Bone Density Response to Once-Yearly ZOL: HORIZON-PFT Extension
Study. J Bone Miner Res. 2014 Sep 11. [Epub ahead of print]
Cosman F, Cauley JA, Eastell R, Boonen S, Palermo L, Reid IR, Cummings SR, Black DM. Reassessment of
Fracture Risk in women after 3 years of treatment with Zoledronic Acid: when is it reasonable to discontinue
treatment? J Clin Endocrinol Metab. 2014 Sep 12:jc20141971. [Epub ahead of print]
Smith-Bindman R, Aubin C, Bailitz J, Bengiamin RN, Camargo CA Jr, Corbo J, Dean AJ, Goldstein RB, Griffey
RT, Jay GD, Kang TL, Kriesel DR, Ma OJ, Mallin M, Manson W, Melnikow J, Miglioretti DL, Miller SK, Mills
LD, Miner JR, Moghadassi M, Noble VE, Press GM, Stoller ML, Valencia VE, Wang J, Wang RC, Cummings
SR. Ultrasonography versus computed tomography for suspected nephrolithiasis. N Engl J Med. 2014 Sep
18;371(12):1100-10.
Napoli N, Strotmeyer ES, Ensrud KE, Sellmeyer DE, Bauer DC, Hoffman AR, Dam TT, Barrett-Connor E,
Palermo L, Orwoll ES, Cummings SR, Black DM, Schwartz AV. Fracture risk in diabetic elderly men: the
MrOS study. Diabetologia. 2014 Oct;57(10):2057-65.
Hue TF, Cummings SR, Cauley JA, Bauer DC, Ensrud KE, Barrett-Connor E, Black DM. Effect of
bisphosphonate use on risk of postmenopausal breast cancer: results from the randomized clinical trials of
alendronate and zoledronic acid. JAMA Intern Med. 2014 Oct;174(10):1550-7.
Cawthon PM, Haslam J, Fullman R, Peters KW, Black D, Ensrud KE, Cummings SR, Orwoll ES, BarrettConnor E, Marshall L, Steiger P, Schousboe JT; Osteoporotic Fractures in Men (MrOS) Research Group.
Methods and reliability of radiographic vertebral fracture detection in older men: the osteoporotic fractures in
men study. Bone. 2014 Oct;67:152-5.
Bertrand KA, Tamimi RM, Scott CG, Jensen MR, Pankratz V, Visscher D, Norman A, Couch F, Shepherd J,
Fan B, Chen YY, Ma L, Beck AH, Cummings SR, Kerlikowske K, Vachon CM. Mammographic density and
risk of breast cancer by age and tumor characteristics. Breast Cancer Res. 2013 Nov 4;15(6):R104.
Katzman SM, Strotmeyer ES, Nalls MA, Zhao Y, Mooney S, Schork N, Newman AB, Harris TB, Yaffe K,
Cummings SR, Liu Y, Tranah GJ; for the Health, Aging, and Body Composition Study. Mitochondrial DNA
Sequence Variation Associated With Peripheral Nerve Function in the Elderly. J Gerontol A Biol Sci Med Sci.
2014 Nov 13. [Epub ahead of print]
Dan Evans (Ph.D.), Assistant Scientist
Publications
Zhang L., Evans D.S., Raheja U.K., Stephens S.H., Stiller J.W., Reeves G.M., Johnson M., Ryan K.A., Weizel
N., Vaswani D., McLain H., Shuldiner A.R., Mitchell B.D., Hsueh W., Snitker S., Postolache T.T. Chronotype
and seasonality: Morningness is associated with lower seasonal mood and behavior changes in the Old Order
Amish. Journal of Affective Disorders 174C:209-214, (2014).
Gottlieb D.J., Hek K., Chen T., Watson N.F., Eiriksdottir G., Cornelis M., Warby S.C., Bandinelli S., Byrne E.M.,
Cherkas L., Evans D.S., et al. Novel Loci Associated with Usual Sleep Duration: The CHARGE Consortium
Genome-Wide Association Study. Molecular Psychiatry (2014).
Postmus, I., Trompet, S., Deshmukh, H.A., Barnes, M.R., Li, X., Warren, H.R., Chasman, D.I., Zhou, K.,
Arsenault, B.J., Donnelly, L.A., Wiggins, K.L., Avery, C.L., Griffin, P., Feng, Q., Taylor, K.D., Li, G., Evans D.S.,
et al. Pharmacogenetic meta-analysis of genome-wide association studies of LDL cholesterol response to
statins. Nature Communications 5, 5068 (2014).
Broer, L., Buchman, A.S., Deelen, J., Evans D.S., Faul, J.D., et al. GWAS of Longevity in CHARGE
Consortium Confirms APOE and FOXO3 Candidacy. J Gerontol A Biol Sci Med Sci (2014).
Ng, M.C., Shriner, D., Chen, B.H., Li, J., Chen, W.M., Guo, X., Liu, J., Bielinski, S.J., Yanek, L.R., Nalls, M.A.,
Comeau, M.E., Rasmussen-Torvik, L.J., Jensen, R.A., Evans D.S., et al. Meta-analysis of genome-wide
association studies in African Americans provides insights into the genetic architecture of type 2 diabetes.
PLoS Genetics 10, e1004517 (2014).
78
C O M P E N D IUM
Eriksson, J., Evans D.S., Nielson, C.M., Shen, J., Srikanth, P., et al. Limited Clinical Utility of a Genetic Risk Score
for the Prediction of Fracture Risk in Elderly Subjects. Journal of Bone and Mineral Research (2014). Jul 15.
Arking, D.E., Pulit, S.L., Crotti, L., van der Harst, P., Munroe, P.B., Koopmann, T.T., Sotoodehnia, N., Rossin,
E.J., Morley, M., Wang, X., Johnson, A.D., Lundby, A., Gudbjartsson, D.F., Noseworthy, P.A., Eijgelsheim, M.,
Bradford, Y., Tarasov, K.V., Dorr, M., Muller-Nurasyid, M., Lahtinen, A.M., Nolte, I.M., Smith, A.V., Bis, J.C.,
Isaacs, A., Newhouse, S.J., Evans D.S., et al. Genetic association study of QT interval highlights role for
calcium signaling pathways in myocardial repolarization. Nature Genetics 46, 826-36 (2014).
Evans D.S., Cailotto, F., Parimi, N., Valdes, A.M., Castano-Betancourt, M.C., Liu, Y., Kaplan, R.C.,
Bidlingmaier, M., Vasan, R.S., Teumer, A., Tranah, G.J., Nevitt, M.C., Cummings, S.R., Orwoll, E.S., BarrettConnor, E., Renner, J.B., Jordan, J.M., Doherty, M., Doherty, S.A., Uitterlinden, A.G., van Meurs, J.B., Spector,
T.D., Lories, R.J. & Lane, N.E. Genome-wide association and functional studies identify a role for IGFBP3 in
hip osteoarthritis. Annals of the Rheumatic Diseases (2014). Jun 13.
Evans D.S., Calton, M.A., Kim, M.J., Kwok, P.Y., Miljkovic, I., Harris, T., Koster, A., Liu, Y., Tranah, G.J.,
Ahituv, N., Hsueh, W.C. & Vaisse, C. Genetic Association Study of Adiposity and Melanocortin-4 Receptor
(MC4R) Common Variants: Replication and Functional Characterization of Non-Coding Regions. PLoS One 9,
e96805 (2014).
Yokoyama, J.S., Evans D.S., Coppola, G., Kramer, J.H., Tranah, G.J. & Yaffe, K. Genetic modifiers of
cognitive maintenance among older adults. Human Brain Mapping 35, 4556-65 (2014).
Patel, S.R., Hayes, A.L., Blackwell, T., Evans D.S., Ancoli-Israel, S., Wing, Y.K. & Stone, K.L. The association
between sleep patterns and obesity in older adults. International Journal of Obesity (Lond) 38, 1159-64 (2014).
Evangelou, E., Kerkhof, H.J., Styrkarsdottir, U., Ntzani, E.E., Bos, S.D., Esko, T., Evans D.S., et al. A metaanalysis of genome-wide association studies identifies novel variants associated with osteoarthritis of the hip.
Annals of the Rheumatic Diseases 73, 2130-6 (2014).
Avery, C.L., Sitlani, C.M., Arking, D.E., Arnett, D.K., Bis, J.C., Boerwinkle, E., Buckley, B.M., Ida Chen, Y.D.,
de Craen, A.J., Eijgelsheim, M., Enquobahrie, D., Evans D.S., et al. Drug-gene interactions and the search for
missing heritability: a cross-sectional pharmacogenomics study of the QT interval. Pharmacogenomics J 14,
6-13 (2014).
Stephanie Harrison (MPH), Senior Statistician
Publications
Jamal SA, Arampatzis S, Harrison SL, Bucur RC, Ensrud K, Orwoll ES, Bauer DC. Hyponatremia and
Fractures: Findings from the Osteoporotic Fractures in Men Study. J Bone Miner Res. 2014 Oct 7.
Katzman WB, Harrison SL, Fink HA, Marshall LM, Orwoll E, Barrett-Connor E, Cawthon PM, Kado DM;
for the Osteoporotic Fractures in Men (MrOS) Study Research Group. Physical Function in Older Men With
Hyperkyphosis. J Gerontol A Biol Sci Med Sci. 2014 Nov 27.
Massa J, Stone KL, Wei EK, Harrison SL, Barrett-Connor E, Lane NE, Paudel M, Redline S, Ancoli-Israel S,
Orwoll E, Schernhammer E. Vitamin D and Actigraphic Sleep Outcomes in Older Community-Dwelling Men:
The MrOS Sleep Study. Sleep. 2015 Feb 1;38(2):251-7.
Arnold Kahn (Ph.D.), Senior Scientist
Publications
Sorensen MD, Hsi RS, Chi T, Shara N, Wactawski-Wende J, Kahn AJ, Wang H, Hou L, Stoller ML; Women’s
Health Initiative Writing Group. (2014) Dietary intake of fiber, fruit and vegetables decreases the risk of incident
kidney stones in women: a Women’s Health Initiative Report. J Urol 2014 Dec;192(6):1694-9. Epub 2014
May 22.
Sorensen MD, Chi T, Shara NM, Wang H, Hsi RS, Orchard T, Kahn AJ, Jackson RD, Miller J, Reiner AP,
Stoller ML. 2014. Activity, energy intake, obesity and the risk of incident kidney stones in postmenopausal
women: a report from the Women’s Health Initiative. J Am Soc Nephrol. 2014 Feb;25(2):362-9. Epub 2013
Dec 12.
79
Li-Yung Lui (MA, MS), Statistician
Publications
Kado DM, Miller-Martinez D, Lui LY, Cawthon P, Katzman WB, Hillier TA, Fink HA, Ensrud KE. Hyperkyphosis,
kyphosis progression, and risk of non-spine fractures in older community dwelling women: the study of
osteoporotic fractures (SOF). J Bone Miner Res. 2014 Oct; 29(10): 2210-6.
Barbour KE, Lui LY, Ensrud KE, Hillier TA, Leblanc ES, Ing SW, Hochberg MC, Cauley JA; Study of
Osteoporotic Fractures (SOF) Research Group. Inflammatory markers and risk of hip fracture in older white
women: the study of osteoporotic fractures. J Bone Miner Res. 2014 Sep; 29(9): 2057-64.
Lane NE, Parimi N, Lui LY, Wise BL, Yao W, Lay Ya, Cawthon PM, Orwoll E; Osteoporotic Fractures in Men
Study Group. Association of serum uric acid and incident nonspine fractures in elderly men: the Osteoporotic
Fractures in Men (MrOS) study. J Bone Miner Res. 2014 Jul; 29(7): 1701-7.
Schafer AL, Napoli N, Lui L, Schwartz AV, Black DM; Study of Osteoporotic Fractures. Serum
25-hydroxyvitamin D concentration does not independently predict incident diabetes in older women. Diabet
Med. 2014 May; 31(5): 564-9.
Presentations
Hip Fracture Vital Signs: Simple Observations at a Medical Visit Estimate Hip Fracture Risk in Women and
Men. Presented at ASBMR in September 2014.
Progression of Disability amongst Community-dwelling Women in the Tenth Decade of Life. Presented at GSA
in November 2014.
Burden of Late-life Depressive Symptoms and Risk of Long-term Care Placement in Older Women. Presented
at GSA in November 2014.
Health Care Utilization (HCU) and Sarcopenia in Older Women. Presented at GSA in November 2014.
Physical Performance, Cognition, and Inpatient Health Care Utilization (HCU) in Older Women. Presented at
GSA in November 2014.
Healthcare Utilization and Vertebral Fracture in Older Women: Study of Osteoporotic Fractures (SOF).
Presented at GSA in November 2014.
Katherine Peters (MS), Statistical Analyst
Publications
Cawthon PM, Haslam J, Fullman R, Peters KW, Black D, Ensrud KE, Cummings SR, Orwoll ES, BarrettConnor E, Marshall L, Steiger P, Schousboe JT; for the Osteoporotic Fractures in Men (MrOS) Research
Group. Response to BONE-D-14-00884. Bone. 2014 Dec 4.
Cawthon PM, Haslam J, Fullman R, Peters KW, Black D, Ensrud KE, Cummings SR, Orwoll ES, BarrettConnor E, Marshall L, Steiger P, Schousboe JT; Osteoporotic Fractures in Men (MrOS) Research Group.
Methods and reliability of radiographic vertebral fracture detection in older men: the osteoporotic fractures in
men study. Bone. 2014 Oct;67:152-5.
Slinin Y, Peters KW, Ishani A, Yaffe K, Fink HA, Stone KL, Steffes M, Ensrud KE; for the Study of
Osteoporotic Fractures. Cystatin C and Cognitive Impairment 10 Years Later in Older Women. J Gerontol A
Biol Sci Med Sci. 2014 Nov 1.
Maglione JE, Ancoli-Israel S, Peters KW, Paudel ML, Yaffe K, Ensrud KE, Stone KL; Study of Osteoporotic
Fractures Research Group. Subjective and objective sleep disturbance and longitudinal risk of depression in a
cohort of older women. Sleep. 2014 Jul 1;37(7):1179-87.
Ensrud KE, Taylor BC, Peters KW, Gourlay ML, Donaldson MG, Leslie WD, Blackwell TL, Fink HA, Orwoll
ES, Schousboe J; Osteoporotic Fractures in Men Study Group. Implications of expanding indications for
drug treatment to prevent fracture in older men in United States: cross sectional and longitudinal analysis of
prospective cohort study. BMJ. 2014 Jul 3;349:g4120.
80
C O M P E N D IUM
Dam TT, Peters KW, Fragala M, Cawthon PM, Harris TB, McLean R, Shardell M, Alley DE, Kenny A, Ferrucci
L, Guralnik J, Kiel DP, Kritchevsky S, Vassileva MT, Studenski S. An evidence-based comparison of operational
criteria for the presence of sarcopenia. J Gerontol A Biol Sci Med Sci. 2014 May;69(5):584-90.
McLean RR, Shardell MD, Alley DE, Cawthon PM, Fragala MS, Harris TB, Kenny AM, Peters KW, Ferrucci
L, Guralnik JM, Kritchevsky SB, Kiel DP, Vassileva MT, Xue QL, Perera S, Studenski SA, Dam TT. Criteria
for clinically relevant weakness and low lean mass and their longitudinal association with incident mobility
impairment and mortality: the foundation for the National Institutes of Health (FNIH) sarcopenia project. J
Gerontol A Biol Sci Med Sci. 2014 May;69(5):576-83.
Cawthon PM, Peters KW, Shardell MD, McLean RR, Dam TT, Kenny AM, Fragala MS, Harris TB, Kiel DP,
Guralnik JM, Ferrucci L, Kritchevsky SB, Vassileva MT, Studenski SA, Alley DE. Cutpoints for low appendicular
lean mass that identify older adults with clinically significant weakness. J Gerontol A Biol Sci Med Sci. 2014
May;69(5):567-75.
Studenski SA, Peters KW, Alley DE, Cawthon PM, McLean RR, Harris TB, Ferrucci L, Guralnik JM, Fragala
MS, Kenny AM, Kiel DP, Kritchevsky SB, Shardell MD, Dam TT, Vassileva MT. The FNIH sarcopenia project:
rationale, study description, conference recommendations, and final estimates. J Gerontol A Biol Sci Med Sci.
2014 May;69(5):547-58.
Wong AK, Cawthon PM, Peters KW, Cummings SR, Gordon CL, Sheu Y, Ensrud K, Petit M, Zmuda JM,
Orwoll E, Cauley J; Osteoporotic Fractures in Men (MrOS) Research Group. Bone-muscle indices as risk
factors for fractures in men: the Osteoporotic Fractures in Men (MrOS) Study. J Musculoskelet Neuronal
Interact. 2014 Sep;14(3):246-54.
Alley DE, Shardell MD, Peters KW, McLean RR, Dam TT, Kenny AM, Fragala MS, Harris TB, Kiel DP, Guralnik
JM, Ferrucci L, Kritchevsky SB, Studenski SA, Vassileva MT, Cawthon PM. Grip strength cutpoints for the
identification of clinically relevant weakness. J Gerontol A Biol Sci Med Sci. 2014 May;69(5):559-66.
Katie Stone (Ph.D.), Senior Scientist
Publications
Koo BB, Mehra R, Blackwell T, Ancoli-Israel S, Stone KL, Redline S. Periodic limb movements during sleep
and cardiac arrhythmia in older men. J Clin Sleep Med 2014; 10(1): 7-11.
Stone KL, Blackwell TL, Ancoli-Israel S, Cauley JA, Redline S, Marshall LM, Ensrud KE. Sleep disturbances
and risk of falls in older community-dwelling men: the Outcomes of Sleep Disorders in Older Men (MrOS
Sleep) Study. J Am Geriatr Soc. 2014; 62(2):299-305.
Akatsu H, Ewing SK, Stefanick ML, Fink HA, Stone KL, Barrett-Connor E, Mehra R, Ancoli-Israel S, Redline
S, Hoffman AR. Association between thyroid function and objective and subjective sleep quality in older men:
The Osteoporotic Fractures in Men (MrOS) Study. Endocr Pract. 2014; 20(6): 576-86.
Patel SR, Hayes AL, Blackwell T, Evans DS, Ancoli-Israel S, Wing YK, Stone KL. The association between
sleep patterns and obesity in older adults. Int J Obes 2014 (epub ahead of print).
Bajaj A, Stone KL, Peters K, Parimi N, Barrett-Connor E, Bauer D, Cawthon PM, Ensrud KE, Hoffman AR,
Orwoll E, Schernhammer ES. Circulating vitamin D, supplement use, and cardiovascular disease risk: the
MrOS Sleep Study. J Clin Endocrinol Metab. 2014 (epub ahead of print).
Metti AL, Yaffe K, Boudreau RM, Ganguli M, Lopez OL, Stone KL, Cauley JA. Change in inflammatory
markers and cognitive status in the oldest-old women from the Study of Osteoporotic Fractures. J Am Geriatr
Soc. 2014; 62(4): 662-6.
Smagula SF. Ancoli-Israel S, Barrett-Connor E, Lane NE, Redline S, Stone KL, Cauley JA. Inflammation, sleep
disturbances, and depressed mood among community-dwelling older men. J Psychosom Res 2014; 76(5):
368-73.
Blackwell T, Yaffe K, Laffan A, Ancoli-Israel S, Redline S, Ensrud KE, Song Y, Stone KL. Associations of
objectively and subjectively measured sleep quality with subsequent cognitive decline in older communitydwelling men. SLEEP 2014; 37(4): 655-63.
81
Magione JE, Ancoli-Israel S, Peters KW, Paudel ML, Yaffe K, Ensrud KE, Stone KL. Subjective and objective
sleep disturbance and longitudinal risk of depression in a cohort of older women. SLEEP 2014; 37(7): 1179-87.
Smagula SF, Ancoli-Israel S, Blackwell T, Boudreau R, Stefanick ML, Paudel ML, Stone KL, Cauley JA.
Circadian rest-activity rhythms predict future increases in depressive symptoms among community-dwelling
older men. Am J Geriatr Psychiatry 2014 (epub ahead of print).
Massa J, Stone KL, Wei EK, Harrison SL, Barrett-Connor E, Lane NE, Paudel M, Redline S, Ancoli-Israel S,
Orwoll E, Schernhammer E. Vitamin D and Actigraphic Sleep Outcomes in Older Community-Dwelling Men:
The MrOS Sleep Study. Sleep. 2015 [Epub ahead of print]
Gottlieb DJ, Hek K, Chen TH, Watson NF, Eiriksdottir G, … Stone KL, Tanaka T, Viikari J, Gharib SA,Punjabi
NM, Räikkönen K, Völzke H, Mignot E, Tiemeier H. Novel loci associated with usual sleep duration: the
CHARGE Consortium Genome-Wide Association Study. Mol Psychiatry. [Epub ahead of print]
Spira AP, Stone KL, Rebok GW, Punjabi NM, Redline S, Ancoli-Israel S, Yaffe K. Sleep-disordered breathing
and functional decline in older women. J Am Geriatr Soc. 2014; 62(11):2040-6.
Ensrud KE, Blackwell TL, Cauley JA, Dam TT, Cawthon PM, Schousboe JT, Barrett-Connor E, Stone KL,
Bauer DC, Shikany JM, Mackey DC; Osteoporotic Fractures in Men Study Group. Objective measures of
activity level and mortality in older men. J Am Geriatr Soc. 2014; 62(11):2079-87.
Slinin Y, Peters KW, Ishani A, Yaffe K, Fink HA, Stone KL, Steffes M, Ensrud KE; for the Study of Osteoporotic
Fractures. Cystatin C and Cognitive Impairment 10 Years Later in Older Women. J Gerontol A Biol Sci Med
Sci. 2014 Nov 1. [Epub ahead of print]
Hall MH, Smagula SF, Boudreau RM, Ayonayon HN, Goldman SE, Harris TB, Naydeck BL, Rubin SM,
Samuelsson L, Satterfield S, Stone KL, Visser M, Newman AB. Association between Sleep Duration and
Mortality Is Mediated by Markers of Inflammation and Health in Older Adults: The Health, Aging and Body
Composition Study. Sleep. 2014 Oct 28 [Epub ahead of print]
Walsh CM, Blackwell T, Tranah GJ, Stone KL, Ancoli-Israel S, Redline S, Paudel M, Kramer JH, Yaffe K.
Weaker Circadian Activity Rhythms are Associated with Poorer Executive Function in Older Women. Sleep.
2014; 37(12):2009-16.
Song Y, Blackwell T, Yaffe K, Ancoli-Israel S, Redline S, Stone KL; for the Osteoporotic Fractures in Men
(MrOS) Study Group. Relationships Between Sleep Stages and Changes in Cognitive Function in Older Men:
The MrOS Sleep Study. Sleep. 2014 Oct 17. [Epub ahead of print]
Cauley JA, Blackwell TL, Redline S, Ensrud KE, Ancoli-Israel S, Fink HA, Orwoll ES, Stone KL; Osteoporotic
Fractures in Men Study. Hypoxia during sleep and the risk of falls and fractures in older men: the Osteoporotic
Fractures in Men Sleep Study. J Am Geriatr Soc. 2014; 62(10):1853-9.
Diem SJ, Ewing SK, Stone KL, Ancoli-Israel S, Redline S, Ensrud KE; the Osteoporotic Fractures in Men
(MrOS) Study Group. Use of non-benzodiazepine sedative hypnotics and risk of falls in older men. J Gerontol
Geriatr Res. 2014; 3(3):158.
Gregory Tranah (Ph.D.), Scientist; Research Professor
Publications
Kripke DF, Kline LE, Nievergelt CM, Murray SS, Shadan FF, Dawson A, Poceta JS, Cronin J, Jamil SM,
Tranah GJ, Loving RT, Grizas AP, Hahn EK.Genetic variants associated with sleep disorders. Sleep Med.
2014 Dec 5.
Maglione JE, Ancoli-Israel S, Peters KW, Paudel ML, Yaffe K, Ensrud KE, Tranah GJ, Stone KL; Study of
Osteoporotic Fractures Research Group.Depressive symptoms and circadian activity rhythm disturbances in
community-dwelling older women. Am J Geriatr Psychiatry. 2014 Apr;22(4):349-61.
82
C O M P E N D IUM
Elbers CC, Garcia ME, Kimura M, Cummings SR, Nalls MA, Newman AB, Park V, Sanders JL, Tranah GJ,
Tishkoff SA, Harris TB, Aviv A.Comparison between southern blots and qPCR analysis of leukocyte telomere
length in the health ABC study. J Gerontol A Biol Sci Med Sci. 2014 May;69(5):527-31.
Tranah GJ, Yokoyama JS, Katzman SM, Nalls MA, Newman AB, Harris TB, Cesari M, Manini TM,
Schork NJ, Cummings SR, Liu Y, Yaffe K; Health, Aging and Body Composition Study.Mitochondrial DNA
sequence associations with dementia and amyloid-β in elderly African Americans. Neurobiol Aging. 2014
Feb;35(2):442.e1-8.
Stone KL, Blackwell TL, Ancoli-Israel S, Cauley JA, Redline S, Marshall LM, Ensrud KE; Osteoporotic
Fractures in Men Study Group. J Am Geriatr Soc. 2014 Feb;62(2):299-305.
Moayyeri A, Hsu YH, Karasik D, Estrada K, Xiao SM, …Tranah G, Brown SJ, Williams FM, Soranzo N,
Jakobsdottir J, et al .Genetic determinants of heel bone properties: genome-wide association meta-analysis
and replication in the GEFOS/GENOMOS consortium. Hum Mol Genet. 2014 Jun 1;23(11):3054-68.
Yokoyama JS, Evans DS, Coppola G, Kramer JH, Tranah GJ, Yaffe K.Genetic modifiers of cognitive
maintenance among older adults. Hum Brain Mapp. 2014 Sep;35(9):4556-65.
Evans DS, Calton MA, Kim MJ, Kwok PY, Miljkovic I, Harris T, Koster A, Liu Y, Tranah GJ, Ahituv N, Hsueh
WC, Vaisse C.Genetic association study of adiposity and melanocortin-4 receptor (MC4R) common variants:
replication and functional characterization of non-coding regions. PLoS One. 2014 May 12;9(5):e96805.
Evans DS, Cailotto F, Parimi N, Valdes AM, Castaño-Betancourt MC, Liu Y, Kaplan RC, Bidlingmaier M, Vasan
RS, Teumer A, Tranah GJ, Nevitt MC, Cummings SR, Orwoll ES, Barrett-Connor E, Renner JB, Jordan JM,
Doherty M, Doherty SA, Uitterlinden AG, van Meurs JB, Spector TD, Lories RJ, Lane NE. Genome-wide
association and functional studies identify a role for IGFBP3 in hip osteoarthritis. Ann Rheum Dis. 2014 Jun 13.
Broer L, Buchman AS, Deelen J, Evans DS, Faul JD, …Tranah GJ, Weir DR, Newman AB, van Duijn CM,
Murabito JM.GWAS of Longevity in CHARGE Consortium Confirms APOE and FOXO3 Candidacy. J Gerontol
A Biol Sci Med Sci. Epub 2014 Sep 8.
Kripke DF, Klimecki WT, Nievergelt CM, Rex KM, Murray SS, Shekhtman T, Tranah GJ, Loving RT, Lee HJ,
Rhee MK, Shadan FF, Poceta JS, Jamil SM, Kline LE, Kelsoe JR. Circadian polymorphisms in night owls, in
bipolars, and in non-24-hour sleep cycles. Psychiatry Investig. 2014 Oct;11(4):345-62.
Eriksson J, Evans DS, Nielson CM, Shen J, Srikanth P, Hochberg M, McWeeney S, Cawthon PM, Wilmot B,
Zmuda J, Tranah G, Mirel DB, Challa S, Mooney M, Crenshaw A, Karlsson M, Mellström D, Vandenput L,
Orwoll E, Ohlsson C. Limited clinical utility of a genetic risk score for the prediction of fracture risk in elderly
subjects. J Bone Miner Res. Epub 2014 Dec 26.
Sleep Disorders
Brandon Lu (M.D.), Medical Director of Sutter Pacific Medical Foundation’s
Sleep Health Center
Publication
Mander BA, Rao V, Lu B, Saletin JM, Ancoli-Israel S, Jagust WJ, Walker MP. “Impaired Prefrontal
Sleep Spindle Regulation of Hippocampal-Dependent Learning in Older Adults.” Cereb Cortex. 2014
Dec;24(12):3301-9.
83
Other Clinical Research
Ian Jaffee (M.D.), Pathologist
Publications
Weilert F, Bhat YM, Binmoeller KF, Kane S, Jaffee IM, Shaw RE, Cameron R, Hashimoto Y, Shah JN. EUSFNA is superior to ERCP-based tissue sampling in suspected malignant biliary obstruction: results of a
prospective, single-blind, comparative study. Gastrointest Endosc. 2014 Jul;80(1):97-104. Epub 2014 Feb 19.
Goodson WH 3rd, Luciani MG, Sayeed SA, Jaffee IM, Moore DH 2nd, Dairkee SH. Activation of the mTOR
pathway by low levels of xenoestrogens in breast epithelial cells from high-risk women. Carcinogenesis. 2011
Nov;32(11):1724-33. Epub 2011 Sep 1.
Watson RR, Binmoeller KF, Hamerski CM, Shergill AK, Shaw RE, Jaffee IM, Stewart L, Shah JN. Yield and
performance characteristics of endoscopic ultrasound-guided fine needle aspiration for diagnosing upper GI
tract stromal tumors. Dig Dis Sci. 2011 Jun;56(6):1757-62. Epub 2011 Mar 1.
Jaffee IM, Rahmani M, Singhal MG, Younes M. Expression of the intestinal transcription factor CDX2 in
carcinoid tumors is a marker of midgut origin. Arch Pathol Lab Med. 2006 Oct;130(10):1522-6.
Acosta M, Edwards R, Jaffee IM, Yee DL, Mahoney DH, Teruya J. A practical approach to pediatric patients
referred with an abnormal coagulation profile. Arch Pathol Lab Med. 2005 Aug;129(8):1011-6. Erratum in:
Arch Pathol Lab Med. 2005 Nov;129(11):1368.
Lara-Torre E, Dietrich JE, Kaplan A, Lopez H, Jaffee I. A case of poorly differentiated Sertoli-Leydig tumor of
the ovary. J Pediatr Adolesc Gynecol. 2004 Feb;17(1):49-52.
Elliott Main (M.D.), Obstetrician-Gynecologist; Director of Maternal Fetal Medicine
Publications
Main EK, Menard MK. Maternal mortality: time for national action. Obstet Gynecol. 2013 Oct;122:735-6.
Swank ML, Caughey AB, Farinelli CK, Main EK, Melsop KA, Gilbert WM, Chung JH. The impact of change in
pregnancy body mass index on the development of gestational hypertensive disorders. J Perinatol. 2014 Jan
2. doi: 10.1038/jp.2013.168. [Epub ahead of print]
D’Alton ME, Main EK, Menard MK, Levy BS. The national partnership for maternal safety. Obstet Gynecol.
2014 May;123(5):973-7.
Callaghan WM, Grobman WA, Kilpatrick SJ, Main EK, D’Alton M. Facility-based identification of women with
severe maternal morbidity: it is time to start. Obstet Gynecol. 2014 May;123(5):978-81.
Menard MK, Main EK, Currigan SM. Executive summary of the reVITALize initiative: standardizing obstetric
data definitions. Obstet Gynecol. 2014 Jul;124(1):150-3.
Swank ML, Caughey AB, Farinelli CK, Main EK, Melsop KA, Gilbert WM, Chung JH. The impact of change
in pregnancy body mass index on macrosomia. Obesity (Silver Spring). 2014 Sep;22(9):1997-2002 7. Swank
ML, Marshall NE, Caughey AB, Main EK, Gilbert WM, Melsop KA, Chung JH. Pregnancy outcomes in the
super obese, stratified by weight gain above and below institute of medicine guidelines. Obstet Gynecol. 2014
Dec;124(6):1105-10.
84
C O M P E N D IUM
© Sutter CPMCRI. All rights reserved.
85
www.cpmcri-currents.org
15-SHSO-0003134
86